Machine perfusion in kidney transplantation: clinical application & metabolomic analysis by Guy, Alison Jane
 MACHINE PERFUSION IN KIDNEY TRANSPLANTATION: 
CLINICAL APPLICATION & METABOLOMIC ANALYSIS 
 
 
By ALISON J GUY (MBChB, FRCS) 
 
 
A thesis submitted to the 
University of Birmingham  
for the degree of 
DOCTOR OF MEDICINE 
 
 
 
Department of Immunity and Infection 
University of Birmingham 
 &          
Department of Renal Surgery 
University Hospitals Birmingham 
30th March 2015 
 
 
 
 
 
 
 
 
 
University of Birmingham Research Archive 
 
e-theses repository 
 
 
This unpublished thesis/dissertation is copyright of the author and/or third 
parties. The intellectual property rights of the author or third parties in respect 
of this work are as defined by The Copyright Designs and Patents Act 1988 or 
as modified by any successor legislation.   
 
Any use made of information contained in this thesis/dissertation must be in 
accordance with that legislation and must be properly acknowledged.  Further 
distribution or reproduction in any format is prohibited without the permission 
of the copyright holder.  
 
 
 
  2 
ABSTRACT 
 
Kidney Transplantation is the gold standard treatment for patients with end-stage 
renal failure. Most kidneys used for transplantation are from deceased donors and 
ensuring successful outcomes depends on many factors. One of these is organ 
storage. 
 
Hypothermic Machine Perfusion (HMP) of deceased donor organs has been shown 
to have several benefits. However, it has not been widely adopted and the underlying 
mechanism is poorly understood. 
 
The first section of this thesis examines the introduction of HMP into clinical practice. 
HMP outcomes were similar to those of standard storage techniques but with the 
additional benefit of increasing safe storage times. This was likely due to inherent 
benefits of the machine itself, improved recipient preparation and better peri-
operative conditions. 
 
The second part of this study analysed HMP perfusate using metabolomics (Nuclear 
Magnetic Resonance) to identify potential predictors of graft outcome. Differences 
were identified in the metabolic profiles of perfusate from kidneys with immediate and 
delayed graft function. These may have a future role in viability assessment. 
Improved understanding of metabolism during storage may help target optimization 
strategies for deceased donor organs. 
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The final part of this study describes the development of a porcine model of 
transplantation to test future hypotheses. 
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CHAPTER ONE: INTRODUCTION 
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1.1 CHRONIC KIDNEY DISEASE (CKD) 
 
1.1.1 CKD - DEFINITIONS & STAGING  
 
Chronic kidney disease (CKD) was defined by the US National Kidney Foundation in 
2002 as the presence of kidney damage or decreased kidney function for three 
months or more, irrespective of the underlying cause. This can manifest with various 
markers of kidney damage or reduction in the glomerular filtration rate (GFR < 60 
mL/min/1.73m2) (National Kidney Foundation, 2002).  
 
A staging system based on GFR has also been defined: 
 
Table 1.1: Staging System for CKD – National Kidney Foundation 
Stage Description GFR (mL/min/1.73m2) 
1 Kidney damage with normal or ↑GFR ≥ 90 
2 Kidney damage with mild ↓GFR 60-89 
3 Moderate ↓GFR 30-59 
4 Severe ↓GFR 15-29 
5 Kidney Failure <15 or dialysis 
 
This staging system was revised in 2012 by the Kidney Disease Improving Global 
Outcomes (KDIGO) CKD Work Group (KDIGO, 2013). 
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Table 1.2: Revised Staging System for CKD - KDIGO 
GFR category GFR (ml/min/1.73m2) Terms 
G1 ≥90 Normal or high GFR 
G2 60-89 Mildly decreased GFR 
G3a 45-59 Mild to moderately decreased GFR 
G3b 30-44 Moderately to severely decreased GFR 
G4 15-29 Severely decreased GFR 
G5 <15 Kidney failure 
 
In addition to GFR, a grading system for the level of albuminuria was also introduced 
in recognition of its contribution to the prognosis of patients with CKD. 
 
Table 1.3: Grading System for Albuminuria - KDIGO 
Category AER (mg/24hours) 
ACR 
(mg/mmol) 
ACR 
(mg/g) Terms 
A1 <30 <3 <30 Normal/mildly increased 
A2 30-300 3-30 30-300 Moderately increased 
A3 >300 >30 >300 Severely increased 
 
AER: Albumin Excretion Rate, ACR: Albumin Creatinine Ratio 
 
This KDIGO group also recommended that a cause should be assigned based on the 
presence or absence of systemic disease and the location within the kidney of 
observed or presumed pathological-anatomical findings. 
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Progression through the stages of CKD results in significant complications such as 
hypertension and cardiovascular disease, anaemia, malnutrition, neuropathy and a 
poor quality of life. It can ultimately result in Kidney failure, or End-Stage Renal 
Failure (ESRF). This is defined as a GFR of less than 15 mL/min/1.73m2, or the 
need for Renal Replacement Therapy (RRT) (Levey & Coresh, 2012). This is the 
most serious complication of CKD and can only be treated by dialysis or 
transplantation. 
 
 
1.1.2 CKD - PREVALENCE, INCIDENCE & ECONOMIC BURDEN 
 
Worldwide 
 
CKD is a worldwide public health problem. A recent estimate suggests that 10% of 
the world's population is affected by CKD (Eckardt et al., 2013). Prevalence tends to 
increase with age, exceeding 20% in those over the age of 60 and 35% in those over 
the age of 70 (Levey & Coresh, 2012). 
 
Prevalence, and incidence, does vary considerably across the world as 
demonstrated in Figure 1.1 (Jha et al., 2013).  These figures can be underestimated 
in poorer countries where patients are unlikely to be registered on a RRT 
programme. 
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Figure 1.1: Annual Incidence (A) & Prevalence Rates (B) of ESRF in Different 
Countries (Reproduced from Jha et al., 2013) 
 
 
In countries that can afford to offer RRT, mainly in the form of dialysis, to all patients 
who have progressed to renal failure, the proportion of health-care expenditure for 
this group of patients is far out of proportion to its size (Kerr et al., 2012; Vanholder et 
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al., 2012). In many countries, economic considerations allow only restricted access, 
or in some cases no access, to this expensive long term treatment. It is in these 
poorer parts of the world that the number of patients with CKD is expected to 
increase most rapidly in the next decade (Couser et al., 2011). 
 
CKD was ranked 18th in the list of causes of total number of global deaths in 2010. 
This equates to an annual death rate of 16.3 per 100,000 (Lozano et al., 2012). This 
figure has increased significantly from previous years and is likely to be an 
underestimate due to the contribution of CKD to death from other causes. 
 
UK 
 
According to the UK renal registry, there were 54,824 adult patients receiving RRT in 
the UK at the end of 2012, an increase of 3.7% from 2011. This corresponds to a 
prevalence per million population of 881. The median age of these patients was 58 
years, 3 years older than in 2000, and the percentage of RRT patients aged over 70 
had increased from 19.2% in 2000 to 24.9% in 2012. Prevalence rates across age 
groups in the UK are shown in Figure 1.2.  
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Figure 1.2: Prevalence Rates for RRT per Million Population by Age Group and UK 
Country on 31/12/2012 (Reproduced from Caskey et al., 2013). 
 
 
 
 
The incidence in the UK has remained relatively stable over the last seven years with 
6,891 patients requiring initiation of RRT in 2012 - this equates to an incidence of 108 
per million population (Caskey et al., 2013). 
 
The overall number of people with lesser stages of CKD is more difficult to ascertain. 
A large primary care study suggested that the age standardised prevalence of stage 
3-5 CKD was around 8.5% (Stevens et al., 2007). Repeating the trend seen 
worldwide, the prevalence of CKD rose dramatically with age, Figure 1.3. 
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Figure 1.3: Prevalence of Stage 3-5 CKD in the UK (Reproduced from Stevens et 
al., 2007) 
 
 
Prevalence is likely to increase along with an ageing population and increasing 
numbers with risk factors such as diabetes (Meguid El Nahas & Bello, 2005). 
 
ESRF has a significant impact on healthcare budgets. More than 2% of the total NHS 
budget is spent on renal replacement therapy (dialysis and transplantation) for those 
with established renal failure (Sharif & Baboolal, 2011). 
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1.1.3 CKD - AETIOLOGY/PATHOLOGY 
 
There are many diseases that can cause kidney damage. Some are renal in origin 
and others are systemic diseases that affect the kidney. These are summarised in 
the table below: 
 
Table 1.4: Classification of Causes of CKD (Reproduced from Eckardt et al., 2013) 
 
This classification system is based on the presence or absence of systemic disease 
and on the location within the kidney of pathological-anatomical findings. 
 
 
 Examples of primary kidney diseases 
Examples of systemic diseases 
affecting the kidney 
Glomerular 
diseases 
 
Diffuse, focal or crescentic proliferative 
glomerulonephritis; focal and 
segmental glomerulosclerosis, 
membranous nephropathy and minimal 
change disease 
 
Obesity, metabolic syndrome and 
diabetes, systemic autoimmune 
diseases, systemic infections, drugs, 
complement diseases, neoplasia and 
haemopoietic diseases 
Vascular 
diseases 
ANCA-associated renal limited 
vasculitis, and fibromuscular dysplasia 
 
Hypertension, atherosclerosis, 
ischaemia, cholesterol emboli, systemic 
vasculitis, thrombotic microangiopathy, 
and systemic sclerosis 
Tubulointerstitial 
diseases 
Urinary tract infections, stones, and 
obstruction 
 
Systemic infections, sarcoidosis, drugs, 
urate, environmental toxins and 
neoplasia 
Cystic and other 
congenital 
diseases 
Renal dysplasia, medullary cystic 
disease, and podocytopathies 
 
Autosomal-dominant polycystic kidney 
disease, Alport syndrome, and Fabry 
disease 
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Diabetes and hypertension are the leading causes of CKD in all developed and many 
developing countries (Jha et al., 2013). In the UK, diabetic renal disease accounts for 
26% of cases of renal failure with some variation according to age group, table 1.5. 
 
Table 1.5: Percentage Distribution of Primary Renal Diagnosis by Age, 2012 
(Reproduced from Caskey et al., 2013) 
 
 Percentage with Diagnosis 
Diagnosis Age < 65 Age ≥ 65 All Patients 
Diabetes 28.6 22.3 25.6 
Glomerulonephritis 17.3 10.4 14.0 
Pyelonephritis 6.8 6.4 6.6 
Hypertension 6.2 8.8 7.4 
Polycystic kidney 10.1 3.1 6.7 
Renal vascular 1.7 10.9 6.1 
Other 17.4 18.0 17.7 
Uncertain aetiology 11.8 20.1 15.9 
 
 
In developed countries, causes tend to be lifestyle related. In developing or low 
income countries, infectious diseases continue to be a significant contributor to the 
development of renal disease along with environmental pollution, pesticides, 
analgesic abuse, herbal medications and unregulated food additives (Ayodele & 
Alebiosu, 2010; Jha, 2004). 
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1.1.4 CKD - DISEASE PROGRESSION 
 
The early stages of kidney disease are often asymptomatic but, if recognised through 
biochemical testing, may be reversible. Once established, the rate of progression of 
CKD is variable. Rapidly progressive diseases may lead to kidney failure within 
months whereas some patients do not progress during many years of follow-up 
(Levey & Coresh, 2012). Risk factors for disease progression have been identified.  
 
Non- modifiable factors include genetics, race, age, and sex. For example, there is 
evidence that the rate of progression of CKD is faster among patients who are 
elderly, male, or African-American (Jungers et al., 1996; Hsu et al., 2003).  
 
Significant modifiable risk factors include hypertension, hyperlipidaemia and cigarette 
smoking (Jafar et al., 2003; Klahr et al., 1994). There is considerable overlap 
between factors associated with the progression of CKD and increased 
cardiovascular risk (KDIGO, 2013). In diabetic nephropathy, poor diabetic control 
accelerates disease progression (Adler et al., 2003; The Diabetes Control and 
Complications (DCCT) Research Group, 1995). Obesity has also been linked to 
progression of CKD caused by glomerulonephritides, focal segmental 
glomerulosclerosis and IgA nephropathy (Bonnet et al., 2001; de Jong et al., 2002; 
Kambham et al., 2001; Verani, 1992). 
 
Other suggested progression factors include regular and heavy alcohol consumption 
(Perneger et al., 1999), recreational opioid use (Perneger et al., 2001) and 
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analgesics (Klag et al., 1996; Morlans et al., 1990; Perneger et al., 1994). Proteinuria 
is a well-recognised marker of severity and prediction of progression of CKD, as 
suggested by the revised guidelines on staging, but controversy exists as to its 
possible role as a risk factor (Meguid El Nahas & Bello, 2005). 
 
One percent of the CKD population will progress to need RRT. However it remains 
the most expensive of the chronic diseases and reduces lifespan significantly 
(KDIGO, 2013). 
 
 
1.1.5 CKD - MANAGEMENT 
 
Treatments for CKD aim to prevent progression, reduce complications of a 
decreased GFR, reduce the associated risks of cardiovascular disease and improve 
survival and quality of life (Levey & Coresh, 2012). 
 
Management of all stages of CKD is beyond the scope of this thesis but figure 1.4 
represents the different stages of CKD and suggested management strategies at 
each stage. 
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Figure 1.4: Conceptual Model of CKD (Reproduced from Levey et al., 2009) 
 
This diagram represents the continuum of development, progression and 
complications of CKD, along with strategies to improve outcomes. EOL = End of Life. 
 
 
 
 
 
Once in renal failure, RRT is required to maintain life. This can take the form of 
dialysis or transplantation. Data from the most recent UK renal registry report 
(Caskey at al., 2013) indicated that transplantation continued to be the most common 
treatment modality (50.4%) for renal failure. 
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1.2 RENAL TRANSPLANTATION (RT) 
 
1.2.1 RT – OVERVIEW / DEFINITIONS 
 
Kidney Transplantation is considered to be the gold standard treatment for patients 
with ESRF providing both survival benefit and improved quality of life when 
compared to dialysis (Wolfe et al., 1999). Patient and graft survival rates for 
transplantation exceed 90% per year (Taylor & Baicu, 2010).  Survival on dialysis is 
poor in comparison with only 35% of patients alive after 5 years (Collins et al., 2008). 
 
There is also an economic advantage. A recent estimate suggested that kidney 
transplantation provides a cost benefit of £25,800 per year in the second and 
subsequent years compared to maintaining a patient on dialysis. Over a period of 10 
years, a functioning kidney transplant will provide a cost benefit of £241,000 when 
compared to dialysis over the same period (NHSBT Factsheet 7, 
www.organdonation.nhs.uk). 
 
Procedures are classified depending on the source of the donor organ. The majority 
of kidneys used for transplantation are from deceased donors (cadaveric organs) 
(McAnulty, 2010). However, an increasing number of living-donor transplants are 
being performed. These can be from genetically related individuals, unrelated 
individuals or from altruistic donors where donation is non-directed. 
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Deceased donors (DD) can be further classified into Donation after Brain Death 
(DBD) donors or Donation after Cardiac Death (DCD) donors. These were previously 
termed heart-beating or non-heart-beating donors. DBD organs constitute the 
majority of cadaveric kidneys for transplantation although numbers of DCD organs 
available are on the increase. The graph below shows the trend for each type of 
donor procedure between 1997 and 2007 in the UK. 
 
 
Figure 1.5: Number of Deceased and Living Donors in the UK 1/4/1997-31/3/2007 
(Reproduced from  Forsythe, 2013) 
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1.2.2 RT - COLD ISCHAEMIC TIME 
 
Cold Ischaemic Time (CIT) is defined as the time from perfusion of an organ by cold 
solutions until transplantation into the recipient (Monbaliu et al., 2012).  
 
Initial cold flush of the organ at retrieval aims to clear the vasculature of blood and 
lower the temperature. Traditionally, cold temperatures are then maintained until the 
time of transplantation with the aim of slowing down metabolism and preserving 
kidney function. Cold preservation has been key to the development of clinical 
transplant programmes; however, there are disadvantages of cooling ischaemic 
tissue. 
 
CIT, particularly if prolonged, is associated with renal ischaemic injury which impacts 
negatively on graft function and survival (Watson et al., 2010). It is therefore of key 
consideration when organising deceased donor transplants.  
 
 
1.2.3 RT - OUTCOMES 
 
A number of outcomes can be observed following kidney transplantation.  
 
In the early post transplant period, kidneys can display immediate graft function (IGF) 
or may suffer from delayed graft function (DGF).  
 
  38 
DGF is most often defined as the requirement for dialysis within the first post-
operative week (Polyak et al., 1999). The criticism of this definition is that it is 
subjective and over-estimates the true rate of DGF as it includes patients who 
underwent dialysis following transplantation for any reason. An alternative definition 
is functional DGF (fDGF) where creatinine fails to decrease by 10% for 3 consecutive 
days in the first postoperative week. Lack of consistency in the definition of DGF can 
make it difficult to compare this outcome between studies (Yarlagadda et al., 2008). 
 
DGF is associated with significant morbidity during the peri-transplant period and is 
an important risk factor for acute rejection (Gjertson, 2002), graft loss (Ojo et al., 
1997) and death with a functioning graft (Tapiawala et al., 2010). It also results in 
prolonged hospital stays with associated increased costs (Yarlagadda et al., 2009). 
 
Primary non-function (PNF) occurs when the transplanted kidney never works 
sufficiently to allow cessation of dialysis. As mentioned above, graft loss can occur 
which can result from a variety of causes, such as renal vein thrombosis or recurrent 
disease, and kidneys can also suffer from rejection.  
 
Survival outcome is often measured as survival with or without a functioning 
transplant. Long-term function of transplanted kidneys is influenced by donor- 
dependent factors (such as age, cause of death or mode of death) duration and type 
of organ preservation and recipient factors (such as co-mobidity, gender, ethnicity) 
(Polyak et al., 1999). 
 
  39 
1.2.4 RT - THE ORGAN SHORTAGE & MARGINAL ORGANS 
 
A shortage of suitable donor organs has always limited clinical transplantation. As 
solid organ transplantation changed from an experimental procedure with a low 
chance of success to being the current gold-standard, increasing numbers of patients 
have required a transplant (Henry & Guarrera, 2012).  
 
For every patient that receives a transplanted organ in the US, there are four more 
on the waiting list. This pattern is repeated across Europe. In addition, it is said that a 
patient dies from the lack of a transplant almost every 1½ hours (Lee & Mangino, 
2009).  
 
A number of measures have been introduced in order to address the donor shortage. 
One of these measures is the increased used of organs that may previously have 
been considered as too high risk for transplantation. These are termed marginal 
organs. Marginal organs include DCD organs and organs from older donors with co-
morbidity (Extended Criteria Donors, ECDs). 
 
All organs for transplantation are exposed to ischaemic injury as a result of 
interruption to blood supply. DCD organs are exposed to a period of warm ischaemic 
time (WIT) prior to retrieval. WIT per minute, is much more harmful than the same 
length of exposure of cold ischaemia - this adversely affects graft outcome (Shiroki et 
al., 1998). DCD organs essentially experience two insults - the initial warm ischaemia 
followed by the cold ischaemic storage time. Effects of this combined insult became 
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more noticeable as increased storage times were required with the growth of clinical 
transplantation. DGF rates began to approach 60-80% - much higher than with 
shorter transport times or with DBD organs (Brasile et al., 2001). However, it is of 
utmost importance to address this mechanism of injury, as DCD organs constitute 
the deceased donor group with the largest potential for growth (Hayakawa et al., 
2006). 
 
ECD kidneys are those from donors aged 60 or over, or those aged between 50-59 
with two or more of the following; hypertension, intra-cerebral cause of death or 
creatinine over 132 µmol (Port et al., 2002). 
 
Both types of marginal organs carry a higher risk of Delayed Graft Function (DGF) 
and ECD kidney recipients have a 69% higher relative risk for graft failure (Metzger 
et al., 2003a). However, long-term survival of functioning grafts and survival of 
recipients are similar in both groups (Gok et al., 2002; Keizer et al., 2005; Nicholson 
et al., 2000). In addition, patient survival is better in recipients of marginal kidneys 
than in patients on dialysis, with a gain in life expectancy ranging from 3 to 9 years 
(Ojo et al., 2001). 
 
To increase the number of patients benefitting from kidney transplantation, use of 
marginal organs has to be increased and outcomes improved. Some have suggested 
that the main reason for underutilisation of these organs is because static cold 
storage (SCS), the main storage method worldwide and in the UK, is inadequate 
(Lee & Mangino, 2009; McAnulty 2010). This limits the timeframe to organise the 
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transplant process and seems particularly problematic for DCD organs as SCS 
becomes ineffective when the warm ischaemic time exceeds 20 minutes (Lee & 
Mangino, 2009). 
 
 
1.2.5 RT - ISCHAEMIA-REPERFUSION INJURY 
 
Ischaemia 
 
In order to retrieve organs for transplantation, it is unavoidable that they are subject 
to a period of ischaemia. Almost immediately after interruption of the blood supply, 
tissues become completely or partially starved of oxygen and metabolism is very 
rapidly switched from aerobic to anaerobic (Taylor & Baicu, 2010). Less energy, in 
the form of adenosine triphosphate (ATP), is produced by this type of metabolism for 
on-going cellular processes. Metabolic substrates to support anaerobic glycolysis are 
limited and intermediates from this process, such as lactate and protons, increase 
cellular osmotic load. ATP and adenosine diphosphate (ADP) are broken down into 
their constituent parts which can escape from the cell. This means that, even when 
the blood supply is restored, there is a shortage of substrates to form high energy 
phosphates (Kosieradzki & Rowiński, 2008). When ischaemia lasts for over 24 hours 
and energy substrates are lost, ATP can no longer be reformed, leading to lethal cell 
injury (Sammut et al., 2000). 
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The depletion of ATP in ischaemic cells has further repercussions. The energy 
dependent Na+/K+ membrane pump can no longer function effectively to maintain 
the membrane potential and cell excitability. Sodium can enter the cell followed by 
water which produces oedema (Ahmad et al., 2004). Oedema is further worsened by 
the increase in cell osmolarity caused by the intermediates of anaerobic glycolysis 
and ATP/ADP breakdown, as mentioned previously. Water can then enter by simple 
diffusion, aquaporin and chloride channels as well as via the glucose transporter 
(Kosieradzki & Rowiński, 2008).  
 
Oedema results in disruption of all cellular membranes including the membranes of 
endoplasmic reticulum (ER), Golgi apparatus, mitochondria and cytoskeletal 
microtubules. This damage is ischaemia time-dependent and results in cell death 
(Mangino et al., 2008). 
 
Acidosis occurs as an immediate result of anaerobic glycolysis producing lactate. As 
there is no blood flow to remove the lactate, further energy production is halted, and 
cell death results (Kosieradzki & Rowiński, 2008). A decreased pH is uniformly 
observed in ischaemic tissues (Anderson et al., 1999; Soric  al., 2007). 
 
Mitochondrial dysfunction is a critical event during ischaemia as it initiates necrosis 
and apoptosis cascades during reperfusion (Kosieradzki & Rowiński, 2008).  
Dysfunction of cellular membrane pumps and redistribution from intracellular stores 
leads to the accumulation of calcium within the cell early in the ischaemic process 
(Schumacher et al., 1998). Influx of extracellular calcium only occurs during 
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prolonged ischaemia and reperfusion (Kusuoka et al., 1993). Calcium is retained in 
the mitochondrial matrix in order to maintain its membrane potential. Mitochondrial 
calcium overload affects a number of complexes which result in matrix swelling and 
damage to mitochondrial membranes (Kosieradzki & Rowiński, 2008). It also causes 
a non-selective pore (mPT), which is impermeable under normal conditions, to open. 
Prolonged opening of these channels may differentiate reversible from irreversible 
reperfusion injury (Griffiths & Halestrap, 1995; Halestrap, 2006) and may have a role 
in attenuating ischaemia-reperfusion (IR) injury. 
 
Free radicals are formed even during global ischaemia if small amounts of oxygen 
are available. These are believed to be formed by the deamination of adenosine and 
resultant changes to xanthine dehydrogenase in response to ischaemia (Kosieradzki 
& Rowiński, 2008). They can also be formed by the respiratory complex (Chen et al., 
2007).  
 
Reperfusion 
 
It is considered to be the combination of a long period of cold ischaemia followed by 
reperfusion that is responsible for tissue injury in this process. Survival or death of 
the cell depends on the balance between repair and regeneration and harmful 
processes such as apoptosis, autophagy and necrosis (Kosieradzki & Rowiński, 
2008).  Apoptosis requires energy and protein synthesis so occurs mainly on 
reperfusion. The ability of a cell to recover from injury may partly be dependent on 
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whether calcium concentration can be restored to normal levels (Vanden Hoek et al., 
2003). 
 
Rapid release of free radicals on reperfusion is a well-recognised event most 
probably produced by the respiratory chain. These may be a cause of endothelial 
injury and also act to worsen cell oedema (Kosieradzki & Rowiński, 2008). 
Mitochondria are important in the reperfusion process as they have the ability to 
produce free radicals but also have potent radical-scavenging potential.  
 
Damaged ER fragments increase in reperfused tissues which signal upcoming 
cellular disintegration (Kirino & Sano, 1984). Lysosomal activity of proteases and 
cathepsins increase leading to cell death via necrosis or apoptosis. Neutrophils also 
contribute by causing direct cytotoxicity via the generation of oxygen free radicals 
and release of cytokines (Kosieradzki & Rowiński, 2008). 
 
Tissues tend to be hyperaemic initially following reperfusion but flow rates soon drop 
to below normal. This is mostly driven by a decreased metabolic demand and 
extracellular oedema but neutrophil and platelet accumulation in blood vessels can 
diminish blood flow (Galiuto & Crea, 2006). The effects of this are not fully 
understood.  
 
Prevention or suppression of IR injury is important to prevent poor graft function 
following renal transplant with severe injury being associated with DGF and PNF. 
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Marginal kidneys are more prone to this type of injury (Dittrich et al., 2004; Dragun et 
al., 2001; Gok et al., 2004; Harper et al., 2008; Hosgood et al., 2008). 
 
Many components of the transplant procedure can have an effect on injury level and 
one of those factors is the preservation method. 
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1.3 ORGAN PRESERVATION 
 
1.3.1 HISTORY OF ORGAN PRESERVATION 
 
The first recorded attempt to perfuse an isolated organ was using the kidney; this 
was reported as early as 1849 by Loebel (Hoffman, Burger, & Persky, 1965). Also 
among the cited early experimenters were Le Gallois (Le Gallois, 1812), studying 
heart perfusion, and Bernard's work on liver perfusion (Bernard, 1855). 
 
In the 1930s, Alexis Carrel collaborated with the aviator Charles Lindbergh to 
cultivate and perfuse organs with the help of small pumps (Carrel & Lindbergh, 
1935). At this time, most work focused on perfusion at normal body temperatures 
(Fuller & Lee, 2007) with whole blood or cryoprecipitated plasma used as the 
perfusate (Yuan et al., 2010). 
 
When transplantation became a clinical reality in the 1960s, organ preservation 
methods were re-evaluated. The potential benefits of hypothermia in clinical practice 
were beginning to be recognised and renal function had been maintained on a pump 
oxygenator (Couch, Cassie, & Murray, 1958; Levy, 1959). This provided the basis for 
the development of hypothermic perfusion. 
 
Further important contributions to the acceptance of hypothermic perfusion 
techniques were made by the Humphries group (Humphries et al., 1964a, 1964b; 
Humphries et al., 1968b, 1968c) and Belzer who established the technique as 
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clinically useful (Belzer, Ashby, & Dunphy, 1967; Belzer et al., 1968; Belzer et al., 
1972). Belzer developed one of the first reliable transportable hypothermic perfusion 
machines (Fuller & Lee, 2007). He also recognised how useful hypothermic machine 
perfusion (HMP) would be to facilitate an organ matching programme not so limited 
by transport logistics (Belzer et al., 1972). Major advances in hypothermic perfusion 
were initially achieved with the kidney; interest in perfusing other organs then 
followed (Fuller & Lee, 2007). 
 
The majority of kidneys in the US in the 1970s were actually preserved by machine 
perfusion. However, studies at that time failed to demonstrate superiority of HMP 
(Clark et al., 1974; Opelz & Terasaki, 1976, 1982; van der Vliet et al., 1983) whilst 
there were major improvements in immunosuppression which did improve transplant 
outcomes. This, along with cost implications and ease of use, led to SCS being the 
most common form of storage in the 1980s (Yuan et al., 2010). 
 
Further developments in preservation solutions improved the storage of organs by 
SCS. Collins developed a simple, effective SCS solution in 1969 that was modified in 
1976 to form the Euro-Collins (EC) solution (Collins, Bravo-Shugarman, & Terasaki, 
1969; Yuan et al., 2010). In the 1980s Belzer developed the University of Wisconsin 
(UW) solution, which although expensive, gradually became the preservation solution 
of choice for prolonged periods of SCS (Opelz & Döhler, 2007; Ploeg et al., 1988). 
Bretschneider developed an alternative solution, histidine-tryptophan-ketoglutarate 
(HTK), which also showed beneficial effects for the preservation of abdominal organs 
(Groenewoud et al., 1989; Isemer et al., 1988). 
  48 
During the 1990s, interest in HMP returned due to the increasing success of 
transplantation and the need to use more DCD and ECD organs. These organs are 
more prone to cold ischaemic damage and in order to maintain transplant outcomes 
preservation techniques needed to improve. HMP emerged as a technology with 
promising results in experimental preservation of abdominal organs and with clinical 
use in kidney transplantation (Henry & Guarrera, 2012). 
 
 
1.3.2 PRESERVATION FLUIDS 
 
Preservation solutions are designed to counteract the effects of hypothermia and 
extend organ preservation time. Most static cold storage fluids are based on three 
essential constituents: An adequate electrolyte composition, an impermeant to 
prevent cell swelling and a buffer to prevent acidosis (Fuller & Lee, 2007; McAnulty, 
2010). 
 
In terms of HMP, different considerations needed to be addressed. It was recognised 
early in the development process that balancing the oncotic pressure of the solution 
with the applied perfusion pressure was vital to prevent tissue oedema (Fuller & Lee, 
2007). Use of perfusates without colloid had been sub-optimal when the necessary 
perfusion pressure has been applied (Humphries et al., 1968a). Diluted blood was 
used in the initial experiments with HMP but there were problems with increased 
viscosity and thrombus formation (Humphries et al., 1964a; Humphries et al., 1964b; 
Humphries et al., 1968c). Similar problems were found with the use of diluted plasma 
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(Belzer et al., 1968). Methods to fractionate the plasma were developed which 
helped to address these issues (Belzer et al., 1968; Toledo-Pereyra, Buselmeier, & 
Najarian, 1975; Toledo-Pereyra et al., 1974). Perfusates based on serum albumin 
were developed around the same time (Claes et al., 1972; Pegg & Green, 1972).  
 
A completely synthetic perfusate, with hydroxy-ethyl-starch (HES) as the colloid, was 
developed in the 1980s by Belzer which allowed longer periods of perfusion 
(McAnulty et al., 1989; Pienaar et al., 1990). Although this was adopted by many 
North American centres using machine perfusion, the development of UW solution 
shortly afterwards allowed longer periods of SCS and as such, SCS remained the 
storage method of choice worldwide (Henry & Guarrera, 2012).  
 
There have been many preservation solutions developed for use in clinical 
transplantation and many are still in development in the experimental stages. The 
more common perfusion fluids in clinical use for SCS and HMP are briefly described 
below: 
 
Collins solution, developed in 1969, is a crystalloid solution containing high 
concentrations of glucose and the impermeant magnesium sulphate. These 
compounds acted to decrease cell swelling and allowed longer SCS times. This was 
modified by the Eurotransplant Organisation in 1976 to Euro-Collins' solution. 
Magnesium sulphate was omitted and the dextrose concentration was increased 
(Toledo-Pereyra, Palma-Vargas, & Toledo, 2010). Euro-Collins solution has been 
widely used for SCS with successful clinical results (Squifflet et al., 1981). 
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Hyperosmolar citrate (HOC) is a basic solution routinely used in the UK. It is less 
viscous than some other solutions and adequately flushes and cools the kidney 
(Wilson et al., 2007). It was developed to try to improve upon the Euro-Collins 
solution. Citrate replaces phosphate and mannitol replaces glucose.  
 
University of Wisconsin (UW) solution was developed by Belzer in the 1980s. It is 
currently the most widely used preservation solution and is considered to be the gold-
standard for SCS (Yuan et al., 2010). It contains metabolically inert substances, 
lactobionate and raffinose, to maintain the necessary osmotic concentration and HES 
as a colloid to prevent influx of water into the cell. ATP precursors (adenosine) are 
present for energy and oxygen free radical scavengers (glutathione and allopurinol) 
to attenuate IR injury.  
 
SCS with UW provides satisfactory short and long-term outcomes (Opelz & Döhler, 
2007). However, it does have high viscosity which can compromise the 
microcirculation (Tojimbara et al., 1997). It also has a high potassium concentration 
which can cause vasoconstriction and may contribute to the hyper-aggregation of 
HES (Morariu et al., 2003; Olschewski et al., 2008). It is also expensive and has 
fallen out of favour for the flushing of abdominal organs (McAnulty, 2010). 
 
A modified version of UW exists for HMP, Belzer Machine Perfusion solution 
(BMPS), where lactobionate is replaced with gluconate and the potassium 
concentration is reduced (Bessems et al., 2005; Pienaar et al., 1990). Many of the 
other HMP fluids have been developed based on this. 
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Histidine-Tryptophan-Ketoglutarate (HTK) solution was also introduced in the 1980s 
by Bretschneider, originally for use as a cardioplegic solution (Bretschneider, 1980). 
Histidine is present as a buffer, tryptophan for membrane stabilisation and 
ketoglutarate for anaerobic metabolism. HTK has a low viscosity which may allow for 
improved microcirculation (Maathuis, Leuvenink, & Ploeg, 2007; Mühlbacher, Langer, 
& Mittermayer, 1999). 
 
Comparative studies between HTK and UW for the SCS of kidneys had failed to 
consistently show superiority of either solution (Agarwal, Murdock, & Fridell, 2006; de 
Boer et al., 1999; Lynch et al., 2008; Roels et al., 1998). However, a recent 
retrospective multi-centre analysis demonstrated an increased risk of graft loss for 
cadaveric kidneys preserved by HTK compared to those stored in UW solution 
(Stewart et al., 2009). HTK is less expensive per litre than UW, but increased 
volumes of HTK are required (Mühlbacher et al., 1999). 
 
Celsior solution was originally developed for heart transplantation (Menasché et al., 
1994). It combines the osmotic efficacy of UW (lactobionate, mannitol) and the potent 
buffering ability of HTK (Yuan et al., 2010). In comparisons with UW, studies have 
demonstrated similar rates of DGF and graft survival (Marcén et al., 2005; Montalti et 
al., 2005; Nunes et al., 2007). 
 
Institute-George-Lopez (IGL-1) was developed more recently by a group in France. It 
contains polyethylene glycol which binds to cell and tissue surfaces, stabilising the 
underlying surfaces from cell interactions - this may modify donor tissue 
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immunogenicity and attenuate IR injury (Eugene, 2004). A reduction in DGF has 
been demonstrated when compared to kidneys stored in UW (Badet et al., 2005) but 
this was not repeated in a recently published multi-centre study (Codas et al., 2009). 
 
KPS-1® Kidney Perfusion Solution is a solution marketed by Organ Recovery 
Systems for use with their HMP machine - the LifePort© Kidney Transporter. This is 
the solution used throughout this study. It has the same composition as the machine 
solution produced by Belzer. The constituents of KPS-1® are shown below in table 
1.6: 
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Table 1.6: Constituents of KPS-1® 
 
Constituents Amount/1000mL Concentration mM 
Calcium chloride (dehydrate) 0.068g 0.5 
Sodium hydroxide 0.70g  
HEPES (free acid) 2.38g 10 
Potassium phosphate (monobasic) 3.4g 25 
Mannitol (USP) 5.4g 30 
Glucose, beta D (+) 1.80g 10 
Sodium Gluconate 17.45g 80 
Magnesium Gluconate (D (-) gluconic 
acid, hemimagnesium salt) 
1.13g 5 
Ribose, D (-) 0.75g 5 
Hydroxyethyl starch (HES) 50.0g n/a 
Glutathione (reduced form) 0.92g 3 
Adenine (free base) 0.68g 5 
Sterile water for injection (SWI) To 1000mL volume n/a 
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1.3.3 STATIC COLD STORAGE 
 
Static Cold Storage (SCS) is the most common storage method used for cadaveric 
kidneys in the UK and worldwide. Following initial cold flush at retrieval, to remove 
the blood and lower the temperature, kidneys are simply stored in preservation fluid 
within an ice-box. This has the advantage of being cheap and it requires no special 
equipment or training. 
 
The standard recommended temperature for cold storage is 4°C. Below these 
temperatures, freezing can occur which can cause coagulative necrosis upon 
reperfusion. Temperatures over 4°C in static storage conditions are not sufficient to 
suppress metabolism. Injury can result from depletion of ATP, accumulation of 
lactate and mitochondrial dysfunction (Henry & Guarrera, 2012). 
 
SCS has been invaluable in allowing the establishment of sustainable clinical 
transplant programmes (Calne et al., 1963). However, as the cold ischaemic time 
(CIT) increases during SCS, so does the risk of suffering from delayed graft function 
(Koning et al., 1997; Locke et al., 2007; Ojo et al., 1997; Peters et al., 1995; Schold 
et al., 2005) and subsequent graft failure (Locke et al., 2007; Meier-Kriesche, Schold, 
& Kaplan, 2004; Opelz & Döhler, 2007). Whilst early experiments with improved 
preservation solutions in the 1960s allowed SCS time to be extended beyond 24 
hours for kidneys (Collins, Bravo-Shugarman & Terasaki, 1969; Collins et al 1969), a 
safe limit of around 18 hours has been suggested more recently (Opelz & Döhler, 
2007). However, in the context of marginal organs, this is probably generous. 
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1.3.4 HYPOTHERMIC MACHINE PERFUSION 
 
Hypothermic Machine Perfusion (HMP) is a mechanical method of preservation 
during which cold preservation solution is actively pumped through the vasculature of 
the kidney during storage time. It is based upon the principle that devices can be 
designed to facilitate the replacement of blood in the circulation of an ex-vivo organ 
with specifically designed fluids to maximise the protective effects of hypothermia on 
the ischaemic tissue (Taylor & Baicu, 2010). Machine perfusion is not a new concept. 
It was equally in practice in the early days of transplantation but gradually lost favour 
due to a range of logistical and economic issues (Calne et al., 1963). Several factors 
have now led to a renewed interest in HMP as an alternative to SCS. 
 
Technology has improved since the early perfusion systems were developed. Belzer 
developed one of the first reliable, transportable HMP machines (figure 1.6) (Fuller & 
Lee, 2007) but the equipment was bulky and difficult to operate. 
 
Modern commercially available machines, such as the LifePort© Kidney Transporter 
1.0 (Organ Recovery Systems) or the Waters Medical Systems’ RM3 Renal 
Preservation System, are much smaller, easier to transport and, although some 
training is required, quite easy to use. 
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Figure 1.6: Transportable Renal HMP Machine Pioneered by Belzer 
 
 
Professor Belzer with the first 
‘transportable’ HMP machine 
 
 
Figure 1.7: LifePort© Kidney Transporter 1.0 (Organ Recovery Systems) 
 
Modern HMP machine 
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There is also increasing evidence of the benefits of HMP. It has been suggested that 
HMP achieves improved perfusion of the microvasculature along with improved 
removal of waste products and an increased ability to support oxidative metabolism; 
this may reduce tissue injury (Fuller & Lee, 2007). Evidence of benefit in clinical 
application continues to increase (Section 1.3.8) with particular value identified for 
marginal kidneys (Moers et al., 2009). Some have recommended HMP as the 
preferred storage for ECD and DCD kidneys (Kosieradzki & Rowiński, 2008). 
 
HMP also provides a unique opportunity for assessment of organ viability prior to 
transplantation. Accurate evaluation of allograft quality is essential to prevent 
unnecessary kidney discard, allow maximised donor-recipient matching and to plan 
appropriate peri-operative care. Viability assessment is even more important in the 
context of marginal organs where the most common concern is organ quality. The 
ability to evaluate potentially transplantable organs by machine in-vitro perfusion may 
significantly increase the number of organs available for use (Taylor & Baicu, 2010). 
HMP parameters, and/or biomarkers, may be able to indicate the extent of ischaemic 
injury and may have stronger predictive value for graft function than conventional 
clinical criteria alone (Polyak et al., 1997; Kosieradzki & Rowiński, 2008). 
 
HMP also permits pharmacological manipulation of the perfusate, for example, with 
cytoprotective or immune modulating drugs. There is also the possibility of providing 
metabolic support. One of the most commonly discussed additions is supplementary 
oxygen. Opinion on this particular addition is divided. Oxygen may have a protective 
effect of limiting mitochondrial damage and reducing the formation of oxygen free 
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radicals during reperfusion (Maathuis et al., 2007; Treckmann et al., 2009). Others 
have reported enhanced free radical production (Fuller, Gower & Green, 1988; 
Mcanulty & Huang, 1997). There is not a clear consensus on this type of injury. 
 
Some studies have implied that the use of HMP can safely allow longer storage times 
(Ciancio et al., 2010; Schold et al., 2005). This is of particular interest in this study, as 
a safe extension of CIT could have significant benefits in providing a safe and 
successful clinical transplant service. 
 
Some training is required to operate the perfusion machines, certainly more than is 
required to place an organ in SCS. However, the procedure is not difficult. There is 
also the initial cost associated with purchasing the machine and disposables with 
some questioning its cost-effectiveness when compared with SCS (Bond et al., 
2009). However, there is increasing evidence that HMP lowers DGF rates. Reducing 
dialysis requirements and hospital stay following the use of HMP could off-set 
perfusion costs (Wight et al., 2003a; Groen et al., 2012). 
 
There is a suggestion that to gain the most benefit from HMP, organs should be 
placed on the machine from retrieval (Irish & Katz, 2010). In the UK, retrieval teams 
do not have this resource available so kidneys are transported to the receiving centre 
in SCS prior to a decision to use HMP. It could be that the combination of techniques 
lessens the benefit from HMP (Hosgood & Nicholson, 2011), or differing ratios of 
HMP to SCS might have different effects. 
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The diagram below (figure 1.8) summarises the benefits of HMP and the possible 
underlying mechanisms: 
  
 
Figure 1.8: Schematic Summary of the Important Benefits of HMP for Clinical 
Transplantation (Reproduced from Henry & Guarrera, 2012) 
 
 
Outcome benefits are shown on the left side, mechanistic considerations on the right 
side 
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1.3.5 HMP MECHANISMS 
 
Although beneficial effects have been demonstrated using HMP, the mechanisms 
underlying these effects are poorly understood.  
 
One of the most simplistic contributing factors is likely to be the maintenance of renal 
vascular bed patency by the regulated flow (Yuan et al., 2010). However, there has 
been much debate over the years regarding the ideal type of flow provided by HMP 
and also the best perfusion pressure.  
 
Pumps in HMP machines were developed that produced either continuous or 
pulsatile flow. Whilst some studies demonstrated comparable results (Kozaki et al., 
1995; Kozaki et al., 2000) others have shown improved microcirculation and organ 
function using pulsatile perfusion for abdominal organs (Dutkowski et al., 1998; 
Fukae et al., 1996). It was hypothesised that pulsatile flow could overcome the initial 
opening pressure of the capillary bed without requiring continuous high pressure.  
 
High-pressure flow has been linked to endothelial injury and the development of 
oedema: this can reduce perfusion (Fuller & Lee, 2007; Gattone et al., 1985). 
Mechanical injury associated with HMP can be attenuated by using lower perfusion 
pressures and appropriate solutions (Cerra et al., 1977). The Newcastle group 
recommend perfusion pressures of less than 60mmHg (Balfoussia et al., 2012) whilst 
kidneys included in a large European multi-centre randomised control trial were all 
perfused at 30mmHg (Moers et al., 2009). 
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Pulsatile flow and HMP has been linked to the increased expression of endothelial 
protective genes (Boon & Horrevoets, 2009; Yuan et al., 2010). Of particular interest 
is the gene Kruppel-like factor 2 (KLF2), which may be responsible for the inhibition 
of pro-inflammatory responses as part of the innate immune system, which would 
otherwise cause endothelial damage (Tullius & Garcia-Cardena, 2009; Parmar et al., 
2006; Sebzda et al., 2008). KLF2 is also linked to the production of endothelial-
derived nitric oxide, a potent vasodilator, and the expression of anti-thrombogenic 
genes (Tullius & Garcia-Cardena, 2009). 
 
HMP is able to provide efficient delivery of nutrients and oxygen to support tissue 
metabolism and is able to do this over a prolonged period (Maathuis et al., 2007; 
Yuan et al., 2010).  It is also able to facilitate recovery of energy stores to maintain 
cellular processes (McAnulty, 2010). Interestingly, in porcine liver experiments using 
nuclear magnetic resonance (NMR) imaging, ATP levels were identifiable in HMP 
livers but not those stored by SCS (Changani et al., 1997). In addition to supply of 
nutrients, HMP may also improve the 'washout' removal to toxic metabolites (Yuan et 
al., 2010). 
 
 
1.3.6 HMP VIABILITY ASSESSMENT 
 
Accurate assessment of graft viability is essential to prevent unnecessary kidney 
discard, ensure ideal matching of donor and recipient and to plan post-operative 
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care. This is becoming increasingly important with the use of marginal organs and 
their higher risk of poor graft function.  
 
Whilst donor information, such as patient age, co-morbidity or terminal serum 
creatinine, along with kidney biopsy data can be useful, these methods have limited 
accuracy for prediction of graft outcomes (Jochmans & Pirenne, 2011; Louvar et al., 
2009). Predictive models have been developed using different combinations of these 
parameters some of which are in clinical use (Anglicheau et al., 2008; Cockfield et 
al., 2010; Munivenkatappa et al., 2008; Nyberg et al., 2003; Rao et al., 2009; Schold 
et al., 2005).  
 
Biomarkers measured in urine and perfusate have an advantage over biopsy data of 
being non-invasive and can be measured more frequently and objectively (Bhangoo 
et al., 2012). HMP is an ideal method of storage for biomarker assessment providing 
easy and safe access to perfusate and tissue during storage time. 
 
A recent review highlighted the biomarkers that have been assessed in urine and 
machine perfusate in regards to graft outcome (Bhangoo et al., 2012). Few studies 
were recent, and even fewer were deemed to be of good quality. Several perfusate 
markers were significantly associated with allograft outcomes; Lactate 
dehydrogenase (LDH), glutathione-S-transferase (GST) and aspartate transaminase 
(AST) were linked to DGF in the greatest number of studies. Further validation was 
recommended. Other markers investigated in kidney perfusate included glucose, 
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lactate, electrolytes, pH, gas pressures, osmolarity, redox active iron, 
malondialdehyde and total antioxidant status.   
 
Machine perfusion parameters, such as flow rate and vascular resistance, are 
generally accepted as good indicators of graft quality (Kozaki et al., 2000; Matsuno et 
al., 2000; Polyak et al., 2000). Kidneys showing the best functional outcome during 
HMP tend to have reduced intra-renal resistance during the perfusion process, 
implying that the machine improves renal micro-vascular circulation (Wight et al., 
2003a). Several studies, however, have warned of the dangers of using resistance 
values to determine kidney discard and although it has been demonstrated as an 
independent predictor of DGF, its predictive value is poor (Jochmans & Pirenne, 
2011; Jochmans et al., 2011; Sonnenday et al., 2003; de Vries et al., 2011).  
 
The Newcastle clinical viability protocol devised for HMP kidneys from DCD donors 
uses a combination of HMP parameters and a perfusate biomarker. It requires a 
perfusion flow rate of 0.4mL/min/100g/mmHg or more and a perfusate GST 
concentration of less than 100 IU/L/100g renal mass (Navarro et al., 2008). Other 
similar protocols also exist (Matsuno et al., 2006). 
 
Despite considerable interest in various indicators and markers of graft quality, few 
are used routinely in clinical practice, and no single biomarker or parameter has yet 
proven to be definitive. 
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1.3.7 HMP PHARMACOLOGICAL MANIPULATION 
 
In addition to viability assessment during HMP time, there is also the opportunity to 
modify the perfusate with various pharmacological agents.  
 
Several groups have studied the use of prostaglandin-1 (PGE1) added to the 
perfusate. PGE1 may act to stabilise endothelial cell membranes, inhibit platelet 
aggregation that can cause microvascular thrombi and attenuate neutrophil 
sequestration and degranulation (Fantone & Kinnes, 1983; Schlondorff, Yoo, & 
Alpert, 1978). Other studies have cited its role in ameliorating mitochondrial 
ischaemic injury and reducing release of calcium ions into the perfusate as its 
beneficial mechanism (Polyak et al., 2000; Polyak et al., 1999). Its use with HMP has 
been shown to markedly improve early graft function compared with SCS (Polyak et 
al., 1999).  
 
Other groups have examined the use of nitric oxide, an important factor in 
maintaining vascular endothelium. Its addition has been shown to be beneficial in 
experimental models of kidney transplantation (Erkasap & Ates, 2000). 
 
Machine perfusate has also been modified with nitroglycerin and polyethylene 
glycolsuperoxide dismutase - these additions to Belzer Machine Perfusion Solution 
(BMPS) have been shown to improve DGF when compared to the solution alone 
(Guarrera et al., 2004). Phentolamine mesylate, hydralazine and calcium channel 
blockers have also been used experimentally (Henry & Guarrera, 2012). 
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Manipulation of the perfusate during HMP may allow modification of injuries acquired 
during the retrieval and transport period with the potential to improve graft outcomes. 
 
 
1.3.8 HMP CLINICAL OUTCOMES 
 
There is an increasing body of evidence to support the benefits of HMP over SCS as 
the preservation method of choice for cadaveric renal transplantation. However, early 
evidence was equivocal. 
 
Initial studies comparing HMP to SCS failed to show consistent benefits of either 
storage method in terms of DGF or graft survival (Barber et al., 1988; Burdick et al., 
1997; Clark et al., 1974; Halloran & Aprile, 1987; Light et al., 1995; Sellers et al., 
2000). In the studies that showed reduced DGF with HMP, the possibility of reduced 
costs associated with dialysis requirements and hospital stay was also suggested. 
However, many of these studies were retrospective, non-randomised and compared 
a different donor and recipient profile compared to the current transplant population. 
 
Some of the earlier studies compared paired kidneys from the same donor, one 
stored in SCS and the other by HMP, in an attempt to control for donor factors. One 
of these studies found a significant decrease in post-transplantation dialysis in 
kidneys undergoing HMP, but only 29 kidney pairs were analysed (Alijani et al., 
1985). Two larger studies of kidney pairs failed to show any difference in dialysis 
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rates post-transplantation in the different storage groups (Merion et al., 1990; Mozes 
et al., 1985). 
 
Recent studies have been better powered and more accurately represent the current 
situation regarding marginal donors, more challenging recipients and advances in 
transplantation, such as immunosuppression.  
 
In 2003, a meta-analysis and systematic review demonstrated a 20% reduction of 
DGF with the use of HMP (Wight et al., 2003b). In supporting studies, not only was 
DGF reduced, but HMP led to an increased utilisation of ECD kidneys (Matsuoka et 
al., 2006; Schold et al., 2005). It was also noted that by decreasing DGF, overall 
costs should consequently decrease. This was supported by a review of cost-
effectiveness (Wight et al., 2003a). 
 
A recent study lent strong support to the beneficial effects of HMP over SCS. Moers 
et al (as part of the Eurotransplant trial) conducted the first multi-centre, prospective, 
randomised clinical trial comparing 336 consecutive deceased donors from which 
one kidney was stored in SCS and the paired kidney preserved by HMP (Moers et 
al., 2009). The study demonstrated a reduced DGF rate for HMP kidneys compared 
to SCS (20.8% v 26.5%) and an improved 1-year graft survival (94% v 90%). Similar 
findings were reported in smaller studies (Kwiatkowski et al., 2007; Moustafellos et 
al., 2007; Polyak et al., 2000; Shah et al., 2008a).  
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The Eurotransplant trial group later reported on subgroup analysis and long-term 
outcomes. They found a significantly reduced rate of DGF and an improved 1-month 
graft survival in DCD kidneys stored by HMP rather than SCS (Jochmans et al., 
2010). In terms of 3-year graft survival, this was better in HMP kidneys, particularly 
for those from ECD donors. A number of studies have also demonstrated improved 
outcomes with HMP for ECD donors (Matsuoka et al., 2006; Stratta et al., 2006; 
Stratta et al., 2007; Sung et al., 2008) along with lower costs when compared to SCS 
(Buchanan, et al., 2008). However, whilst 3-year graft survival was better for HMP 
kidneys from DBD donors, the initial improved DGF rates for DCD kidneys did not 
translate into an improved long-term graft survival (Moers et al., 2012). 
 
Interestingly, a UK multi centre study conducted at a similar time to the 
Eurotransplant trial, demonstrated conflicting results for DCD kidneys. Watson et al 
examined DCD kidneys only and found that HMP had no benefit over SCS in the 
reduction of DGF (Watson et al., 2010).  
 
This was surprising given the evidence from the Eurotransplant trial and other 
supporting studies (Moustafellos et al., 2007; Reznik et al., 2008). Differences 
between the UK and European trial may have arisen for several reasons. The rate of 
DGF was significantly lower in the SCS arm of the UK trial (56%) than in the SCS 
arm of the European trial (70%). There was also a variation in the number and 
geographical spread of centres involved, possible differences in blinding and different 
reporting of ischaemic times. Importantly, the UK trial placed kidneys on HMP 
following transport in SCS whereas the European trial kidneys were placed on HMP 
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at retrieval. It has been suggested that kidneys may benefit from HMP only if used for 
the entire preservation period (Irish & Katz, 2010). 
 
Goldstein et al presented a retrospective analysis of 1067 deceased donor kidneys at 
the American Transplant Congress in 2011 (Goldstein et al., 2011). They examined 
the ratio of SCS to HMP where combined storage was used. They found that DGF 
directly correlated with increasing SCS time and that detrimental effects of prolonged 
CIT were ameliorated with increasing the HMP component of CIT. They suggested 
that employing HMP early after recovery would reduce the negative effects of CIT 
and increase the utilisation of kidneys with prolonged CIT.  
 
Other studies have suggested the benefits of HMP for longer preservation times. 
Equivocal or reduced rates of DGF have been demonstrated with HMP where the 
HMP group has had a longer CIT than the SCS group (Ciancio et al., 2010; 
Kwiatkowski et al., 2007; Lodhi et al., 2012; Schold et al., 2005). Ciancio also found 
that HMP pump times of over 24 hours were associated with significantly lower rates 
of biopsy-proven acute rejection (BPAR) and favourable graft survival outcomes. 
They suggested that 'in the presence of relatively short SCS times, use of machine 
perfusion provides a truer, more successful form of hypothermic preservation and 
superior early outcomes, even with pump times as long as 48 hours'. A recent 
publication suggests however that although HMP is associated with reduced DGF, it 
is still important to minimise CIT in deceased donor transplants (Gill et al., 2014). 
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Overall, the evidence has swung in favour of HMP, rather than SCS, as the preferred 
storage method for deceased donor kidneys. HMP clearly reduces the risk of DGF in 
deceased donor kidneys, particularly in the ECD group, and long-term outcomes look 
promising. Some controversy still remains over the use of HMP in DCD organs, 
particularly in terms of graft survival. Although HMP equipment and training is 
associated with an initial cost, evidence clearly suggests reduced overall costs 
associated with reduced DGF and shorter hospital stay. 
 
Still of interest is the ability of HMP to extend CIT without detriment to graft function. 
The ideal duration of HMP, and the ratio of it to SCS, is yet to be established, as is 
the maximum safe HMP time. Safe extension of CIT could have a significant impact 
on clinical practice. 
 
 
1.3.9 OTHER PRESERVATION METHODS 
 
Alternatives to SCS and HMP are warm/normothermic perfusion and oxygen 
persufflation. These are briefly summarised below: 
 
Warm/Normothermic Perfusion 
 
Early experiments in organ perfusion were often conducted at normothermic or warm 
temperatures. However, its use was limited due to available perfusates and problems 
with thrombus formation, vascular damage and infection (Fuller & Lee, 2007). The 
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benefits of cold temperatures were beginning to be discovered, so storage methods 
focused on hypothermic techniques. With the increased use of marginal organs, 
which are particularly susceptible to cold ischaemic damage (Saba, Munusamy, & 
Macmillan-Crow, 2008), there has been a recently renewed interest in perfusion at 
warmer temperatures. 
 
The main aim of warmer perfusion temperatures is to maintain the kidney in a near 
normal physiological state providing oxygen and nutrients to support aerobic 
metabolism. Table 1.7 summarises the proposed advantages and disadvantages of 
normothermic preservation. In addition to the disadvantages listed in the table, the 
current techniques of warm/normothermic perfusion demand an additional human 
resource requirement. 
 
Table 1.7: Proposed Advantages  & Disadvantages Of Normothermic Preservation 
(Reproduced from Hosgood & Nicholson, 2011) 
 
Advantages Disadvantages 
Aerobic metabolism Technical support/equipment 
Restoration of function Logistics of transportation 
Avoid/reduce hypothermic injury Cost 
Organ assessment  
Resuscitation  
Regeneration and repair  
Treatment and modification  
  71 
Before retrieval, organs are normally perfused in-situ with cold preservation solution. 
However, some benefit has been shown with the use of extracorporeal membrane 
oxygenation (ECMO) at normal body or room temperature prior to cold flush. A study 
using 60 minutes of normothermic recirculation in DCD donors before cold flush 
showed a reduced rate of DGF and PNF compared to standard cooling (Valero et al., 
2000). Similar results have been reproduced (Gravel et al., 2004) and there have 
been promising results with normothermic recirculation and long-term graft survival 
(Lee et al., 2005).  
 
It was demonstrated in the 1970s in an animal model that warm flush prior to cold 
flush limits the vasoconstrictive effect of hypothermia (Das et al., 1979). Flushing rat 
kidneys with normothermic UW solution was also shown to be superior to cold flush 
with other solutions (Hughes et al., 1996). More recently, no detrimental effect was 
found in porcine kidneys flushed with a novel non-phosphate buffered solution called 
AQIX (AQIX Ltd, London,UK) at 32°C  (Kay et al., 2011). This solution has sufficiently 
maintained viability in porcine kidneys flushed and statically stored for 2 hours at 32 
32°C (Kay et al., 2007). 
 
There has been some evidence of the usefulness of combined hypothermic and 
normothermic techniques. Canine kidneys were preserved for a total of 144 hours by 
a combination of autologous blood at normal body temperatures and hypothermic 
perfusion (van der Wijk et al., 1980). In a similar study, perfusion time was extended 
to 6 days (Rijkmans, Buurman, & Kootstra., 1984). Periods of warmer perfusion 
seemed to 'resuscitate' the kidneys and this was supported by other experimental 
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trials on canine kidneys (Maessen et al., 1989a, 1989b). These extended 
preservation times are not currently required in clinical practice but kidneys with a 
higher injury burden, such as DCD and ECD kidneys, may benefit from this type of 
repair. 
 
Further work with a canine autotransplant model demonstrated that a period of ex-
vivo normothermic perfusion could allow functional recovery following severe warm 
and cold ischaemic injury and that prolonged periods of normothermic preservation 
were more beneficial than hypothermic techniques (Brasile et al., 2005; Brasile et al., 
2002). Normothermic perfusion of porcine kidneys demonstrated enhanced renal 
blood flow during reperfusion and a porcine transplant model was developed to 
demonstrate that this technique could be safely and feasibly applied to clinical 
practice (Bagul et al., 2008; Hosgood et al., 2011b). 
 
Since then, promising results have been achieved clinically. The Leicester group 
reported on the first case of ex-vivo normothermic renal transplant perfusion in man 
(Hosgood & Nicholson, 2011b). Each kidney was retrieved from an ECD following 
cardiopulmonary arrest with a significant period of warm ischaemia; one kidney was 
stored in SCS and the other underwent normothermic perfusion. The kidney 
preserved by normothermic perfusion exhibited superior early graft function. This was 
followed up by the first in-man clinical study comparing 18 ECD kidneys that 
underwent normothermic perfusion prior to transplantation to a control group of SCS 
kidneys (Nicholson & Hosgood, 2013). A reduced rate of DGF was shown in the 
normothermic group and the technique was deemed to be feasible and safe. 
  73 
The main disadvantages of systems that use warm perfusion temperatures are their 
complexity and the level of supervision required. This makes them less attractive for 
use in the clinical setting with the current available technology. This is likely to 
change in the future, with advances in available systems and the need to improve 
preservation for marginal organs. 
 
Oxygen Persufflation 
 
This technique uses gaseous oxygen that is bubbled through the vasculature of an 
organ. The gas then escapes through small perforations in the organ's surface (Lee 
& Mangino, 2009). Oxygen Persufflation (OP) was first tested on canine kidneys and 
has also undergone pilot clinical studies in kidney and liver preservation (Rolles, 
Foreman, & Pegg, 1989; Sachweh et al., 1972; Stegemann et al., 2009). Most work 
using this technique has been performed on animal models of kidney and liver 
perfusion, where it has shown some benefit in treating DCD organs (Fischer et al., 
1978; Lee & Mangino, 2009; Rolles, Foreman, & Pegg, 1984). 
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1.4 OVERALL AIMS 
 
Aims 
 
The aims of this study were as follows: 
 
1. Assessment of Clinical Application 
 
To examine the effects of the introduction of HMP into existing clinical practice on the 
renal surgery unit at University Hospitals Birmingham (UHB). Of particular interest 
was outcome data compared to kidneys stored by SCS and the ability of HMP to 
safely extend CIT to allow improved management of logistics. 
 
 
2. Analysis of HMP Perfusate 
 
Could analysis of HMP perfusate predict graft outcome following kidney 
transplantation? Perfusate samples were collected during HMP of DD kidneys for 
analysis by Nuclear Magnetic Resonance (NMR) imaging (metabolomics). The aim of 
which was to interrogate the metabolic profile of kidney perfusate during HMP and 
identify any differences between the perfusate of DGF and IGF kidneys which might 
aid in prediction of outcome. If possible, harmful processes in the metabolism of DGF 
kidneys would be identified. 
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3. Development & Assessment of a Porcine Model 
 
In order to test hypotheses and modify the metabolism occurring during HMP, an 
animal model needed to be developed. A porcine model representing DCD 
conditions was designed and perfusate and histology analysed to ascertain the 
validity of the model. 
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CHAPTER TWO: ASSESSMENT OF CLINICAL UTILITY 
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2.1 BACKGROUND 
 
Cold Ischaemic Time (CIT) is recognised as a major factor influencing early post-
transplant graft function (Irish et al., 2003; Koning et al., 1997; Lee et al., 2000; Ojo et 
al., 1997; Peters et al., 1995). As CIT increases during SCS so does the risk of 
subsequent DGF and graft failure. It is often this consideration that drives the 
logistics of clinical transplantation. There are many other factors, however, that 
demand equal consideration and optimisation if the best outcomes in renal 
transplantation are to be achieved - particularly in an era when DD renal 
transplantation is increasingly complex.  
 
As previously discussed, kidneys available for transplantation have become 
increasingly marginal (Cohen et al., 1997; Cohen et al., 2005). A growing number of 
ECD kidneys are being utilised and these, along with DCD kidneys, are associated 
with an increased risk of delayed graft function (DGF) when compared to SCD 
kidneys (Audard et al., 2008; Metzger et al., 2003b; Ojo et al., 2001; Port et al., 
2002). 
 
The recipient population of DD kidneys is also more challenging. Recipients are 
frequently older with significant comorbidity, often previously considered 
inappropriate for transplantation (Ojo et al., 2001; Forsythe, 2013}. This is 
exacerbated by the observation that many patients with less significant co-morbidity 
now receive early living donor transplants. In consequence, it is now common 
experience that patients waiting for a DD transplant have no living donor option and 
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long histories of dialysis with its associated complications. Patients may also 
deteriorate between listing and admission for transplantation (Danovitch et al., 2002). 
Optimising these patients during an emergency admission for renal transplantation 
can be problematic and the need for new investigations or interventions can extend 
CIT. 
 
DD organ transplantation is frequently undertaken outside of normal working hours in 
an attempt to minimise CIT. In this time-critical situation, recipient issues may receive 
less attention than is ideal. Furthermore, in an attempt to minimise CIT, transplants 
may be performed on emergency operating lists staffed by general teams with limited 
experience of managing the specific needs of renal failure patients (Seow, Riad, & 
Dyer, 2006; Shaw et al., 2012). Such compromise carries the inherent risks that care 
may fall below a level of excellence. 
 
Means by which acceptable extensions in CIT could be achieved without impacting 
upon early graft function would therefore be of value. Against this background, the 
role of Hypothermic Machine Perfusion (HMP) has been investigated as a tool by 
which this might be obtained.  
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2.1.1 AIMS 
 
The objective for this section of the study was to examine the effects of the 
introduction of HMP into existing clinical practice on our renal surgery unit. In 
particular: 
 
Could graft function be maintained or even improved during longer cold ischaemia 
times using HMP? 
 
Could we simultaneously acquire the benefits of an optimised recipient with improved 
use of logistics and expertise? 
 
 
2.1.2 SETTING 
 
This assessment of clinical utility was performed in a large teaching hospital 
providing a regional transplant service to a mixed demographic population of over 6 
million. Approximately 190 kidney transplants are performed annually, 120 of which 
are DD transplants.   
 
After recovery, DD kidneys arrive at our unit in SCS. Emergency operating theatre 
space is available on a competitive basis with other specialties and consequently it is 
not always possible to ensure a short CIT. Furthermore, emergency teams often 
consist of staff who do not regularly deal with renal failure patients. Incoming 
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transplant recipients have multifaceted medical problems and may have been 
managed at peripheral dialysis units. Accordingly, they may need considerable pre-
operative re-evaluation and preparation that may include peri-operative dialysis.  
 
As a compromise to 24-hour operating theatre availability, the unit has a dedicated 
renal transplant theatre team available between 8am and 8pm. Where possible such 
complex renal cases are directed towards this resource.  
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2.2 METHODS 
 
2.2.1 PATIENT RECRUITMENT 
 
All DD kidneys accepted for transplantation were included except for paediatric 
cases, which are performed on a different site, and kidneys transplanted as part of a 
combined liver or heart transplant procedure, which involve combined care. 
 
 
2.2.2 KIDNEY PRESERVATION 
 
All DD kidneys arrive on the unit in SCS. In this study, as in normal departmental 
practice, the decision to transfer to HMP was based on donor - recipient readiness 
and theatre availability. If the predicted time to theatre was within elective hours (8am 
to 8pm), allowing transplant to take place in the dedicated renal transplant theatre, 
the kidney was transplanted from SCS. If the predicted time to theatre was outside of 
these hours (8pm to 8am) the kidney was transferred to HMP and then transplanted 
at the earliest opportunity on the next available dedicated transplant list.  
 
Machine Perfusion 
 
All HMP kidneys were preserved using the Lifeport© Kidney Transporter 1.0 from 
Organ Recovery Systems. Perfusion pressure was set at 30mmHg and not altered 
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during perfusion time. This setting is recommended by the manufacturer and used in 
the Eurotransplant trial (Moers et al., 2009).  
 
The machine was prepared for each case by filling the insulated ice container with 
ice and cold water. The disposable perfusion circuit was then loaded into the 
machine and fitted into the pump mechanism. The organ tray was filled with 1 litre of 
cold KPS-1® (kidney perfusion solution). The machine was then set to 'flush' to 
ensure any air bubbles were removed from the tubing. When complete, the machine 
was 'primed' ready for use. 
 
Meanwhile, the kidney was prepared as standard for a transplant procedure. This 
ensures that the vessels are clearly visible. Depending on the arrangement and 
number of arteries on the donor kidney, the kidney was attached to an appropriate 
cannula.  
 
The kidney was then transferred into the organ tray and connected to the tubing via 
the cannula. Perfusion was commenced ensuring there were no leaks present. 
Sterile techniques were used throughout.  
 
 
2.2.3 DATA COLLECTION & OUTCOME MEASURES 
 
Clinical data were collected prospectively including donor and recipient 
demographics, CIT, operative factors and post-operative outcomes. HMP parameters 
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(flow, resistance, pressure, temperature) were also recorded throughout perfusion 
time. 
 
The primary outcome measure was DGF (defined as the requirement for dialysis, for 
any reason, within the 1st post-operative week following kidney transplant). 
 
Secondary outcomes were CIT, timing of surgery, HMP parameters, complications, 
length of hospital stay and post-operative creatinine measurements. 
 
 
2.2.4 STATISTICAL ANALYSIS 
 
Data were analysed using GraphPad Prism 6.0c (GraphPad Software, La Jolla 
California USA) and IBM SPSS 19 (IBM Corp. Armonk, NY). Continuous variables 
were expressed as arithmetic or geometric means with 95% confidence intervals, or 
as medians and interquartile ranges, as appropriate. Comparisons of demographics 
and complication rates between HMP and SCS kidneys were made using Mann-
Whitney tests or Fisher's Exact test for continuous and categorical data respectively.  
The trends over time in resistance and creatinine levels were assessed using 
Repeated Measures ANOVA models, with the dependent variables being log10-
transformed where necessary. Throughout the analysis, P<0.05 was considered to 
be indicative of statistical significance. 
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2.3 RESULTS 
 
During the observation period (January 2012 - December 2013 inclusive) 196 
cadaveric kidneys were accepted to the unit for transplantation.  
 
Kidneys transplanted as part of a combined heart or liver transplant procedure were 
excluded (n=5). Three kidneys were discarded due to severe atherosclerosis of the 
renal artery with an adverse donor history, a hypoplastic cystic kidney and 
inadequate flush at recovery. No kidneys were discarded based on machine 
parameters. Paediatric cases were also excluded (n=13). 
 
Of the 175 kidneys included in the study, 74 (42%) underwent HMP and 101 (58%) 
were transplanted from SCS. These two groups are compared throughout. 
 
 
2.3.1 DONOR & RECIPIENT DEMOGRAPHICS 
 
Donor and recipient demographics for the two storage groups are shown in table 2.1.  
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Table 2.1: Donor and recipient demographics 
Demographic HMP (n=74) SCS (n=101) P Value 
Donor    
Male gender 42 (57%) 47 (47%) 0.221 
Median age (IQ range) 52 (40-60) 51 (35-61) 0.831 
CMV +ve 32 (43%) 49 (49%) 0.541 
DCD 9 (12%) 26 (26%)  0.035* 
ECD 27 (36%) 35 (35%) 0.873 
Marginal 34 (46%) 55 (54%) 0.287 
Recipient    
Male gender 47 (64%) 62 (61%) 0.875 
Median age (IQ range) 51 (44 - 57) 50 (39-57) 0.423 
Ethnicity:   British 
                  Asian 
                  Black 
                  Other 
45 (61%) 
16 (22%) 
9 (12%) 
4 (5%) 
48 (48%) 
33 (33%) 
6 (6%) 
14 (14%) 
 0.041* 
Virology:    CMV+ 
                  HAV+ 
                  HBV cAb+ 
                  HBV sAb+ 
                  HCV Ab+ 
                  HIV+ 
38 (51%) 
10 (14%) 
6 (8%) 
1 (1%) 
1 (1%) 
1 (1%) 
70 (69%) 
20 (20%) 
7 (7%) 
0 (0%) 
1 (1%) 
2 (%) 
 0.019* 
0.315 
0.778 
0.423 
1.000 
1.000 
Dialysis:     HD 
                  PD 
                  Pre 
48 (65%) 
21 (28%) 
5 (7%) 
68 (67%) 
27 (27%) 
6 (9%) 
0.967 
 
 
Previous transplant ≥1 8 (11%) 8 (8%) 0.599 
PRA level >5% 32 (43%) 34 (34%) 0.210 
0.0.0 mismatches 11 (15%) 10 (10%) 0.352 
Immunosuppression standard 65 (88%) 94 (93%) 0.291 
 
ECD = defined as age >60 or 50-59 with 2 or more of hypertension, intracranial cause of death, creatinine >132, Marginal = 
DCD or ECD, Standard immunosuppression: Basiliximab, Tacrolimus, Mycophenolate mofetil, Prednisolone. Data reported as: 
"Median (Quartiles)" or "N (%)", with p-values from Fisher's exact tests or Mann-Whitney tests, as appropriate  *Significant at p 
< 0.05 
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The two groups were generally well matched, although the HMP group had 
significantly lower rates of DCD kidneys (12% vs. 26%, p=0.035) and less recipients 
who were cytomegalovirus (CMV) positive (51% vs. 69%, p=0.019). There was also a 
difference in recipient ethnicity between the two groups (p=0.041), with increased 
numbers of Asian recipients in the SCS arm. 
 
 
2.3.2 DELAYED GRAFT FUNCTION (DGF) 
 
DGF was the most frequently occurring graft complication with 67 transplant 
recipients overall (38%) requiring dialysis within the first week. Twenty HMP kidneys 
suffered from DGF (27%) compared to 47 (47%) in the SCS group (p=0.012).  
 
For donation after brain death (DBD) kidneys only, 15 of the 65 (23%) kidneys in the 
HMP group developed DGF compared to 30 of 75 (40%) kidneys in the SCS group 
(p=0.046).  
 
For DCD kidneys only, 5 of 9 (56%) kidneys in the HMP group developed DGF 
compared to 17 of 26 (65%) in the SCS group (p = 0.698). 
 
These findings are summarised in the table 2.2: 
 
 
 
  87 
Table 2.2: Delayed Graft Function by Donor Type and Storage Group 
 
Kidney Group 
DGF in HMP Group 
(Total 74) 
DGF in SCS Group 
(Total 101) 
P Value 
All 20 (27%) 47 (47%) 0.012* 
DBD only 15 (23%) 30 (40%) 0.046* 
DCD only 5 (56%) 17 (65%) 0.698 
 
P values: Fischer's Exact 2-tailed test 
 
The median duration of DGF, from operation to the last dialysis session, was similar 
for both storage groups (p=0.628). For both groups the duration was 5 days with an 
IQ range of 2.25–6.75 and 2.00–8.50 for HMP and SCS respectively. The median 
number of dialysis sessions required was identical across the two groups (IQ range 
1.00-3.00 and IQ range 1.00–5.00 for HMP and SCS respectively). 
 
 
2.3.3 COLD ISCHAEMIC TIME AND TIMING OF SURGERY 
 
Overall, the median CIT in the HMP group was 23.85 hours (IQ range 19.30–26.62) 
which was significantly longer than the median of 13.00 hours (IQ range 11.79–
15.36) in the SCS group (p=<0.0001).  
 
For DBD kidneys only, the median CIT in the HMP group was 24.18 hours (IQ range 
20.73-26.93) which was significantly longer than the median of 13.32 hours (IQ range 
10.66-16.13) in the SCS group (p=<0.001). 
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For DCD kidneys only, the median CIT in the HMP group was 16.60 hours (IQ range 
13.27-26.53) which was significantly longer than the median of 12.72 hours (IQ range 
12.00-14.04) in the SCS group (p=<0.0070). 
 
This is represented in Figure 2.1.  
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Figure 2.1: Cold Ischaemic Time by Donor Type and Storage Group 
 
All Kidneys  
 
 
DBD Kidneys Only  
 
 
DCD Kidneys Only 
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In the HMP group, 58 of 74 kidneys (78%) were transplanted during elective hours 
(8am to 8pm) which was significantly more than the 58 of 101 kidneys (57%) in the 
SCS group (p = 0.006).   
 
 
2.3.4 HMP PARAMETERS 
 
Overall, kidneys spent a median of 58% (IQ range 48–64) of their total CIT 
undergoing HMP. The median time of HMP during CIT was 14.5 hours (IQ range 
9.75–15.75). Perfusion pressure was constant at 30mmHg. Temperature remained at 
or below 4°C.  
 
HMP kidneys exhibiting IGF had a significantly higher proportion of HMP time within 
their total CIT with a median of 59% (total range 13-79%) compared to 46.5% (total 
range 13-77%) for DGF kidneys (figure 2.2). 
 
Figure 2.2: Proportion of HMP Time During CIT for Storage Groups 
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Changes in flow and resistance during machine perfusion mostly occurred within the 
first 60 minutes. An example of this can be seen in figure 2.3 below.  
 
Figure 2.3: LifePort Kidney Transporter Case Report Showing Machine Parameters 
 
These graphs illustrate the machine parameters that are recorded during perfusion 
time. These are systolic and diastolic perfusion pressures (mmHg), flow (mL/minute), 
resistance (mmHg/mL/min) and the temperature within the ice and the ‘trap’ which 
contains the kidney (°C). The machine will alarm and halt perfusion if the temperature 
rises above 7°C. Data can be recorded for a 48-hour period. 
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Overall, flow increased from a median of 53 mL/min (IQ range 39.5–76.0) to 100 
mL/min (IQ range 81.0–128.5). Resistance decreased from a median of 0.48 
mmHg/mL/min (IQ range 0.33–0.66) to 0.22 mmHg/mL/min (IQ range 0.18-0.29).  
 
A repeated measures ANOVA model found that, whilst the change in resistance over 
time was significant (p=<0.001) reflecting the large decline in resistance over the first 
hour, there was no significant difference in resistance between immediate graft 
function (IGF) or DGF kidneys (p=0.827). The interaction term in the model was also 
non-significant (p=0.841) hence there is no evidence that the trend in resistance over 
time is related to DGF (figure 2.4). 
 
Figure 2.4: Repeated Measures ANOVA Model for Change in Resistance During 
HMP Time in IGF & DGF Kidneys 
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2.3.5 COMPLICATIONS & LENGTH OF STAY 
 
There was one recipient death in the HMP group due to a cardiac event. Two of the 
175 patients developed Primary Non-Function (PNF), one of which required graft 
excision. These were both in the SCS group. Ten patients overall suffered graft loss 
(HMP n=5, SCS n=5): vessel thrombosis (n=7), renal vein tear (n=1), PNF (n=1) and 
graft failure of unknown cause (n=1).  
 
Table 2.3 provides a summary of other in-patient complications across both patient 
cohorts.  
 
Table 2.3: In-patient Complications Following DD Renal Transplantation 
 
Complication 
Overall 
(n=175) 
HMP 
(n=74) 
SCS 
(n=101) 
P Value 
Respiratory Infection 12 (7%) 3 (4%) 9 (9%) 0.243 
Diarrhoea/Ileus 10 (6%) 4 (5%) 6 (6%) 1.000 
Bleeding* 9 (5%) 5 (7%) 4 (4%) 0.497 
NODAT 8 (5%) 1 (1%) 7 (7%) 0.141 
Cardiac dysrhythmia 5 (3%) 0 (0%) 5 (5%) 0.074 
Wound infection/ 
Superficial dehiscence 
4 (2%) 2 (3%) 2 (2%) 1.000 
Hydronephrosis** 4 (2%) 2 (3%) 2 (2%) 1.000 
Abdominal collection** 3 (2%) 1 (1%) 2 (2%) 1.000 
DVT/PE 2 (1%) 2 (3%) 0 (0%) 0.177 
Drug Reaction 2 (1%) 1 (1%) 1 (1%) 1.000 
 
Data reported as: "N (%)", with p-values from Fisher's exact tests, * requiring further surgery or transfusion, ** Requiring 
intervention 
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Median length of in-patient stay was 9 days in both groups (IQ range 7-12 and 8-14 
in the HMP and SCS groups respectively)(p=0.310). 
 
 
2.3.6 POST-OPERATIVE CREATININE 
 
Geometric mean creatinine levels for HMP kidneys were 134 µmol/L, 144 µmol/L and 
154 µmol/L at 3, 6 and 12 months respectively. This compared to levels of 136 
µmol/L, 136 µmol/L and 138 µmol/L in the SCS group (Figure 2.5). A repeated 
measures ANOVA model found that that these values neither differed between the 
groups (p=0.717), nor over time (p=0.594), and that this lack of a significant trend 
over time was common to both groups (interaction p=0.489). 
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Figure 2.5: Repeated Measures ANOVA Model for Post-operative Creatinine in 
HMP & SCS Kidneys 
 
 
 
 
2.3.7 HISTOLOGY 
 
Of the 74 HMP kidneys, 17 (23%) underwent a transplant biopsy within the first 
month of the procedure compared to 26 (26%) from the SCS group. Biopsies are 
performed on clinical indication rather than being protocol driven. Results are shown 
in table 2.4. 
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Table 2.4: Histology of Post-transplant Kidney Biopsies 
 
Biopsy Finding HMP (17) SCS (26) P value 
No rejection 12 (70%) 14 (53%) 0.35 
Borderline 1 (6%) 2 (8%) 1.00 
Rejection 2 (12%) 8 (31%) 0.27 
Inadequate sample 2 (12%) 2 (8%) 1.00 
 
Fisher's Exact 2-tailed test 
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2.4 DISCUSSION 
 
DD renal transplantation is a process with many variables relating to the donor 
kidney, recipient and the hospital environment. Whilst CIT has traditionally been 
regarded as the most significant factor influencing post-transplant outcome, the 
growing complexity of DD transplantation now mandate that other factors should be 
given equal consideration. 
 
 
2.4.1 DONOR & RECIPIENT CONSIDERATIONS 
 
Growing transplant waiting lists have driven the increased use of higher risk ECD and 
DCD organs, despite their greater risk of poor initial graft function when compared to 
SCD kidneys (Metzger et al., 2003b; Ojo et al., 2001; Port et al., 2002). Similarly, 
recipients have become more complex with live donor transplantation selecting out 
less co-morbid patients; those who receive pre-emptive grafts or have shorter 
periods of time on dialysis. Inevitably, the higher-risk patients remain on the DD 
waiting list. 
 
Ensuring that complex recipients of DD kidneys are suitable for surgery can be 
difficult. They often require re-evaluation and additional preparation on admission to 
ensure safe surgery. The combined responsibility of attending to increasingly intricate 
kidney and recipient factors may prolong CIT, increasingly into out-of-hours operating 
time. This compounds an already apparent paradox; living donor recipients, with 
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lower levels of co-morbidity, are transplanted on elective lists with the highest level of 
expertise available. More complex DD recipients are invariably managed outside of 
normal working hours by emergency teams with variable experience of the 
anaesthetic and operative management of complex renal failure patients. In the UK, 
NCEPOD (National Confidential Enquiry into Peri-operative Deaths) reports have 
clearly demonstrated that patients undergoing surgery under such circumstances 
experience a less favourable outcome (Campling, Devlin, & Hoile, 1997; Cullinane, 
2003) . 
 
This being the case, it would appear evident that to achieve the highest standards of 
care either the level of expertise in 'out-of-hours' operating must be upgraded to 
equal that provided for our living donor recipients or DD renal transplantation must be 
an 'in hours' procedure. The former is difficult: providing the highest level of expertise 
round-the-clock, 365 days of the year poses a problem due to the finite limitations on 
human and financial resources. Moving renal transplantation into elective hours 
would reconcile some of the logistic issues but would only be acceptable if CIT could 
be prolonged without detriment to the kidney. 
 
 
2.4.2 USE OF HMP & CIT 
 
In this study, a dedicated renal transplant theatre and team was available between 
8am to 8pm.  This is specific to UHB but could be extrapolated to other situations. 
Ensuring surgery is performed on this list would prolong CITs. To address this, HMP 
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was utilised to bridge longer CITs in the anticipation that this would minimize the 
impact of CIT on graft function. 
 
HMP is an increasingly recognised alternative form of kidney preservation (St Peter, 
Imber, & Friend, 2002). Improved graft outcomes have been achieved using HMP 
although the exact mechanism by which this occurs remains unclear. Studies have 
reported both reduced DGF and improved graft survival using HMP to preserve DD 
kidneys, as previously discussed (Cannon et al., 2013; Kwiatkowski et al., 2007; 
Lodhi et al., 2012; Matsuoka et al., 2006; Moers et al., 2009; Schold et al., 2005; 
Shah et al., 2008b; Stratta et al., 2007; Wight et al., 2003b). 
 
Others studies have implied that HMP may permit longer periods of CIT without 
increasing DGF rates (Ciancio et al., 2010; Schold et al., 2005). This study strongly 
supports this concept. Despite the significantly longer CITs in the HMP group, less 
DGF was experienced than by kidneys stored for shorter periods using SCS. This 
was true overall and for DBD kidneys. In the DCD kidney group, CIT was also 
significantly longer for HMP kidneys but the reduction in graft function just failed to 
reach statistical significance. 
 
HMP kidneys displaying IGF tended to have a higher proportion of HMP time 
compared to SCS time within the total CIT. This indicates that in cases when a period 
of SCS is unavoidable, it may be necessary to employ a longer period of HMP. This 
has been observed in other reports (Goldstein et al., 2011). 
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The study also demonstrates that longer storage periods can be utilised to resolve 
assessment and logistical issues, most specifically permitting more transplants to be 
performed during daylight hours when maximum expertise is available. This may be 
a more efficient use of human resource and may even help to promote recruitment 
into transplantation. The reduced number of cardio-respiratory problems in the HMP 
group may reflect the specialist anaesthetic and recovery care available during 
elective hours, although these numbers were small. The effects of HMP during organ 
storage, increased time for preparation and improved peri-operative conditions may 
all have contributed to the improved outcomes. 
 
 
2.4.3 RESISTANCE 
 
Kidneys showing the best functional outcome during HMP tend to have reduced 
intra-renal resistance during the perfusion process, implying that the machine 
process improves renal microvascular circulation (Wight et al., 2003a). Several 
studies have warned of the dangers of using resistance values to determine kidney 
discard and although it has been demonstrated as an independent predictor of DGF, 
its predictive value is poor (Jochmans & Pirenne, 2011; Jochmans et al., 2011; 
Sonnenday et al., 2003; de Vries et al., 2011). In this study, there was no significant 
difference in resistance or change in resistance between the DGF and IGF kidneys 
and no kidneys were discarded based on these measurements.  
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2.4.4 POST-OPERATIVE CREATININE 
 
Creatinine levels following transplantation were similar in both groups. Longer-term 
follow-up of graft function in the two groups is clearly necessary but if 1-year 
creatinine level is accepted as a surrogate marker of future outcome, then HMP 
treated kidneys would appear to have similar potential to SCS kidneys despite longer 
CITs at the time of transplantation. 
 
 
2.4.5 BIOPSY-PROVEN ACUTE REJECTION RATES 
 
BPAR rates did not vary significantly between the two preservation methods. Similar 
proportions of HMP and SCS kidneys also underwent a biopsy. This is unexpected 
as increased rates of DGF in the SCS kidneys might be expected to result in more 
biopsies in this group. It might be that other reasons were identified as causes of 
DGF in the SCS group negating the need for histology or that clinical decision-
making is inconsistent. 
 
 
2.4.6 LIMITATIONS 
 
There are several limitations to this study. Allocation of kidneys to storage type was 
non-randomised therefore subject to selection bias. The purpose of this study, 
however, was not to prove superiority of HMP over SCS - this has been 
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demonstrated in larger trials. The aim was to investigate how HMP could be utilised 
within our existing clinical practice to improve or maintain outcomes by optimising as 
many peri-operative factors as possible. 
 
A further limitation is the small number of DCD kidneys and their increased 
representation in the SCS group. This almost certainly demonstrates a bias to 
transplant DCD kidneys more expeditiously despite some studies suggesting that 
DCD kidneys may be a group likely to benefit most from a period of HMP (Jochmans 
et al., 2010; Moers et al., 2009). The increased number of DCD donors in the SCS 
group could be anticipated to bias the results in favour of HMP, but if DBD kidneys 
alone are analysed then the beneficial results of HMP on graft function are still 
significant. For DCD kidneys alone there was no difference between the storage 
methods in terms of early graft function. Even equivalence with an extended CIT may 
be of benefit to allow optimisation of other factors. 
 
In the UK, DD kidneys arrive at the transplanting centre from the organ recovery 
centre in SCS. Consequently, in this study and according to departmental guidelines, 
the decision to take kidneys from SCS and place them on HMP was made. This 
decision was based upon the prediction of CIT, which was itself based on a 
consideration of other logistical factors. It is common experience that these 
predictions are frequently inaccurate. Equally, logistics rarely change to reduce 
timescales. In this study, despite unit guidelines, not all HMP kidneys were 
transplanted during elective hours as planned and a number of SCS kidneys were 
also transplanted out-of-hours. These guideline breaches were most often due to 
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predicted theatre times becoming unavailable due to delays with recipient 
preparation, theatre team unavailability or previously unexpected competing 
emergency cases. Furthermore, the complex logistics associated with multiple kidney 
offers occasionally resulted in HMP kidneys originally designated to elective lists 
being transplanted in emergency theatre time. Such unpredictability is inherent in the 
workings of a busy hospital, and thus largely unavoidable. As this study 
demonstrates that HMP protects kidneys against increased DGF with longer CITs, 
the case could be made that the decision to leave some kidneys in SCS and put 
others on HMP becomes redundant. If all kidneys had been put on HMP at the time 
of arrival in the unit they would have been pre-emptively protected against all 
reasonable eventualities. Since evidence suggests that the effect of HMP on DGF is 
heightened if perfusion is commenced immediately after recovery, it would seem 
even more reasonable to commence all deceased donor kidneys on HMP at source 
rather than at the implanting unit (Moers et al., 2009; Watson et al., 2010). This 
would maximise the benefit of HMP on DGF and also permit a reasonable 
prolongation of CIT, allowing for improved assessment of recipients and more flexible 
operating logistics to ensure the highest level of available expertise.  
 
 
2.4.7 CONCLUSION 
 
Traditional concerns about CIT have dictated that surgery must be expedited, 
possibly at the cost of other factors. However, these patients demand careful 
assessment and sometimes intervention on the day of transplantation. This study 
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demonstrates that comparable outcomes can be achieved with longer CITs by 
utilizing HMP storage rather than traditional SCS. This effect is likely to be multi-
factorial including the inherent effects of HMP itself, improved recipient preparation 
and possibly better peri-operative conditions. Additional larger studies of subgroups 
and long-term outcomes would be beneficial in further defining the utility of HMP.  
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CHAPTER THREE: ANALYSIS OF HMP PERFUSATE 
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3.1 BACKGROUND 
 
HMP provides a unique opportunity for assessment of deceased donor kidneys 
during storage with easy and safe access to perfusate samples, kidney tissue and 
information regarding flow dynamics. As previously discussed, accurate evaluation of 
allograft quality is essential to prevent unnecessary kidney discard, allow maximised 
donor-recipient matching and to plan appropriate peri-operative care. Viability 
assessment is of increasing importance with the higher utilisation rates of marginal 
DD kidneys. Despite considerable interest in various indicators and markers of graft 
quality, few are used routinely in clinical practice, and no single biomarker or 
parameter has proven to be definitive. 
  
Although the clinical benefits of HMP are well documented, recent advances in 
normothermic perfusion have led some to question whether HMP will remain 
relevant. For the foreseeable future, HMP has the advantage of being far less labour 
intensive, therefore cheaper, and is much easier to operate than the complex 
arrangement requirement for normothermic perfusion. The exact mechanism by 
which HMP produces its beneficial effects remains unclear. Whilst initially the 
mechanism of action was thought to be largely due to maintaining the patency of 
vascular beds, there is increasing evidence that substantial metabolic activity occurs 
(Fuller & Lee, 2007). However the metabolic activity in this ex vivo, hypoxic, 
hypothermic environment is poorly understood.  
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‘Metabolomics’, or in this case NMR analysis of HMP perfusate, could provide an 
insight into this activity and identify potential biomarkers for graft quality. With a better 
understanding of the underlying processes occurring in the HMP kidney, it may be 
possible to ‘resuscitate’ and modify an injured kidney thereby improving outcomes 
and maximising the number of good kidneys available for transplantation. 
 
 
3.1.1 METABOLOMICS 
 
Systems biology, aiming to understand living organisms at the molecular systems 
level, is still in its early stages of development. However, it is emerging as an area of 
research that will use metabolomics, along with other 'omics' including genomics, 
transcriptomics and proteomics, as key investigative processes (Dettmer, Aronov, & 
Hammock, 2007). 
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Figure 3.1: The “Omics” Cascade  
 
 
'Metabolomics' is defined as the systematic analysis of the chemical 'fingerprints' of 
specific cellular processes. It tends to refer to metabolites in one sample, which might 
be derived from only one cell type, whereas 'metabonomics' is the global study of 
systems that regulate metabolism, including variations over time (Hunter, 2009). 
Often these terms are used interchangeably.  
 
Metabolomics has a number of potential applications including diagnostics, drug 
treatment and discovery and nutritional research. As a diagnostic tool it is powerful, 
providing a snapshot of an organism's metabolic state through the systematic 
analysis of its metabolites (Hunter, 2009). Any deviations from the normal range 
indicate possible pathological aberrations or changes due to environmental stimuli. 
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Metabolomics is the endpoint of the "omics cascade" and therefore provides the 
closest indication of phenotype (Dettmer, Aronov, & Hammock, 2007). 
 
The metabolome represents a vast number of components that belong to a wide 
variety of compound classes such as amino acids, lipids, organic acids and 
nucleotides (Dettmer, Aronov, & Hammock, 2007). It is estimated that in humans 
there are around 2000 major metabolites - these are diverse in their physical and 
chemical properties and occur in a wide concentration range (Beecher, 2003).  
 
A variety of analytical techniques can be used for metabolomic analysis, most 
commonly mass spectrometry and/or nuclear magnetic resonance (NMR) 
spectroscopy. These methods can identify compounds and their quantities in fluids or 
tissue samples. Given the diversity of metabolic compounds no single-instrument 
platform can currently analyse all metabolites, however, this is not normally 
necessary (Dettmer, Aronov, & Hammock, 2007). 
 
Mass spectroscopy (MS) uses electrical fields to separate compounds, whereas 
NMR relies on magnetic fields. NMR spectroscopy provides the most comprehensive 
information about a wide range of metabolites and is generally preferred for large-
scale applications (Hunter, 2009). NMR spectroscopy can simultaneously detect, 
identify and quantify hundreds of metabolites, some of which may have prognostic or 
therapeutic value (Serkova et al., 2005). 
 
 
  110 
3.1.2 METABOLOMIC INVESTIGATIONS 
 
There are two methods to approaching metabolomic analysis: metabolic profiling and 
metabolic fingerprinting (Dettmer & Hammock, 2004). Both of these can be used to 
identify new biomarkers. 
 
Metabolic Profiling 
 
Metabolic profiling aims to examine a specific cellular pathway via the involved 
metabolites or compounds (Dettmer, Aronov, & Hammock, 2007). A specific analyte, 
for example a biomarker of a particular disease, can also be targeted, identified and 
quantified (Fiehn, 2002). This technique is mostly hypothesis-driven. The main 
disadvantage of this approach is that due to its focused methodology, it may exclude, 
as yet, unrecognised pathways or metabolites (Dettmer, Aronov, & Hammock, 2007). 
 
Metabolic Fingerprinting 
 
This alternative approach aims to identify specific patterns of metabolites, known as 
‘fingerprints’, which might change in response to trigger factors. These factors might 
be, for example, a change in disease stage. This method has been applied to 
examine a number of substances such as urine, blood products, saliva and cells or 
tissues. The analysis of substances excreted into or taken up from these fluids can 
provide important information on cellular processes and the condition of the tissues 
being examined. The use of metabolic fingerprinting using NMR techniques has 
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proven to be an extremely powerful tool for screening samples and has been widely 
used in the field of biochemistry. An example of its use is as a diagnostic test: the 
metabolic fingerprint of an individual can be compared to one with and without a 
disease. Alternatively, it could be used to measure the success of a treatment if a 
fingerprint changes from ‘abnormal’ back to that of a healthy individual (Dettmer, 
Aronov, & Hammock, 2007). 
 
 
3.1.3 PRINCIPLES OF NUCLEAR MAGNETIC RESONANCE (NMR) 
 
NMR is an effect whereby nuclei in a magnetic field absorb and re-emit 
electromagnetic energy.  
 
Each nucleus has one or more protons and neutrons, except for the hydrogen 
nucleus 1H which only contains a single proton. Protons and neutrons both have an 
intrinsic property known in quantum mechanics as 'spin'. Inside an oriented magnetic 
field, the spin of the nuclei can either be parallel or anti-parallel with the external 
magnetic field. The energy absorbed or emitted by the nuclei is at a specific 
resonance frequency, distinct to each nucleus.  
 
Molecules respond differently to the resonating magnetic field according to the 
electron density distribution around the nuclei. Each proton resonates at a slightly 
different frequency, called the chemical shift. This can be used to generate highly 
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refined spectral patterns that yield a great deal of data about the metabolites in a 
sample (Hunter, 2009). 
 
 
3.1.4 NMR IN DISEASE STUDIES 
 
NMR-based metabolomics is widely used in disease studies (Nicholson, Lindon, & 
Holmes, 1999). For example, 1H-NMR has been used to distinguish markers in 
human serum predictive of coronary artery disease and hypertension (Brindle et al., 
2002). It has also been used extensively to investigate diabetes both in rat models 
(Serkova et al., 2005; Zhao et al., 2010) and in human subjects for diagnosis and 
management of diabetic patients (Griffin & Vidal-Puig, 2008) and for identification of 
complications such as nephropathy (Mäkinen et al., 2006).  
 
A full review of its experimental and clinical applications is beyond the scope of this 
study but NMR has the potential to diagnose disease, monitor the success of 
interventions and provide new biomarkers to assess human health (Dettmer, Aronov, 
& Hammock, 2007). 
 
 
3.1.5 NMR IN TRANSPLANTATION 
 
Several studies have demonstrated the use of NMR-based metabolomics within 
transplantation. Various isolated metabolites in the blood and urine have been found 
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to be indicators of kidney injury following transplantation. These metabolites are 
intermediates or end products of cellular processes and, therefore, reflect the global 
integrated response of an organ or entire biological system to pathophysiologic 
stimuli (Nicholson et al., 1999). 
 
Hauet et al investigated the use of 1H-NMR on urine to assess the level of renal 
damage at retrieval in a porcine transplant model (Hauet et al., 2000a). They 
concluded that "NMR spectroscopy, which is a non-invasive and non-destructive 
technique, is more efficient in assessing renal damage than conventional histology 
and biochemical analysis."  
 
NMR based analysis has also been used in rat models to establish markers of 
Ischaemia-Reperfusion (IR) injury (Serkova et al., 2005) and various NMR-based 
publications have reported trimethylamine-N-oxide (TMAO) to be a urine marker for 
nonspecific medullar injury (Foxall et al., 1993; Hauet et al., 2000a; Hauet et al., 
2000b; Richer et al., 2000). 
 
HMP perfusate has been examined by NMR techniques in liver transplantation 
experiments. Liu et al examined the use of 1H-NMR to discriminate warm ischaemic 
injury of the liver during HMP in a porcine model (Liu et al., 2009). They discovered 
that AST, alanine and histidine in HMP perfusate discriminated warm ischaemic 
injury in porcine liver grafts and suggested them as potential biomarkers for viability. 
They also concluded that 1H-NMR is a valid screening tool to analyse the 
composition of the perfusate during liver HMP.  
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More recently, Bon et al used NMR spectroscopy to examine HMP perfusate in a 
porcine autotransplant model (Bon et al., 2014). They concluded that multivariate 
analysis of biomarkers during perfusion using NMR data could be an interesting tool 
to assess graft quality. They also reported that NMR analysis could be performed in a 
timeframe that allows clinical utility.  
 
Whilst several publications have demonstrated the feasibility of NMR for evaluating 
different clinical scenarios in transplantation no previous studies, to our knowledge, 
have examined the perfusate of human cadaveric kidneys during HMP using NMR. 
 
 
3.1.6 KEY METABOLIC PATHWAYS 
 
Metabolism encompasses all biological and chemical reactions that can be carried 
out by cells. It is a balance between anabolism and catabolism controlled by 
regulatory thermodynamic mechanisms (Ophardt, 2003). Whilst a complete review of 
cellular metabolism is well beyond the scope of this study, there are a number of 
important cellular pathways that might be relevant in the cold stored kidney. The 
most significant pathways in cellular metabolism are outlined below and in figure 3.2.  
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Figure 3.2: Summary of the Main Metabolic Pathways (Reproduced from Ophardt, 
2003) 
 
 
 
3.1.6.1 GLYCOLYSIS  
 
The most important requirement of all cells in the body is for an immediate source of 
energy, often in the form of glucose. Glucose is transported into cells as needed 
where a series of reactions can take place. The three major carbohydrate energy-
producing reactions are glycolysis, the citric acid cycle and the electron transport 
chain (Ophardt, 2003). 
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The major steps of glycolysis are outlined in figure 3.3. Each glucose molecule is 
converted into two pyruvic acid molecules. Whilst energy is required to initiate this 
process a net gain of energy, in the form of ATP, is produced (Ophardt, 2003). 
 
 
Figure 3.3: Glycolysis (Reproduced from www.moodle2.halesowen.ac.uk) 
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However, glycolysis releases relatively little ATP so reactions continue to convert 
pyruvic acid to acetyl coenzyme A (acetyl CoA) and then to citric acid in the citric acid 
cycle.  
 
 
3.1.6.2 THE CITRIC ACID CYCLE 
 
As mentioned above, the Citric Acid Cycle begins with acetyl CoA. Acetyl CoA, 
sourced from either glycolysis or the fatty acid cycle, joins with a four-carbon 
compound to form citric acid. The cycle, along with the electron transport chain, is 
responsible for the synthesis of most of the body’s ATP (Ophardt, 2003). 
 
Acetyl CoA is converted from pyruvic acid prior to entry into the citric acid cycle. If 
necessary, pyruvic acid can instead be transformed back into glucose or glycogen 
(gluconeogenesis) or converted by transamination into alanine, an amino acid. If 
conditions are anaerobic, pyruvic acid is converted into lactc acid. This allows for 
continued energy production, in the form of ATP, despite the unavailability of oxygen 
(Ophardt, 2003). 
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Figure 3.4: The Citric Acid Cycle (Reproduced from Ball, 2011) 
 
 
 
 
3.1.6.3 OXIDATIVE PHOSPHORYLATION 
 
Oxidative phosphorylation uses electrons released by other processes, for example 
glycolysis and the citric acid cycle, to produce and store energy in the form of ATP  
(Berg, Tymoczko and Stryer, 2002). 
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Figure 3.5: Oxidative Phosphorylation (Reproduced from Hinkle, 2005) 
 
 
 
 
3.1.6.4 THE PENTOSE PHOSPHATE PATHWAY 
 
This pathway is primarily a cytoplasmic anabolic pathway that converts the six 
carbons of glucose to five carbon (pentose) sugars and reducing equivalents. This 
process oxidises glucose and its products can be completely oxidised to glucose and 
water. The pathway has both oxidative and non-oxidative arms.  
 
The oxidative part occurs at the beginning of the pathway, utilising glucose-6-
phosphate and producing NADPH. Non-oxidative reactions generate ribose 5-
phosphate. The pentose phosphate pathway also converts 5 carbon sugars into 6 
and 3 carbon sugars that can then be used for glycolysis (Sheriff, 2004). 
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Figure 3.6: The Pentose Phosphate Pathway (Reproduced from Sheriff, 2004) 
 
The upper part of the pathway to ribulose-5-P is the oxidative arm. The lower part of 
the pathway provides a link from ribose-5-P to the glycolytic pathway, 
gluconeogenesis, and back. 
 
 
 
 
3.1.6.5 THE UREA CYCLE  
 
Urea is the main end product of nitrogen metabolism in humans and mammals. 
Ammonia, the product of oxidative deamination reactions, is toxic in even small 
amounts. The urea cycle converts ammonia into urea. This process is shown in 
figure 3.7. 
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Figure 3.7: The Urea Cycle (Reproduced from Ophardt, 2003) 
 
 
 
 
3.1.6.6 FATTY ACID BETA-OXIDATION 
 
The major reaction to produce energy from lipids is the fatty acid spiral. The beta-
oxidation of fatty acids occurs by the removal of two carbons at a time as acetyl CoA 
in a spiral type reaction. These reactions occur in the mitochondria and thus are 
closely associated with the electron transport chain to produce energy in the form of 
ATP. In addition, the acetyl CoA which is produced is fed mostly into the citric acid 
cycle.  
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Figure 3.8: Fatty Acid Beta-Oxidation (Reproduced from Ophardt, 2003). 
 
 
 
 
3.1.6.7 GLUCONEOGENESIS  
 
Gluconeogenesis is the mechanism by which glucose is produced from sources other 
than carbohydrates. There are a variety of molecules from which this process can 
begin, such as oxaloacetic acid and dihydroxyacetone phosphate, but most often the 
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pathway starts with pyruvic acid. Other substances that can be converted into 
glucose are lactic acid, glycerol and some amino acids  (Ophardt, 2003). 
 
If the process starts with pyruvic acid, this is first converted into oxaloacetic acid. In 
the presence of low levels of acetyl CoA and high concentrations of ATP, oxaloacetic 
acid proceeds along the gluconeogenesis pathway. Alternatively, oxaloacetic acid 
can enter the citric acid cycle and interact with acetyl CoA. This is summarised in the 
diagram below.  
 
 
Figure 3.9: Gluconeogenesis (Reproduced from Ophardt, 2003). 
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3.2 AIMS 
 
The aim of this part of the study was to use NMR spectroscopy (metabolomics - 
metabolic fingerprinting) to examine the metabolic profile of the perfusate of human 
cadaveric kidneys for transplantation and to identify possible discriminators between 
the profiles of kidneys with delayed and Immediate Graft Function (IGF).  
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3.3 METHODS 
 
3.3.1 ETHICS & SPONSORSHIP 
 
Ethical approval was obtained from the West of Scotland Research Ethics Service for 
this study on the 10th of July 2012 (REC reference number: 12/WS/0166).  
 
A research project authentication for this study was obtained from UHB on 25th April 
2012 (RRK 4459 Machine Perfusion in Transplantation). 
 
 
3.3.2 PATIENT RECRUITMENT 
 
Adult cadaveric kidneys accepted for transplantation and undergoing HMP at UHB 
between July 2012 and August 2013 were included. This was subject to agreement 
for the use of tissue/fluid for research during the standard donor consent process and 
recipient agreement for follow-up. Paediatric cases were excluded.  
 
Demographic and clinical data were collected prospectively. Delayed Graft Function 
(DGF) was defined as the requirement for dialysis within the first post-operative 
week. IGF kidneys were those not requiring dialysis support post-operatively. 
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3.3.3 KIDNEY PRESERVATION 
 
Kidneys were cold stored in the period following retrieval and transferred to the 
LifePort© Kidney Transporter 1.0 (Organ Recovery Systems) at UHB under aseptic 
conditions. The decision to perfuse kidneys was determined by clinical protocol 
taking into account donor-recipient issues and theatre availability as per the clinical 
part of the study. Perfusion pressure was set at 30mmHg and kidneys were perfused 
with 1L of KPS-1® at 4°C. No additional oxygen was supplied. 
 
 
3.3.4 SAMPLE COLLECTION 
 
The LifePort© Kidney Transporter has a sampling port as part of the disposable 
tubing mechanism. 12 mL of perfusate was sampled from the port during perfusion 
time at the following time intervals:  
 
• 0 minutes, 15 minutes, 30 minutes, 45 minutes, 60 minutes 
• 4 hours, 8 hours 
• The end of perfusion (a variable time-point) 
 
2 mL of perfusate from each sample was transferred into a cryogenic vial and stored 
at -20°C until thawed at room temperature, prepared and processed for NMR 
analysis. 
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The remaining 10 mL of each sample was transferred into a centrifuge tube and 
stored in a standard fridge. It was then centrifuged at 4°C for 5 minutes at 1700 RPM. 
The supernatent was separated and stored at -80°C. The remaining pellet was mixed 
with 1 mL of freezing media (5mL DMSO/45mL FCS) and also stored at -80°C. 
These were stored as reserve samples for repeat or further analysis. 
 
 
3.3.5 SAMPLE PROCESSING 
 
NMR samples were prepared by mixing 150 µL of a 400 mM pH 7.0 phosphate buffer 
solution containing 2 mM TSP [(3-trimethylsilyl)propionic-(2,2,3,3-d4)-acid sodium 
salt] with 390 µL of each perfusate sample and 60 µl of deuterium oxide (D2O) to 
reach a final phosphate buffer concentration of 100 mM and a final TSP 
concentration of 500 µM. D20 provides a field-frequency lock, whereas TSP is used 
as a chemical shift as well as a concentration reference. After mixing, the 600 µL 
samples were pipetted into NMR tubes and centrifuged to remove any air bubbles. 
 
 
3.3.6 SPECTRAL ACQUISITION 
 
1H-NMR spectra were acquired using a Bruker AVII 500 MHz spectrometer equipped 
with a 5 mm inverse Cryoprobe. The sample temperature was set to 300 K, excitation 
sculpting was used to suppress the water resonance (Hwang & Shaka, 1995). One-
dimensional spectra were acquired using a 6 kHz spectral width, 32768 data points, 
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4 s relaxation delay and 128 transients. Matching was manual prior to acquisition of 
first sample and each sample was automatically shimmed (1D-TopShim) to a TSP 
line width of less than 1 Hz prior to acquisition. Samples with a TSP line width >1 Hz 
were acquired again after manual shimming where the TSP half height line width was 
shimmed below 1 Hz. Total experimental time was approximately 15 minutes per 
sample. 
 
All data sets were processed using the MATLAB based MetaboLab software (Ludwig 
& Günther, 2011). Data sets were zero filled to 65536 data points. An exponential 
line broadening of 0.3 Hz was applied before Fourier transformation. The chemical 
shift axis was calibrated by referencing the TMSP signal to 0 ppm. Spectra were 
manually phase corrected and baseline correction using a spline before segmental 
alignment of all resonances using Icoshift (Savorani, Tomasi, & Engelsen, 2010). 
Spectra were then exported into Bruker format. 
 
 
3.3.7 SPECTRAL ANALYSIS 
 
Resultant spectra were examined at two time-points for each set of perfusate 
samples - 45 minutes and 4 hours.  
 
Spectra were examined using Chenomx 7.0 (Professional edition, version 7, 
Chenomx, Edmonton, AB, Canada). This allows peaks on the spectrum to be 
identified and quantified. Firstly, the peaks corresponding to compounds known to be 
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present in KPS-1® were assigned. Other peaks on the spectrum were than assigned 
where possible. Chemical shift assignments are shown in table 3.1 and figure 3.10. 
Each signal annotation and quantification was checked manually. 
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Table 3.1: Chemical Shifts References Used for Metabolite Quantification 
 
Some metabolites are represented by more than one peak on the NMR spectrum. 
The concentration of a metabolite is measured by the height of one of these peaks 
above the baseline. To ensure consistent measurement across samples, the same 
peak must be used for each sample. The chemical shift references shown here 
represent the position of the peak on the spectrum that has been used for 
quantification of each metabolite.  
 
 
Metabolite 
NMR Chemical 
Shift Reference 
(ppm) 
Metabolite 
NMR Chemical 
Shift Reference 
(ppm) 
3-Hydroxybutyrate 1.204 Hippurate 7.82 
3-Methylxanthine 8.02 Hypoxanthine 8.20 
Acetate 1.91 Inosine 6.055 
Adenine 8.11 Isoleucine 0.997 
Alanine 1.46 Isopropranolol 1.162 
Citrate 2.67 Lactate 1.40 
Ethanol 1.17 Leucine 0.948 
Formate 8.44 Malonate 3.11 
Fumarate 6.51 Mannitol 3.840 
Gluconate 4.12 N-Phenylacetylglycine 7.412 
Glucose 3.524 Ribose 2.21 
Glutamate 2.341 Tyrosine 6.877 
Glutathione 2.97 Uracil 7.52 
Glycine 3.54 Valine 1.029 
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Figure 3.10: Examples of Spectral Assignments  
 
These images show an example spectrum along with magnified areas of the 
spectrum demonstrating the use of Chenomx software. The black line represents the 
spectrum produced from sample analysis. The shaded areas are ‘ghost’ images 
produced by the software that can be matched to spectral patterns to identify peaks. 
 
 
Whole Spectra Uracil 
 
  
 
 
 
3-Methylxanthine  
 
 
 
Citrate 
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Hippurate Hypoxanthine 
  
 
 
 
 
Isopropranolol Malonate 
 
 
 
 
 
 
 
N-Phenylglycine 
 
 
Tyrosine 
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3.3.8 STATISTICAL ANALYSIS 
 
Data were analysed using GraphPad Prism version 6.0c for Mac (GraphPad 
Software, La Jolla California USA, www.graphpad.com) and IBM SPSS 19 (IBM 
Corp. Armonk, NY).  
 
Metabolite averages are stated as median values due to non-parametric data 
distribution. Change in metabolite concentration over time was analysed by Wilcoxon 
signed rank test. Metabolite concentrations were compared using Mann Whitney-U 
test.  
 
The rules for outliers in the boxplots are the ones used by default in SPSS. The 
outliers represented by circles on the plot are those cases that are greater than 1.5 
times the height of the box above or below the box. The stars are classified as 
extreme outliers, which are greater than three times the height of the box above or 
below the box. All available data (including the "outliers") were used in the 
significance tests. The tests used were non-parametric (i.e. based on ranks), and so 
were insensitive to these outliers.  
 
Comparison between glucose measurements using NMR and glucometer readings 
were analysed using non-parametric Spearman correlation. P<0.05 was considered 
to be indicative of statistical significance.  
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3.4 RESULTS 
 
Twenty-nine kidneys were included in the study. Three kidneys were rejected for 
implantation following HMP. Reasons included severe atherosclerosis of the renal 
artery with an adverse donor history, a hypoplastic cystic kidney and inadequate 
initial flush of the kidney at recovery. No kidneys were rejected on HMP parameters. 
Transplantation proceeded in the remaining 26 kidneys. Donor and recipient 
characteristics are shown in table 3.2. HMP parameters and storage times are shown 
in table 3.3. There were no statistically significant differences in characteristics or 
parameters between the IGF and DGF kidneys. 
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Table 3.2: Donor and Recipient Characteristics for HMP Kidneys 
 
Characteristic Overall (26) 
IGF 
(19) 
DGF 
(7) 
P 
Value 
Donor     
Male gender 16 (62%) 11 (58%) 5 (71%) 0.67 
Median age (IQ range) 47 (40-60) 47 (42-59) 51 (31-61) 1.00 
CMV +ve 12 (46%) 8 (42%) 4 (57%) 0.67 
DBD 23 (88%) 18 (95%) 5 (71%) 0.17 
DCD 3 (12%) 1 (5%) 2 (29%) 0.23 
SCD 16 (62%) 13 (68%) 3 (18%) 0.37 
ECD 10 (38%) 6 (32%) 4 (57%) 0.37 
Recipient     
Male gender 18 (69%) 12 (63%) 6 (86%) 0.37 
Median age (IQ range) 50 (44-54) 50 (44-55) 50 (44-53) 0.94 
Ethnicity:     British 
                    Asian 
                    Black 
18 (69%) 
5 (19%) 
3 (12%) 
14 (74%) 
4 (21%) 
1 (5%) 
4 (57%) 
1 (14%) 
2 (29%) 
0.64 
1.00 
0.17 
Virology:      CMV+ 
                    HAV+ 
                    HBV cAb+ 
                    HBV sAb+ 
12 (46%) 
2 (8%) 
3 (12%) 
1 (4%) 
7 (37%) 
1 (5%) 
1 (5%) 
1 (5%) 
5 (71%) 
1 (14%) 
2 (29%) 
0 (0%) 
0.19 
0.47 
0.17 
1.00 
Dialysis:      HD 
                    PD 
                    Pre 
18 (69%) 
6 (23%) 
2 (8%) 
12 (63%) 
5 (26%) 
2 (11%) 
6 (86%) 
1 (14%) 
0 (0%) 
0.37 
1.00 
1.00 
Previous transplant ≥1 3 (12%) 3 (16%) 0 (0%) 0.54 
PRA level >5% 13 (50%) 9 (47%) 4 (57%) 1.00 
0.0.0 mismatches 4 (15%) 4 (21%) 0 (0%) 0.55 
Immunosuppression 
standard 
24 (92%) 19 (100%) 5 (71%) 0.06 
 
CMV: cytomegalovirus. HAV: Hepatitis A virus, HBV: hepatitis B virus. cAb: core antibody, sAb: surface antibody. PRA: panel 
reactive antibodies. Standard immunosuppression: Basiliximab, Tacrolimus, Mycophenolate mofetil, Prednisolone. Data 
reported as: “Median (Quartiles)” or “N (%)”, with p-values from Fisher’s exact tests or Mann-Whitney tests, as appropriate 
*Significant at p < 0.05 
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Table 3.3: HMP Parameters & Storage Times 
 
 
Characteristic Overall (26) 
IGF 
(19) 
DGF 
(7) 
P 
Value 
Storage Times (hours)     
Cold Storage time 7 (6-11) 8 (6-11) 7 (5-10) 0.33 
HMP time 15 (7-17) 15 (10-17) 15 (5-22) 1.00 
Total CIT 23 (16-27) 24 (17-27) 22 (15-29) 0.92 
HMP Parameters     
Initial Flow mL/min 64 (43-88) 67 (49-92) 47 (39-65) 0.20 
End Flow mL/min 108 (86-138) 111 (92-135) 95 (74-170) 0.72 
Increase in Flow mL/min 45 (26-58) 45 (22-57) 44 (32-69) 0.43 
Initial Resistance 
mmHg/mL/min 
0.42 
(0.30-0.64) 
0.37 
(0.28-0.56) 
0.58  
(0.39-0.66) 
0.18 
End Resistance 
mmHg/mL/min 
0.21 
(0.16-0.27) 
0.20 
(0.17-0.25) 
0.25 
(0.15-0.31) 
0.52 
Decrease in Resistance 
mmHg/mL/min 
0.21 
(0.08 -0.34) 
0.16 
(0.07-0.29) 
0.26 
(0.21-0.40) 
0.19 
 
 
 
3.4.1 IDENTIFIED METABOLITES 
 
Twenty-eight metabolites were identified in the perfusate of HMP kidneys at both 
examined time-points. Some of these were known to be constituents of KPS-1® 
(table 1.6) and some were 'new' metabolites i.e. not known constituents of the 
perfusion fluid. 
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3.4.2 METABOLITES IN KPS-1® 
 
Six of the 28 identified metabolites were recognised constituents of the KPS-1® fluid. 
These were adenine, gluconate, glucose, glutathione (reduced form), mannitol and 
ribose. Median concentrations of these metabolites measured by 1H-NMR at each 
time-point and the p-values for change over time are shown in table 3.4. Notably, 
there was a significant change in concentration of glucose and glutathione between 
the two time points.  
 
 
Table 3.4: Metabolite Concentrations (mM) for Constituents of KPS-1® Identified 
in Kidney Perfusate 
 
Metabolite 
Median 
Conc at 45 
mins of 
HMP 
Interquartile 
range 
Median 
Conc at 
4 hours 
of HMP 
Interquartile 
range 
P-value 
(change 
over time) 
Adenine 4.82 4.12-5.51 4.69 3.92-5.57 0.804 
Gluconate 53.05 50.69-59.02 56.31 51.08-61.87 0.340 
Glucose 9.07 8.32-10.04 9.75 8.35-10.79  0.041* 
Glutathione 0.89 0.79-0.94 0.50 0.40-0.60 <0.001* 
Mannitol 32.13 31.13-34.68 34.84 29.65-40.50 0.111 
Ribose 0.00 0.00-0.00 0.00 0.00-0.00 0.129 
 
Statistically significant at <0.05, Wilcoxon signed rank test 
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3.4.3 NEW METABOLITES IN PERFUSATE 
 
The remaining 22 identified metabolites are not listed as constituents of KPS-1®. 
Median concentrations of these metabolites at each time-point and p-values for 
change over time are shown in Table 3.5. Most of these metabolites changed 
significantly (highlighted in bold). 
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Table 3.5: Metabolite Concentrations (mM) Measured in Kidney Perfusate Not 
Listed as Constituents of KPS-1® 
 
Metabolite 
Median 
Conc at 
45 mins 
of HMP 
Interquartile 
range 
Median 
Conc at 4 
hours of 
HMP 
Interquartile 
range 
P-value 
(change 
over time) 
3-Hydroxybutyrate 0.008 0.006-0.014 0.021 0.014-0.030  <0.001* 
3-Methylxanthine 0.016 0.014-0.018 0.017 0.013-0.019  0.363 
Acetate 0.100 0.082-0.113 0.087 0.062-0.102  0.085 
Alanine 0.047 0.034-0.065 0.121 0.077-0.147  <0.001* 
Citrate 0.477 0.000-0.830 0.621 0.000-1.299  <0.001* 
Ethanol 0.017 0.014-0.020 0.015 0.011-0.019  0.282 
Formate 0.051 0.037-0.071 0.055 0.037-0.086    0.013* 
Fumarate 0.002 0.001-0.003 0.003 0.001-0.004    0.005* 
Glutamate 0.145 0.065-0.325 0.646 0.375-0.807  <0.001* 
Glycine 0.469 0.391-0.541 1.363 0.902-1.792  <0.001* 
Hippurate 0.003 0.000-0.005 0.002 0.000-0.006  0.093 
Hypoxanthine 0.041 0.020-0.067 0.086 0.034-0.157  <0.001* 
Inosine 0.006 0.002-0.015 0.008 0.003-0.020    0.014* 
Isoleucine 0.003 0.002-0.004 0.004 0.003-0.006  <0.001* 
Isopropranolol 0.015 0.010-0.021 0.015 0.012-0.021  0.164 
Lactate 0.602 0.481-0.694 1.158 0.932-1.322 <0.001* 
Leucine 0.008 0.006-0.010 0.012 0.008-0.016 <0.001* 
Malonate 2.136 1.050-2.344 1.975 0.000-2.408 0.568 
N-Phenylacetylglycine 0.003 0.000-0.006 0.004 0.000-0.012   0.009* 
Tyrosine 0.003 0.002-0.003 0.004 0.003-0.006 <0.001* 
Uracil 0.007 0.003-0.008 0.009 0.006-0.013 <0.001* 
Valine 0.005 0.004-0.006 0.003 0.006-0.010 <0.001* 
 
Statistically significant at <0.05, Wilcoxon signed rank test 
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3.4.4 GRAFT FUNCTION & METABOLOMIC PROFILE 
 
Of the 26 transplanted kidneys following HMP, 19 (73%) kidneys displayed IGF post 
transplant and 7 (27%) suffered from DGF. There were differences between the 
metabolomic profile of these groups – metabolites that were significantly different at 
one or both timepoints between the groups were glucose, inosine, leucine and 
gluconate. 
 
 
3.4.4.1 GLUCOSE 
 
Glucose concentrations were significantly lower in DGF kidney perfusate compared 
to the perfusate of kidneys with IGF at both 45 minutes (7.772 v 9.459 mM, p=0.006) 
and 4 hours (8.202 v 10.235 mM, p=0.003) (figure 3.11).  
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Figure 3.11: Box and Whisker Plot to Represent Glucose Concentrations in HMP 
Kidney Perfusate 
 
 
 
 
3.4.4.1.1 CORRELATION OF GLUCOSE MEASUREMENTS 
 
Following the finding that glucose levels were significantly different between the 
perfusate of DGF and IGF kidneys, the reserve samples were thawed and tested with 
a standard bedside glucometer (CodefreeTM blood glucose monitoring system). 
Seven sets of human perfusate samples (45 minute and 4 hours samples for each) 
were selected at random and thawed at room temperature. Readings were 
performed three times on each sample and the mean average calculated. This was 
then compared with the NMR measured concentrations. 
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Glucose levels measured using the bedside glucometer and by NMR spectroscopy 
did not correlate at 45 minutes (correlation coefficient, CC 0.029; p-value = 1.000) or 
at 4 hours (CC -0.238; p-value = 0.582). This is demonstrated in figure 3.12. 
 
 
Figure 3.12: Correlation of Glucose Levels Measured by NMR and a Standard 
Glucometer 
 
 
At 45 Minutes At 4 Hours 
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3.4.4.2 INOSINE 
 
Concentrations of inosine were significantly lower in DGF than IGF kidney perfusate 
at 45 mins (0.002 v 0.013 mM, p=0.009) but not at 4 hours (figure 3.13). 
 
 
Figure 3.13: Box and Whisker Plot to Represent Inosine Concentrations in HMP 
Kidney Perfusate 
 
 
 
 
3.4.4.3 LEUCINE 
 
Concentrations of leucine were significantly higher in DGF than IGF kidney perfusate 
at 45 mins (0.011 v 0.006 mM, p=0.036) but not at 4 hours (figure 3.14). 
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Figure 3.14: Box and Whisker Plot to Represent Leucine Concentrations in HMP 
Kidney Perfusate 
 
 
 
 
3.4.4.4 GLUCONATE 
 
Gluconate levels were significantly lower in DGF kidney perfusate than in the 
perfusate of IGF kidneys at 4 hours (49.099 v 59.513 mM p=0.009) but not at 45 
minutes (figure 3.15).  
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Figure 3.15: Box and Whisker Plot to Represent Gluconate Concentrations in HMP 
Kidney Perfusate 
 
 
 
 
3.4.4.5 OTHER METABOLITES 
 
Levels of the other identified metabolites did not differ significantly between the 
perfusate of IGF and DGF kidneys at the two timepoints measured. Median levels 
and interquartile ranges are shown in the box and whisker plots in figure 3.16. 
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Figure 3.16: Box and Whisker Plot to Represent Concentrations of Other 
Metabolites in HMP Kidney Perfusate 
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3.4.5 ROCS FOR PREDICTION OF DGF 
 
A Receiver-Operator Characteristic (ROC) curve is a graphical plot of sensitivity 
versus 1- specificity. The area under the ROC (AUROC) is a combined measure of 
these indices and is representative of the overall performance of a diagnostic test. 
The AUROC can be a value between 0 and 1, and the closer the value to 1, the 
better the overall performance of the test. A value of greater than 0.7 is considered to 
be 'fair' and over 0.8 considered to be 'good'. 
 
Receiver-operator Characteristic (ROC) curves assessing the predictive accuracy of 
glucose, inosine, leucine and gluconate for DGF are shown in figure 3.17. Glucose 
yielded an area under the ROC (AUROC) curve of 0.842 (Standard Error; SE 0.080) 
at 45 minutes and 0.895 (SE 0.069) at 4 hours. The AUROC for inosine at 45 
minutes was 0.833 (SE 0.082) and for leucine at 45 minutes was 0.732 (SE 0.135). 
Gluconate at 4 hours had an AUROC of 0.851 (SE 0.089). Cut-off values for the 
ROC curves can be seen in the appendices. 
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Figure 3.17: Receiver-operator Characteristic (ROC) Curves and Areas Under the 
ROC Curves (AUROCs) for Significant Metabolites 
 
 
 
Area Under the Curve 
Test Result Variables Area Std. Errora 
Asymptotic 
Sig.b 
Asymptotic 95% Confidence 
Interval 
Lower Bound Upper Bound 
Glucose 4 hours 0.895 0.069 0.004 0.759 1.000 
Gluconate 4 hours 0.851 0.089 0.011 0.676 1.000 
Glucose 45 minutes 0.842 0.080 0.013 0.686 0.998 
Inosine 0.833 0.082 0.016 0.673 0.993 
Leucine 0.732 0.135 0.092 0.468 0.997 
 
a 
Under the non-parametric assumption 
b Null hypothesis: true area = 0.5 
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3.5 DISCUSSION 
 
This is the first report to detail the metabolomic profile of perfusate during HMP of 
human cadaveric kidneys. Changes in the perfusate composition during this time 
may represent substances being removed by the kidney to supply ongoing cell 
processes or products of metabolism or degradation being released from the kidney. 
This experiment demonstrates that after only 45 minutes of machine perfusion, the 
perfusate is markedly different from the original preservation solution. Furthermore, 
this study has identified differences in the metabolomic profile of IGF and DGF 
kidney perfusate that may allow prediction of functional graft outcome following 
transplantation. 
 
Accurate assessment of graft quality is increasingly important to achieve the highest 
levels of success in transplantation. Whilst donor information, such as patient age, 
co-morbidity or terminal serum creatinine, along with kidney biopsy data is important, 
they still have a limited capacity for accurate prediction of graft outcomes (Jochmans 
& Pirenne, 2011; Louvar et al., 2009). Machine perfusion parameters, such as 
resistance, are generally accepted as good indicators of graft quality but several 
studies have warned of the dangers of using resistance values to determine kidney 
discard (Jochmans et al., 2011; Sonnenday et al., 2003; de Vries et al., 2011). 
 
Theoretically, biomarkers measured in urine and perfusate have an advantage over 
biopsy data of being non-invasive and can be measured more frequently and 
objectively. A recent review highlighted the biomarkers that have been assessed in 
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regards to graft outcome (Bhangoo et al., 2012). Few studies were recent and even 
fewer were deemed to be of good quality. Levels of lactate dehydrogenase (LDH), 
glutathione-S-transferase (GST) and aspartate transaminase (AST) were significantly 
associated with DGF in the greatest number of studies but further validation was 
recommended. Other markers investigated in kidney perfusate include glucose, 
lactate, electrolytes, pH, gas pressures, osmolarity, redox active iron, 
malondialdehyde and total antioxidant status. 
   
Many potential biomarkers have and are being investigated across a variety of 
medical fields. These might predict or assess clinical outcomes or help to monitor 
treatments and responses. Few biomarkers, however, meet the strict criteria that are 
required for them to accurately predict or act as a substitute for clinical outcomes 
(Fleming, 2005). Many criteria have been suggested but a valid biomarker can be 
defined as ‘a biomarker that is measured in an analytical test system with well-
established performance characteristics and for which there is an established 
scientific framework or body of evidence that elucidates the physiological, 
toxicological, pharmacological, or clinical significance of the test results 
(www.fda.gov/cder/guidance/6400fnl.pdf).  
 
Validation of a biomarker is the process by which it is assessed and its performance 
characteristics defined, including the determination of the conditions under which the 
biomarker will give reproducible and accurate results (Wagner, 2002; Lee et al., 
2006). The process can be time-consuming and expensive but is necessary to 
ensure high-quality and reliable biomarkers. Different criteria can be assessed but 
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typically include measurement of sensitivity, specificity, bioanalytical assessment, 
probability of false positives, probability of false negatives and 
apharmacokinetic/pharmacodynamic model (Lesko & Atkinson, 2001). 
 
NMR-based metabolomics is a novel approach for rapidly identifying the changes in 
global metabolite profiles of biological samples and is widely used in disease studies 
(Nicholson et al., 1999). Several studies have demonstrated possibilities for the use 
of NMR-based metabolomics within transplantation. It has shown promise as a tool to 
predict long-term graft outcome based on the energy state of the kidney in-vivo and it 
may be able to assess biomarkers of kidney injury ex-vivo (Hauet et al., 2000c; 
Richer et al., 2000; Seto et al., 2001). More recently, NMR has been used to examine 
HMP perfusate in a pre-clinical DCD porcine model (Bon et al., 2014). This study 
concluded that analysis of biomarkers during HMP using NMR could be an 
interesting tool to assess graft quality and was compatible with clinical application.  
 
 
3.5.1 CONSTITUENTS OF KPS-1®  
 
In this study, the main constituents of KPS-1® were identified by 1H-NMR, except for 
HEPES and HES which the software cannot recognise. Of the identified metabolites, 
median levels of adenine, ribose, mannitol and gluconate did not change significantly 
over HMP time for all perfused kidneys.  
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3.5.1.1 ADENINE & RIBOSE 
 
Adenine is a purine base found in both DNA and RNA. When attached to ribose, it 
becomes the nucleoside adenosine. Adenosine triphosphate (ATP) is formed when 
three phosphate groups are added to adenosine. Adenosine triphosphate is used in 
cellular metabolism as one of the basic methods of transferring chemical energy 
between chemical reactions (www.HMDB,ca Wishart et al., 2013). 
 
Ribose is a 5-carbon sugar found in all living cells. As mentioned above, it is a 
constituent part of ATP. When ATP stores are rapidly depleted, ribose can help to 
restore levels by bypassing the rate-limiting step in the de-novo pathway. Ribose can 
be synthesised by many tissues in the body from other substances, such as glucose 
(www.HMDB,ca Wishart et al., 2013). 
 
Adenine and ribose were historically added to perfusion fluids, in preference to 
adenosine, to increase the synthesis of adenine nucleotides (McAnulty, Southard, & 
Belzer, 1987). Ribose was almost undetectable in the perfusate samples even at 45 
minutes so not detecting a change over time is unsurprising. This could be a true 
reflection of ribose levels or it could due to changes in labelled concentrations during 
the storage period. Ribose also has a complex pattern on spectral analysis and the 
peaks overlap with neighbouring spikes making quantification difficult. Adenine 
concentrations, however, also did not alter over time or between the perfusate of 
kidneys with DGF or IGF possibly reflecting that this is not an important source of 
energy in HMP kidneys. 
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3.5.1.2 GLUCONATE & MANNITOL 
 
Gluconate (like mannitol) is present in preservation solution to provide osmotic 
stability, so a significant change in concentration would be unexpected. Gluconate 
levels were, however, significantly lower in the perfusate of DGF kidneys at 4 hours. 
It is possible that cellular damage in the DGF kidneys allows influx of gluconate into 
the cell which would not normally occur within healthy tissue.  
 
 
3.5.1.3 GLUTATHIONE 
 
Glutathione is included in many preservation solutions, including KPS-1®, and acts 
as a free radical scavenger to attenuate ischaemia-reperfusion injury. It contains the 
crucial thiol (-SH) group that makes it an effective antioxidant (www.HMDB,ca 
Wishart et al., 2013). 
 
Concentrations of reduced glutathione decreased significantly over HMP time in both 
DGF and IGF kidney perfusate. Glutathione in its oxidised form was not detected. 
The oxidisation of glutathione during HMP time could account for this apparent 
decrease. 
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3.5.1.4 GLUCOSE 
 
Glucose is a monosaccharide containing six carbon atoms and an aldehyde group. It 
is a primary source of energy for living organisms. Glucose can be synthesised in the 
kidneys from non-carbohydrate intermediates, such as pyruvate and glycerol, by 
gluconeogenesis (www.HMDB,ca Wishart et al., 2013). 
 
Glucose is included in preservation solutions to prevent energy loss and increase 
osmotic pressure. It actually increased just significantly over perfusion time when all 
kidneys were examined. However, glucose levels in the perfusate of DGF kidneys 
were significantly lower at both time-points than those found in the perfusate of IGF 
kidneys, with good AUROCs for prediction of DGF. Although the reason for this is not 
known, it is possible that more glucose is utilized for repair by damaged DGF kidneys 
or that DGF kidneys are not effectively suppressed by hypothermia and require more 
glucose for metabolism.  
 
Glucose levels measured by NMR did not correlate with levels measured with the 
bedside glucometer. This was attempted to assess the possibility of a simple clinical 
test in comparison to the more complex metabolomics analysis. The glucometer is 
designed for use with blood so the constituents or viscosity of the perfusion solution 
may have affected its accuracy. Samples tested had also been stored for varying 
levels of time at -70ºC. This could have degraded the samples. The accuracy of the 
glucometer also varies with only 66% of readings being within 10% of a standard 
measured by a laboratory glucose monitor. 
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3.5.2 NEW METABOLITES IN PERFUSATE 
 
Of the metabolites discovered that are not part of the preservation solution two of 
these, leucine and inosine, were significantly different in the perfusate of DGF 
kidneys compared to IGF kidney perfusate at 45 minutes.  
 
 
3.5.2.1 LEUCINE 
 
Leucine is one of three branched chain amino acids, an essential amino acid whose 
carbon structure is marked by a branch point. This type of amino acid is particularly 
involved with stress, energy and muscle metabolism (www.HMDB,ca Wishart et al., 
2013). The role of the kidney in the metabolism of branched chain amino acid 
remains incompletely understood (van de Poll et al., 2003). 
 
Leucine was detected in significantly higher levels in the perfusate of DGF kidneys at 
45 minutes. It is known that larger proteins are released into the perfusate during 
HMP as a sign of cellular damage (Hoogland et al., 2013). Raised concentrations of 
amino acids could indicate increased cellular breakdown in the more ischaemically 
damaged DGF kidneys.  
 
Other amino acids identified in the perfusate included the other two branched chain 
amino acids valine and isoleucine along with alanine, glycine, glutamate and 
tyrosine. The concentrations of all of these increased significantly over time in the 
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perfusate of all kidneys but were not significantly different between the DGF and IGF 
groups.  
 
 
3.5.2.2 INOSINE 
 
Inosine is formed from the breakdown of adenosine nucleotides such as adenosine 
monophosphate, adenosine diphosphate and adenosine triphosphate. 
 
Concentrations of inosine were significantly lower in DGF kidney perfusate at 45 
minutes compared to IGF perfusate. The lower levels of inosine detected in the more 
ischaemically damaged DGF kidneys would suggest that this is not being released as 
a product of cellular degradation but is a product of cellular metabolism. Although the 
pathway involved is not clear, it is unlikely that the detected inosine was formed from 
the adenine in the preservation fluid, as adenine levels did not decrease over time to 
correspond with this. The AUROCs for leucine and inosine at 45 minutes were good 
at 0.833 and 0.732. 
 
 
3.5.2.3 OTHER METABOLITES 
 
Other metabolites of interest identified in HMP perfusate include the ketone body 3-
hydroxybutyrate, increasing concentrations of which may indicate ongoing fatty acid 
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metabolism which is the main source of energy in the renal cortex during 
hypothermia (Ayala-García et al., 2012).  
 
Levels of lactate increased in the perfusate of HMP over time, as might be expected, 
due to the production of lactate by glycolysis in anaerobic conditions. Also detected 
to be increasing over time were citrate and glutamate which are both intermediates of 
the citric acid cycle.  
 
Glycine concentrations increased over time and, although just failing to reach 
statistical significance, glycine levels were higher in the perfusate of IGF kidneys 
compared to that from DGF kidneys. Glycine has been shown to prevent renal 
tubular cell injury in a rat model by reducing mild IR injury (Yin et al., 2002). 
 
 
3.5.3 PREDICTION OF DGF 
 
The metabolites identified as significantly different between the HMP perfusate of 
DGF and IGF kidneys show promise as predictors for DGF. The ROC curve analysis 
demonstrates AUROCs of between 0.732 and 0.895 which is considered to be ‘fair’ 
to ‘good’.  
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3.5.4 LIMITATIONS 
 
To further elucidate the processes occurring during HMP, examination of additional 
timepoints would be useful. Two early timepoints were chosen for this study to 
examine the potential for indicators of graft function that would be applicable in a 
clinically useful timeframe and to ensure that samples at comparable times were 
available for all kidneys. Furthermore, HMP parameters changed most markedly 
within the first hour of perfusion which might have been reflected in the metabolic 
profile of the perfusate. A combined analysis of HMP parameters and metabolomic 
data might be of interest but has not been performed in this study. 
 
At present, HMP is not used as a standard preservation technique at organ recovery 
in the UK. In this study, kidneys were placed on HMP at our unit and remained at the 
centre for transplantation. If HMP were utilised from recovery, sample collection for 
studies such as this would be more complicated. However, some evidence suggests 
that using HMP from recovery might be more beneficial than using a combination of 
SCS and HMP (Moers et al., 2009; Watson et al., 2010). 
 
NMR has revealed many metabolites that may help to elucidate the underlying 
metabolic processes occurring during HMP. However, not surprisingly, there are 
limitations. Not every signal produced on the spectra can, as yet, be identified and 
complex molecules can produce spectral patterns that overlap each other. This can 
sometimes make identification and quantification difficult. Furthermore, it is unclear 
how accurately levels of perfusate metabolites reflect intracellular activity. This study 
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has used the technique to screen perfusate and has identified specific metabolites 
(glucose, inosine, leucine, gluconate) that might be predictive of graft function. These 
would require further investigation and validation, as discussed earlier. Studies have 
now commenced to determine whether routine biochemical assays of these 
metabolites would be helpful in providing real time data to support clinical practice. 
 
This type of analysis may not yet be transferrable into general clinical practice. A 
recent study suggested that analysis of perfusate using NMR could be performed in 
less than 2 hours and within accepted timeframes for clinical application (Bon et al., 
2014). This relied on rapid processing of samples, a limited selection of metabolites 
and access to a local spectrometer. Many centres will not have an on-site NMR 
facility with 24-hour access and the necessary expertise to process and analyse the 
samples. This could change in the future but at present, at our facility, would be 
impractical. 
 
 
3.5.5 CONCLUSION 
 
In this study, it has been possible to identify differences in the metabolomic profiles of 
perfusate from kidneys with immediate and delayed graft function. These differing 
metabolites may prove to have a useful predictive role in viability assessment. With a 
better understanding of the underlying metabolic processes occurring in damaged 
kidneys, it may be possible to modify harmful metabolic processes, support cell 
function and possibly extend storage periods prior to transplantation. 
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CHAPTER FOUR: DEVELOPMENT & ASSESSMENT OF A PORCINE MODEL 
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4.1 BACKGROUND 
 
In order to further investigate the mechanisms of HMP and to test future hypothesis, 
an experimental model needed to be developed. Animal models continue to be used 
in medical research to characterize human diseases and to design and test 
therapeutic interventions (Giraud et al., 2011).  
 
Rodent, canine and porcine organs have all been used in such experiments in 
transplantation. The first renal transplantation was performed by Emerich Ullmann in 
a dog in 1902 and the first pig kidney transplant was reported in 1965 (Mery et al., 
1965). The porcine kidney structure, being multilobular, is more similar to the 
structure of human kidneys than rodent or dog kidneys, which have a unilobular 
structure. The similarity in size, physiology, and in organ development and disease 
progression make the pig an ideal model for human disease research (Bon et al., 
2014; Giraud et al., 2011; Sachs 1994). 
 
Porcine organs have been used not only in perfusion experiments on the kidney but 
also in the investigation of HMP on liver (Monbaliu et al., 2007) and pancreas (Taylor 
et al., 2008). They have been used extensively to investigate several areas relevant 
to clinical transplantation: to compare SCS and HMP preservation (Hosgood et al., 
2010; La Manna et al., 2009), to investigate normothermic preservation techniques 
(Hosgood & Nicholson, 2011) and to test novel preservation solutions (Kay et al., 
2011). More recently, perfusate from a porcine HMP auto-transplant model has been 
examined with NMR (Bon et al., 2014). 
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Under normal physiological conditions, the metabolomic profile of porcine blood, 
kidney tissue, urine and serum has been shown to be comparable to humans 
(Merrifield et al., 2011; Nielsen et al., 2014). These experiments, utilising NMR, have 
demonstrated that metabolites observed in pigs are qualitatively comparable to that 
of humans. This has not been validated in the ex-vivo hypothermic environment as 
encountered during HMP.   
 
 
4.2 AIMS 
 
For this section of the study, a porcine kidney model needed to be developed which 
was representative of the retrieval and storage process in humans. If this could be 
achieved, numerous repeated experiments would be possible and modifications 
could be attempted which would not be appropriate with human kidneys. 
 
Using a paired kidney model, the metabolomic profile of perfusate from porcine 
kidneys stored by SCS was compared to the perfusate of those stored by HMP. 
Biopsies for histology were also taken to assess for changes present at the cellular 
level for each storage method. 
 
Then, the parameters and metabolic profile of porcine kidneys during HMP were 
compared to that of the previously examined HMP human kidneys in an attempt to 
assess the validity of the porcine model. 
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4.3 METHODS 
 
4.3.1 SOURCING OF PORCINE KIDNEYS 
 
Facilities for animal retrieval and transplantation are not available at the University of 
Birmingham. Therefore, pig kidneys were sourced from a local abattoir. Initial and on-
going discussion with the abattoir staff ensured that the retrieval process represented 
the human retrieval process as closely as possible. 
 
 
4.3.2 PORCINE KIDNEY RECOVERY 
 
Large white pigs, at 22-26 weeks of age,  
 Kidneys were 
recovered within 20 minutes of in-situ warm ischaemia. A pair of kidneys from each 
pig was retrieved per experiment.  
 
 
4.3.3 PORCINE KIDNEY FLUSH 
 
Kidneys were taken to a sterile area for preparation. Both kidneys were flushed 
simultaneously and as soon as possible following recovery. Each organ was flushed 
with 1 litre of Soltran® kidney perfusion fluid at 4ºC via a giving set and cannula at a 
pressure of 150mmHg. 
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Each kidney was then placed in a bag with 500 ml of KPS-1® and then transferred to 
an ice-box for transport to the laboratory. Once transported, one kidney was placed 
in the fridge in an ice-box (SCS) and the other transferred to HMP. The choice of 
kidney designated to each storage method was performed at random. 
 
 
4.3.4 HMP TECHNIQUE 
 
The kidney allocated to HMP was transferred to a LifePort© Kidney Transporter 1.0 
(Organ Recovery Systems) at the laboratory. This machine was acquired for 
research use only, but was the same as the machine used clinically. The machine 
was prepared as stated in the clinical section of the study with the perfusion pressure 
set at 30mmHg. Kidneys were perfused with a fresh 1L of KPS-1® at 4°C. HMP 
parameters were monitored throughout perfusion time. 
 
 
4.3.5 SAMPLE COLLECTION 
 
Samples were collected at the following time-points from the beginning of HMP:  
 
• start of HMP, 15 minutes, 30 minutes, 45 minutes, 60 minutes 
• 4 hours, 8 hours, 18 hours, 24 hours, 28 hours 
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At each time-point, 10 mL of perfusate was collected from the SCS fluid and from the 
HMP perfusate. For SCS sampling, a 3-way tap was connected to the renal artery 
and 60 mL of the SCS fluid was flushed through the kidney vasculature prior to 
sampling the perfusate. This was to try to ensure that the sample was representative 
of the fluid retained within the kidney. 
 
2 mL of the perfusate was transferred into a cryogenic vial and stored at -20°C until 
thawed at room temperature, prepared and processed for NMR analysis.  
 
The remaining 8 mL was centrifuged at 4°C for 5 minutes at 1700 RPM. The 
supernatant was separated and stored at -80°C. The remaining pellet was mixed with 
1 mL of freezing media (5ml DMSO/45ml FCS) and also stored at -80°C. These were 
stored as reserve samples for repeat or further analysis. 
 
In addition to this, trucut biopsy samples were taken with a 16-gauge needle at 0 
minutes, 18 hours and 28 hours. These were stored in formalin and processed at the 
UHB clinical laboratory for examination by light microscopy (LM). 
 
 
4.3.6 MODIFICATIONS 
 
Following the use of this model with the first five pairs of pig kidneys, a number of 
modifications were made to the design. Several attempts and modifications were 
required to improve the protocol: 
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Attempts were made to increase the sterility of the procedure. Whilst the processing 
at the abattoir was of the standard required by the British Meat Processors 
Association, it was not theatre standard. Theatre drapes were used at the abattoir 
workstation to minimise possible contamination and the pressure bag handles were 
covered with sterile gloves.  
 
To try to minimise contamination from the kidney itself, kidneys were dipped in iodine 
and washed with Soltran®. Iodine was chosen as it has an easily identifiable spike on 
the NMR spectrum so would not cause interference during metabolomic analysis. 
 
The HMP kidney from the second pair of pig kidneys did not perfuse well on the 
machine. It appeared that a distal division had been perfused following recovery 
rather than the main artery. This resulted in inadequate clearance of the vasculature 
in about 40% of the inferior part of the kidney. Following this, kidneys were rejected 
at the abattoir if they didn't perfuse globally. 
 
Examination of the first few sets of histology samples showed that light microscopy 
was insufficient to detect any changes between SCS and HMP kidney tissue. 
Following this fewer samples were taken, at 4 and 28 hours only, but they were 
stored in 4% formaldehyde/10% normal saline to allow more detailed examination 
with electron microscopy (EM). 
 
Additional timepoints were added for collection of samples for NMR analysis. Using 
porcine kidneys allowed increased experimental time as the kidneys were being 
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discarded following use in the model. Additional samples were collected at 48, 72 
and 120 hours when possible. 
 
In the initial protocol, the SCS kidney remained in the same 500mL of preservation 
fluid from recovery through storage time. The HMP kidney was stored with a fresh 1 
litre of fluid when transferred to the machine from storage and transport. This made 
calculations of concentrations more difficult than necessary and changing the fluid 
following transport could have altered the detected concentrations. For further 
experiments, each kidney was placed in 500ml from the same bag of KPS-1® at 
recovery. When back at the laboratory, a further 1L bag of KPS-1® was divided 
between the kidney pair for continued storage. 
 
 
4.3.7 PREPARATION FOR NMR 
 
4.3.7.1 SAMPLE PROCESSING 
 
Sample processing was performed by the same method as described for the human 
perfusate samples in section 3.3.5. 
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4.3.7.2 SPECTRAL ACQUISITION 
 
Spectral acquisition was performed by the same method as described for the human 
perfusate samples in section 3.3.6. 
 
 
4.3.7.3 SPECTRAL ANALYSIS 
 
Resultant spectra were examined at three time-points for the first five pairs of porcine 
perfusate samples - 45 minutes, 4 hours and 28 hours. For the following five pairs, 
additional timepoints were examined – 48, 72 and 120 hours. Spectra were 
examined as previously described in section 3.3.8 using Chenomx 7.0 (Professional 
edition, version 7, Chenomx, Edmonton, AB, Canada). Further examples of spectral 
assignments are shown in figure 4.1.  
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Figure 4.1: Examples of Porcine Spectral Assignments 
 
 
  
Citrate  
  
Lactate  
  
Glutamate 
  
Formate 
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4.3.7.4 STATISTICAL ANALYSIS OF PORCINE DATA 
 
Data were analysed using GraphPad Prism version 6.0c for Mac (GraphPad 
Software, La Jolla California USA, www.graphpad.com) and IBM SPSS 19 (IBM 
Corp. Armonk, NY). A p-value <0.05 was deemed to be indicative of statistical 
significance throughout.  
 
Prior to analysis, the distribution of metabolites was examined. Where non-normality 
was detected, Log10-transformations were applied. Since there were some zero 
measurements, a constant was added to each of the measurements before the 
transformation. This was a multiple of ten one order of magnitude lower than the 
mean value of the metabolite being considered. For example, if the mean was 1, then 
0.1 would be added to all of the values before the Log10-transformation. 
 
Repeated measures ANOVA models were then used to compare metabolite 
concentrations, between HMP and SCS, and across the three timepoints. In addition 
to the main effect terms in the models, interaction terms were also included, in order 
to compare the rate of change over time in the metabolite concentrations between 
HMP and SCS kidneys. Where the assumption of sphericity was violated i.e. when 
the variances of the differences between all combinations of related groups were not 
equal, the Greenhouse-Geisser corrected p-values were used. The Greenhouse-
Geisser calculation corrects the degree of freedom of the F-distribution for a more 
accurate significance value. 
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Data were reported as arithmetic means and 95% confidence intervals for the 
normally-distributed data. Where Log-transformations were used, the resulting 
summary statistics were back transformed, and reported as geometric means and 
95% confidence intervals. 
 
 
4.3.8 HISTOLOGICAL PREPARATION FOR LIGHT MICROSCOPY 
 
Samples were prepared for examination with light microscopy using two different 
stains: haematoxylin and eosin and Periodic acid Schiff. These were prepared using 
the established, standard techniques. 
 
 
4.3.9 HISTOLOGICAL PREPARATION FOR ELECTRON MICROSCOPY (EM)  
 
The protocols used to prepare the porcine kidney samples for electron microscopy in 
the UHB laboratory are described briefly here. 
 
The main ultramicrotome in the unit is the Leica UC7. This is used for cutting semi-
thin and ultra-thin sections of resin embedded tissue. Tissue has to be sectioned very 
thinly in order to obtain optimal resolution of ultrastructural detail.  All semi-thin 
survey sections (0.4-0.7µm thick), for examination at the light microscope (LM) level, 
are cut using a glass knife.  Ultra-thin (70-90nm thick) sections for examination at the 
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EM level can be cut using glass knives, but experienced ultramicrotomists usually 
use a diamond knife.   
 
Semi-thin survey sections: toluidine blue staining 
 
Semi-thin resin sections are used for two purposes. Because the EM uses very high 
magnifications, the area of tissue that can be examined in a reasonable length of 
time is small.  The area available for individual ultra-thin sections is also strictly 
limited.  To reduce as much as possible the sampling problem, several larger pieces 
of tissue are embedded in resin and semi-thin sections are cut from a number of 
these and stained with toluidine blue for examination by LM.  Areas of particular 
interest are selected for ultra-thin sectioning based on the clinical diagnosis and any 
features of interest. 
 
Formvar coated grids 
 
Ultra-thin sections are mounted on slot grids for examination by EM. These are 
coated with a thin film of Formvar which spans the slot and acts as a support for 
sections.  It is then possible to examine the entire section. 
Ultra-thin sections 
 
Unstained ultra-thin sections have no contrast. Uranyl acetate followed by lead citrate 
(an alkaline solution of lead citrate) is the routine staining sequence used for these 
sections.  The heavy atoms of uranium and lead become attached to subcellular 
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structures, increasing their electron density and thus enhancing the contrast of the 
electron image. Uranyl acetate is used dissolved in methanol. 
 
Staining ultra-thin sections with uranyl acetate 
 
1 Clean the grid staining area with alcohol. 
2 Put the grid holder in the glass dish and the dish in the square plastic box. 
3 Carefully place grids to be stained in the grid holder, usually three grids per 
block. 
4 Check name labels in each Petri dish of grids and make a record of which grid 
is in which position on form. 
5 Make sure the grids do not protrude above the level of the holder. 
6 Put the staining dish on the tray. 
7 Pour the methanol from the "Used methanol" into the glass dish around the 
grid holder and cover with the square plastic lid.  This provides a methanolic 
atmosphere and helps reduce the evaporation of methanol from the stain 
solution which could lead to stain deposit on the sections. 
8 Put the bottle of uranyl acetate stain on the tray.  Withdraw approximately half 
a pipette full of stain and transfer quickly to cover the grids; use all the stain in 
the pipette, do not return excess stain to the bottle.  Have the lid off the box for 
as little time as possible. 
9 Wash out the glass pipette with water directly down the plughole.  Set timer for 
18 - 20 minutes for muscle, nerve and renal tissue. 
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10 Set timer for 6 minutes for renal tissue reclaimed from wax. Formalin-fixed 
tissue may require reduced staining times. 
11 Check periodically that the stain has not evaporated, top up with fresh uranyl 
acetate as necessary. 
12 Replace uranyl acetate stain in the fridge making sure the lid is screwed on 
tightly. 
13 Put the three glass rinsing vials on the metal tray and fill with AnalaR 
methanol. 
14 Rinse each grid by dipping into the three vials in turn, approx. 30 dips per vial. 
15 Blot off excess from between tines with filter paper. 
16 Leave grid in fine forceps to dry; place on bench and cover with Petri dish lid. 
17 Leave all grids to air dry for at least half an hour with card indicating Uranyl 
only. 
18 Pour methanol from third rinse into the 'used methanol' vial for next time. 
19 Filter paper contamination should be negligible, dispose of into clinical waste. 
 
Staining ultra-thin sections with Reynold's lead citrate 
 
1 Clean the demarcated grid staining area of the bench with alcohol. 
2 Place the wax sheet over the sodium hydroxide pellets in the Petri dish and 
put the dish on the tray. 
3 Put the bottle of Reynolds lead citrate solution on the tray close to the dish. 
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4 Withdraw about 1mL of the staining solution with a glass pipette and put out 
drops on the wax; grids from the same block can share a drop of stain.  Do not 
return excess stain to the bottle. 
5 Blot tip of pipette with paper. 
6 Place the grids section side down on the drops of stain. 
7 Set timer for 18 - 20 minutes for renal tissue. Formalin-fixed material, or 
samples reclaimed from wax may require reduced staining times. 
8 At the end of the staining period, pick up each grid in turn and rinse thoroughly 
with deionised water, e.g. by dipping into a beaker of fresh water for about 10 
seconds, and then placing them under a stream of about 50ml of water from 
the wash bottle. 
9 Draw off excess water from between tines of forceps with filter paper. 
10 Leave grid in fine forceps to dry; place on bench and cover with plastic lid. 
Leave all grids to air dry for at least half an hour. 
 
Tissue fixation 
 
Glutaraldehyde followed by osmium tetroxide as the secondary fixative is the 
generally recommended fixation sequence for routine electron microscopy.  
 
Glutaraldehyde is a very good fixative for subcellular structures but it has a slow rate 
of penetration. Formaldehyde is included in the primary fixative as it penetrates more 
quickly. Tissue is fixed in a mixture of glutaraldehyde and formaldehyde, "PGP", 
which is 4% paraformaldehyde, 2% glutaraldehyde in 0.1M sodium phosphate buffer, 
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pH 7.2-7.4.  Samples trimmed for EM in the Histopathology lab will go into phosphate 
buffered glutaraldehyde (2.5%)  
 
The osmium tetroxide helps to stabilise lipid components of the tissue, decreasing 
their extraction during subsequent processing with organic solvents.  Osmium 
tetroxide also acts as an electron stain because osmium is a heavy atom. 
 
Tissue Processing 
 
For the examination of tissues by EM, it is necessary to cut very thin sections.  In 
order to do this without the specimen being compressed beyond usefulness, pieces 
of tissue are embedded in resin after the subcellular structure has been preserved by 
a routine fixation sequence of glutaraldehyde followed by osmium tetroxide.  The 
water in the tissue is replaced by increasing concentrations of alcohol and the alcohol 
is in turn replaced by propylene oxide.  This is miscible with Araldite, a thermosetting 
resin in which the tissue is blocked out. 
 
 
4.3.10 COMPARISON OF PORCINE & HUMAN HMP KIDNEYS 
 
In order to enable a valid comparison of HMP parameters and metabolomics, 10 
porcine kidneys were compared with 12 standard criteria cadaveric human kidneys, 
all of which were successfully transplanted with immediate graft function. 
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4.3.11 STATISTICAL ANALYSIS OF PORCINE & HUMAN KIDNEYS 
 
All analysis was performed using GraphPad Prism 6.0c (GraphPad Software, La 
Jolla California USA) and IBM SPSS 19 (IBM Corp. Armonk, NY), with p<0.05 
deemed to be indicative of statistical significance. 
 
Prior to analysis, the distribution of metabolites was examined. Where data was non-
parametric, Log10-transformations were applied, after adding 1 to remove zero 
values. Repeated measures ANOVA models were then used to compare metabolite 
concentrations, both between pig and human samples, and between 45 minute and 4 
hour timepoints. In addition to the main effect terms in the models, interactions were 
also included, in order to compare the rate of change over time in the metabolite 
concentrations between pig and human samples.  
 
Data were reported as arithmetic means and 95% confidence intervals for the 
normally-distributed data. Where Log-transformations were used, the resulting 
summary statistics were back transformed, and reported as geometric means and 
95% confidence intervals. 
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4.4 RESULTS 
 
Ten pairs of porcine kidneys were examined in total - five pairs using the initial 
protocol and the following five pairs with the modified protocol. The HMP kidney from 
pig 2 was excluded from analysis due to inadequate flush at recovery. 
 
 
4.4.1 ISCHAEMIC TIMES 
 
All porcine kidneys underwent a combination of WIT and CIT as comparable to a 
model of DCD donation. 
 
Median WIT during recovery was 18 minutes (IQ range 18-18 minutes). Average CIT 
during transport was 152.5 minutes (IQ range 146.25 - 157.5 minutes). 
 
The first five pairs of pig kidneys then underwent a further 28 hours of HMP or SCS 
depending on their designated storage method, with the following five pairs 
undergoing up to 120 hours of their designated storage method.  
 
 
4.4.2 PORCINE HMP PARAMETERS 
 
Median flow rate at the start of perfusion for all porcine kidneys was 34 mL/min (IQ 
range 29.0-41.0) increasing to a median of 52 mL/min (IQ range 40.0-71.5) at 28 
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hours of perfusion. Median resistance at the start of perfusion was 0.82 
mmHg/ml/min (IQ range 0.67-1.02) decreasing to 0.46 mmHg/mL/min (0.34-0.66) by 
28 hours of perfusion.  
 
Figure 4.2 shows an example of a typical case report from a porcine HMP kidney: 
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Figure 4.2: LifePort Kidney Transporter Case Report Showing Machine Parameters 
for Porcine HMP Kidneys 
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4.4.3 PORCINE NMR ANALYSIS 
 
A total of 30 metabolites were identified in the perfusate of porcine kidneys. The 
following tables and graphs represent the metabolite concentrations and changes 
over time for the SCS & HMP porcine kidneys. Only metabolites with statistically 
significant results are shown. The complete table and figures can be seen in the 
appendices. 
 
 
Table 4.1: Metabolite Concentrations (mM) Measured in Kidney Perfusate of SCS 
& HMP Porcine Kidneys (Significant Metabolites Only) 
 
This table shows the arithmetic or geometric mean (with confidence intervals) for 
metabolites at each timepoint and according to storage method. "Time" is testing 
whether there is a change in the metabolite levels over time (independent of storage 
type), "Storage" is comparing the metabolite concentrations for the two different types 
of kidney storage (independent of timepoint) and "Int." is the interaction term in the 
model. This tests whether the rate of change over time differs between HMP and 
SCS. 
 
 
 
 
Timepoint p-Values 
 
 
Storage 45 Minutes 4 Hours 28 Hours Time Storage Int. 
Ribose# HMP 2.5 (1.9 - 3.0) 2.3 (1.7 - 2.9) 2.4 (2.0 - 2.7) 0.846 0.004* 0.696 
SCS 3.3 (2.8 - 3.8) 3.4 (3.0 - 3.9) 3.4 (3.1 - 3.8) 
Glutathione# HMP 0.96 (0.80 - 1.11) 0.39 (0.24 - 0.54) 0.00 (0.00 - 0.00) <0.001* <0.001* <0.001* 
SCS 1.59 (1.33 - 1.86) 1.64 (1.38 - 1.91) 1.55 (1.31 - 1.79) 
Lactate# HMP 0.58 (0.16 - 0.99) 0.65 (0.47 - 0.83) 1.23 (0.92 - 1.55) <0.001* 0.126 0.755 
SCS 0.43 (0.18 - 1.04) 0.19 (0.12 - 0.27) 0.83 (0.44 - 1.22) 
Citrate HMP 2.3 (1.4 - 3.9) 2.6 (1.7 - 4.1) 3.1 (2.2 - 4.4) <0.001* 0.737 0.236 
SCS 1.6 (0.8 - 3.4) 2.3 (1.1 - 4.7) 3.4 (1.7 - 6.8) 
  185 
Alanine HMP 0.065 (0.049 - 
0.085) 
0.107 (0.075 - 
0.152) 
0.201 (0.152 - 
0.266) 
<0.001* <0.001* 0.056 
SCS 0.025 (0.015 - 
0.041) 
0.031 (0.019 - 
0.051) 
0.103 (0.069 - 
0.152) 
Glutamate HMP 0.38 (0.24 - 0.61) 0.98 (0.74 - 1.30) 2.15 (1.89 - 2.45) 0.001* <0.001* 0.733 
SCS 0.06 (0.03 - 0.15) 0.11 (0.05 - 0.23) 0.25 (0.11 - 0.58) 
Hypoxanthine HMP 0.12 (0.07 - 0.18) 0.18 (0.12 - 0.28) 0.26 (0.22 - 0.32) 0.015* 0.003* 0.704 
SCS 0.04 (0.02 - 0.07) 0.04 (0.02 - 0.09) 0.08 (0.03 - 0.20) 
Fumarate HMP 0.0033 (0.0016 - 
0.0068) 
0.0053 (0.0030 - 
0.0094) 
0.0161 (0.0124 - 
0.0209) 
<0.001* 0.022* 0.362 
SCS 0.0014 (0.0006 - 
0.0036) 
0.0011 (0.0004 - 
0.0031) 
0.0064 (0.0039 - 
0.0106) 
Leucine HMP 0.017 (0.012 - 
0.023) 
0.023 (0.016 - 
0.034) 
0.035 (0.027 - 
0.044) 
<0.001* 0.013* 0.247 
SCS 0.004 (0.002 - 
0.008) 
0.008 (0.004 - 
0.017) 
0.017 (0.008 - 
0.035) 
Valine HMP 0.016 (0.012 - 
0.020) 
0.024 (0.016 - 
0.036) 
0.035 (0.027 - 
0.046) 
<0.001* 0.008* 0.256 
SCS 0.005 (0.002 - 
0.009) 
0.008 (0.004 - 
0.013) 
0.017 (0.008 - 
0.037) 
Glycine HMP 0.58 (0.45 - 0.75) 1.47 (1.12 - 1.93) 2.63 (2.32 - 2.98) <0.001* <0.001* 0.504 
SCS 0.10 (0.04 - 0.23) 0.18 (0.13 - 0.24) 0.52 (0.37 - 0.74) 
Pyruvate 
 
HMP 0.006 (0.003 - 
0.012) 
0.009 (0.005 - 
0.019) 
0.017 (0.007 - 
0.043) 
0.022* 0.169 0.414 
SCS 0.005 (0.002 - 
0.013) 
0.003 (0.001 - 
0.006) 
0.009 (0.004 - 
0.021) 
Hippurate HMP 0.0002 (0.0001 - 
0.0007) 
0.0007 (0.0001 - 
0.0038) 
0.0015 (0.0003 - 
0.0067) 
0.025* 0.532 0.620 
SCS 0.0002 (0.0001 - 
0.0005) 
0.0005 (0.0002 - 
0.0018) 
0.0005 (0.0001 - 
0.0021) 
Isoleucine HMP 0.009 (0.007 - 
0.011) 
0.014 (0.010 - 
0.020) 
0.021 (0.016 - 
0.027) 
0.004* 0.024* 0.348 
SCS 0.005 (0.002 - 
0.011) 
0.005 (0.003 - 
0.009) 
0.015 (0.009 - 
0.023) 
Tyrosine HMP 0.009 (0.007 - 
0.012) 
0.013 (0.009 - 
0.020) 
0.020 (0.016 - 
0.024) 
<0.001* 0.012* 0.211 
SCS 0.004 (0.002 - 
0.006) 
0.005 (0.003 - 
0.008) 
0.013 (0.007 - 
0.024) 
3-Methylxanthine HMP 0.009 (0.003 - 
0.028) 
0.008 (0.002 - 
0.028) 
0.017 (0.016 - 
0.018) 
0.190 0.007* 0.579 
SCS 0.002 (0.001 - 
0.003) 
0.002 (0.001 - 
0.004) 
0.002 (0.001 - 
0.005) 
 
Data reported as geometric means and 95% confidence intervals, unless stated otherwise. 
#Arithmetic means and 95% confidence intervals. 
p-values from repeated measures ANOVA. 
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Figure 4.3: Box and Whisker Plot to Represent Concentrations of Metabolites in 
HMP and SCS Porcine Kidney Perfusate (significant metabolites only) 
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Metabolites with a significant change in concentration over time and a significant 
difference in concentration between storage groups (no significant difference in the 
rate of change between storage goups). 
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Hypoxanthine Fumarate 
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Leucine 
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Glycine 
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Tyrosine 
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Metabolites with a significant change in concentration over time (no significant 
difference in concentration or rate of change between storage groups). 
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Metabolites with a significant difference in concentration between storage groups (no 
significant change in concentration over time or in the rate of change between 
storage groups). 
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4.4.4 PORCINE HISTOLOGY 
 
4.4.4.1 LIGHT MICROSCOPY 
 
Light microscopy performed on samples from the first five pairs of pig kidneys was of 
inadequate power to demonstrate any cellular differences between SCS and HMP 
kidneys. 
 
 
4.4.4.2 ELECTRON MICROSCOPY 
 
Biopsies were examined by electron microscopy at 4 and 28 hours of perfusion for 
two pairs of pig kidneys (pig 8 & 10). Elements examined were endothelial cells, 
epithelial cells, glomerular basement membrane and endothelium, arteriolar smooth 
muscle, tubules and peri-tubular capillaries. 
 
 
4.4.4.2.1 ENDOTHELIAL CELLS 
 
There was little difference between endothelial cells in either of the samples from 
SCS and HMP porcine kidneys. Nuclei were comparable and patterns of chromatin 
were similar (figure 4.4).  
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Figure 4.4: Electron Microscopy Images of Endothelial Cells in SCS & HMP 
Porcine Kidney at 4 & 28 Hours 
 
SCS 4 Hours SCS 28 Hours 
 
Magnification 9300x 
 
 
Magnification 23000x 
HMP 4 Hours HMP 28 Hours 
 
Magnification 11000x 
 
Magnification 30000x 
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4.4.4.2.2 EPITHELIAL CELLS 
 
In epithelial cells, there was little difference detected between biopsies from SCS and 
HMP kidneys at the 4 hour time-point with similar nuclei and normal foot processes 
seen. However, by 28 hours, the SCS cells showed increased evidence of 
cytoplasmic swelling with pale nuclei. This was evident in both pairs of porcine 
kidneys (figure 4.5). 
 
Higher magnification pictures show these changes in more detail with the pale 
swollen cytoplasm evident in the SCS epithelial cells (figure 4.6). 
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Figure 4.5: Electron Microscopy Images of Epithelial Cells in Porcine SCS & HMP 
Kidney at 4 & 28 Hours 
 
SCS 4 Hours SCS 28 Hours 
 
Magnification 1900x 
 
Magnification 1900x 
 
HMP 4 Hours HMP 28 Hours 
 
Magnification 1900x 
 
Magnification 2900x 
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Figure 4.6: Higher Magnification Electron Microscopy Images of Epithelial Cells in 
SCS Porcine Kidney at 28 Hours & HMP Porcine Kidney at 4 Hours 
 
SCS 28 Hours HMP 4 Hours 
 
Magnification 11000x 
 
Magnification 9300x 
 
 
4.4.4.2.3 GLOMERULAR BASEMENT MEMBRANE AND ENDOTHELIUM 
 
There were some differences in the glomerular basement membrane (GBM) of the 
HMP and SCS kidneys in pig 8 but these were not reproduced in pig 10. 
 
The fenestrae in the GBM of the HMP kidneys in pig 8 looked flatter and closer 
together compared to the SCS fenestrae which appeared to be more separated 
(figure 4.7).  
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Figure 4.7: Electron Microscopy Images of the Glomerular Basement Membrane in 
Porcine SCS & HMP Kidney at 4 & 28 Hours (pig 8 only) 
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4.4.4.2.4 ARTERIOLAR SMOOTH MUSCLE  
 
In the HMP kidneys, there appeared to be damage to the smooth muscle layer in the 
arterioles. The endothelium was intact at 4 hours but by 28 hours there was 
increased vacuolation in the smooth muscle layer of the HMP arterioles which 
appeared to be detached from the endothelium. These changed were present in both 
HMP porcine kidneys and not in the paired SCS samples (figure 4.8). 
 
These changes are clearer at higher magnification (figure 4.9). 
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Figure 4.8: Electron Microscopy Images of Arteriolar Smooth Muscle in Porcine 
SCS & HMP Kidney at 4 & 28 Hours 
 
SCS 4 Hours SCS 28 Hours 
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Figure 4.9: Higher Magnification Electron Microscopy Images of Arteriolar Smooth 
Muscle in SCS & HMP Porcine Kidney at 28 Hours 
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Magnification 2900x 
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4.4.4.2.5 TUBULES 
 
Tubular changes were variable. In pig 8, there were no identifiable differences. In pig 
10, the brush border was lost by 28 hours in the SCS kidney but intact in the HMP 
kidney (figure 4.10). 
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Figure 4.10: Electron Microscopy Images of Tubules in Porcine SCS & HMP Kidney 
at 4 & 28 Hours (pig 10 only) 
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4.4.4.2.6 PERITUBULAR CAPILLARIES 
 
There were no visible difference in the peri-tubular capillaries of HMP and SCS 
porcine kidney samples (figure 4.11). 
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Figure 4.11: Electron Microscopy Images of Peri-Tubular Capillaries in Porcine SCS 
& HMP Kidney at 4 & 28 Hours  
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4.4.5 COMPARISON OF PORCINE AND HUMAN HMP KIDNEYS 
 
4.4.5.1 ISCHAEMIC TIMES 
 
The median WIT for porcine kidneys during recovery was 18 minutes (IQ range 18-
18 minutes). None of the human kidneys used for comparison were subjected to a 
warm ischaemic insult prior to storage as they were cooled in-situ during recovery 
(DBD donors). 
 
Average CIT during transport was 152.5 minutes (IQ range 146.25 - 157.5 minutes) 
for the porcine group compared to 465 minutes (IQ range 360 - 679) for the human 
group (p=0.0005). 
 
Porcine kidneys underwent a further 28 hours of HMP. HMP period was variable for 
the human group. Samples were compared at the 45 minutes and 4 hours 
timepoints.  
 
 
4.4.5.2 HMP PARAMETERS 
 
Median flow rate at the start of perfusion for all porcine kidneys was 34 mL/min (IQ 
range 29.0-41.0) compared to 67mL/min (IQ range 53.0-89.0) for the human 
comparator group (p=0.0008). 
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At the end of perfusion time, median flow rate for the porcine kidneys was 52 mL/min 
(IQ range 34.0-82.5) compared to 116 mL/min (IQ range 98.0-129.0) in the sample of 
human kidneys (p=0.0002). 
 
These changes are reflected in the corresponding resistance measurements. The 
graph below shows the change over time for resistance in the porcine kidneys 
compared to the human kidneys. A repeated measures ANOVA model (figure 4.12) 
found that the change in resistance over time was significant in both groups 
(p=0.000). There was also a significant difference between the resistance of porcine 
and human kidneys at all time-points (p=0.000). The interaction term in the model 
was non-significant (p=0.067), hence there is no evidence that the trend in resistance 
over time is related to whether the kidney is human or porcine. 
 
Figure 4.12: Repeated Measures ANOVA Model for Change in Resistance During 
HMP Time in Human & Porcine Kidneys 
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4.4.5.3 METABOLOMICS 
 
A spectral overlay analysis was performed for the mean spectra for pig and human 
samples at 45 minutes and 4 hours. There were similar profiles for both pig and 
human groups (figure 4.13). There were no metabolites present in significant 
quantities that were not detected in the other group.  
 
 
Figure 4.13: NMR Spectral Overlay Plot Demonstrating The Similarity Of HMP 
Perfused Pig (Red) And HMP Perfused Human (Blue) Kidneys After 4 
Hours Of Perfusion 
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There were a total of 30 metabolites identified in the perfusate of both pig and human 
kidneys during hypothermic machine perfusion. Of these six (gluconate, mannitol, 
glucose, adenine, ribose and glutathione) were constituents of the original KPS-1® 
perfusion fluid. There was consumption of glutathione in both pig and human groups 
but no other significant interspecies or time effect for the other metabolites present in 
the preservation fluid. 
 
For the 24 metabolites present de novo, there was an overall change over time for 12 
(50%) with production of lactate, glycine, glutamate, hypoxanthine, alanine, 3-
hydroxybutryate, inosine, N-phenylacetylglycine, leucine, valine, isoleucine and 
fumarate. 
 
When concentrations were analysed according to species, there was no difference 
during HMP between pig and human kidneys for 16 metabolites (53.3%) following a 
repeated measures analysis.  
 
The rate of change of concentration for 3-Hydroxybutyrate was greater in human 
kidneys compared to pig kidneys (0.017 to 0.040mM vs 0.012 to 0.013mM) (p<0.001) 
For the other 29 metabolites (96.7%), there was no difference in the rate of change of 
concentration between pig and human samples (table 4.2). Figure 4.14 demonstrates 
several of the metabolites, that although detected in different concentrations, the rate 
of change was the same. 
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Table 4.2: Concentrations of Metabolites at 45 Minute & 4 Hours Timepoints with 
Repeated Measures Analysis and Comparison of Concentrations 
Between Human & Porcine Perfusate 
 
This table shows the arithmetic or geometric mean (with confidence intervals) for 
metabolites at each timepoint and according to species. "Time" is testing whether 
there is a change in the metabolite levels over time (independent of species), 
"Species" is comparing the metabolite concentrations for the two species 
(independent of timepoint) and "Int." is the interaction term in the model. This tests 
whether the rate of change over time differs between human and porcine perfusate. 
 
 Timepoint p-Values 
 Species 45 Minutes 4 Hours Time Species Int. 
Gluconate Human 92.9 (85.3 - 100.4) 96.6 (84.1 - 109.2) 0.799 0.342 0.616 
Pig 89.6 (78.4 - 100.7) 88.3 (76.4 - 100.3) 
Mannitol Human 48.8 (45.6 - 52.1) 52.3 (46.0 - 58.5) 0.543 0.368 0.667 
Pig 53.3 (45.8 - 60.7) 53.9 (45.0 - 62.7) 
Glucose Human 9.8 (9.0 - 10.6) 10.7 (9.6 - 11.7) 0.158 0.088 0.709 
Pig 11.4 (9.3 - 13.5) 12.9 (9.7 - 16.1) 
Adenine Human 7.0 (5.8 - 8.1) 7.1 (5.7 - 8.5) 0.924 0.681 0.816 
Pig 6.7 (5.7 - 7.7) 6.7 (5.4 - 7.9) 
Ribose Human 3.0 (2.8 - 3.3) 3.0 (2.4 - 3.6) 0.548 0.147 0.718 
Pig 3.7 (2.9 - 4.5) 3.4 (2.6 - 4.3) 
Glutathione Human 1.3 (1.2 - 1.4) 0.8 (0.6 - 0.9) <0.001* 0.731 0.1 
Pig 1.4 (1.2 - 1.7) 0.6 (0.4 - 0.8) 
Malonate Human 2.36 (2.04 - 2.67) 2.42 (1.90 - 2.95) 0.778 0.855 0.91 
Pig 2.26 (1.26 - 3.26) 2.41 (1.58 - 3.23) 
Citrate# Human 1.0 (0.6 - 1.6) 1.1 (0.5 - 1.8) 0.478 0.005* 0.672 
Pig 2.8 (1.7 - 4.5) 3.1 (1.9 - 4.8) 
Lactate# Human 0.94 (0.80 - 1.09) 1.88 (1.49 - 2.33) 0.002* 0.005* 0.057 
Pig 0.73 (0.37 - 1.17) 0.93 (0.69 - 1.22) 
Glycine# Human 0.58 (0.47 - 0.70) 1.86 (1.40 - 2.41) <0.001* 0.086 0.683 
Pig 0.87 (0.67 - 1.09) 2.20 (1.65 - 2.85) 
Glutamate# Human 0.26 (0.22 - 0.30) 1.05 (0.80 - 1.34) <0.001* 0.013* 0.545 
Pig 0.63 (0.34 - 0.99) 1.48 (1.07 - 1.96) 
Hypoxanthine# Human 0.17 (0.12 - 0.22) 0.29 (0.22 - 0.36) 0.005* 0.782 0.888 
Pig 0.19 (0.10 - 0.28) 0.30 (0.16 - 0.45) 
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Acetate# Human 0.13 (0.11 - 0.15) 0.13 (0.09 - 0.17) 0.507 <0.001* 0.462 
Pig 0.31 (0.20 - 0.43) 0.34 (0.23 - 0.47) 
Formate# Human 0.10 (0.07 - 0.13) 0.11 (0.08 - 0.15) 0.594 0.306 0.411 
Pig 0.13 (0.09 - 0.18) 0.13 (0.09 - 0.18) 
Alanine# Human 0.08 (0.07 - 0.09) 0.20 (0.16 - 0.24) <0.001* 0.961 0.133 
Pig 0.10 (0.08 - 0.12) 0.18 (0.13 - 0.23) 
Creatinine# Human 0.031 (0.020 - 0.043) 0.057 (0.049 - 0.065) 0.084 0.031* 0.558 
Pig 0.080 (0.029 - 0.133) 0.133 (0.040 - 0.233) 
Ethanol# Human 0.024 (0.021 - 0.027) 0.036 (0.010 - 0.063) 0.385 0.018* 0.573 
Pig 0.076 (0.040 - 0.114) 0.079 (0.037 - 0.123) 
Isopropanol# 
 
Human 0.023 (0.017 - 0.030) 0.025 (0.018 - 0.032) 0.792 0.063 0.167 
Pig 0.017 (0.015 - 0.019) 0.016 (0.014 - 0.018) 
3- 
Methylxanthine 
 
Human 0.020 (0.016 - 0.025) 0.024 (0.019 - 0.028) 0.361 0.118 0.44 
Pig 0.017 (0.010 - 0.023) 0.017 (0.010 - 0.023) 
3- 
Hydroxybutyrate 
Human 0.017 (0.013 - 0.021) 0.040 (0.031 - 0.048) <0.001* <0.001* <0.001* 
Pig 0.012 (0.006 - 0.017) 0.013 (0.005 - 0.020) 
Inosine# Human 0.017 (0.008 - 0.025) 0.023 (0.011 - 0.035) 0.038* 0.008* 0.241 
Pig 0.003 (0.001 - 0.004) 0.005 (0.002 - 0.007) 
Uracil Human 0.011 (0.010 - 0.012) 0.018 (0.013 - 0.023) 0.05 0.020* 0.258 
Pig 0.007 (0.005 - 0.008) 0.009 (0.000 - 0.017) 
N-Phenylacetyl 
glycine# 
Human 0.011 (0.005 - 0.016) 0.022 (0.010 - 0.034) 0.041* 0.18 0.094 
Pig 0.009 (0.003 - 0.014) 0.010 (0.004 - 0.016) 
Pyruvate# Human 0.011 (0.006 - 0.016) 0.010 (0.005 - 0.015) 0.371 0.112 0.24 
Pig 0.012 (0.005 - 0.019) 0.020 (0.010 - 0.030) 
Leucine# Human 0.008 (0.006 - 0.010) 0.017 (0.009 - 0.025) 0.020* <0.001* 0.787 
Pig 0.027 (0.016 - 0.037) 0.038 (0.025 - 0.052) 
Valine# Human 0.008 (0.006 - 0.010) 0.013 (0.010 - 0.016) 0.002* <0.001* 0.082 
Pig 0.024 (0.018 - 0.029) 0.041 (0.025 - 0.057) 
Tyrosine# Human 0.007 (0.001 - 0.012) 0.006 (0.005 - 0.008) 0.132 0.001* 0.083 
Pig 0.014 (0.010 - 0.017) 0.020 (0.014 - 0.026) 
Hippurate# Human 0.005 (0.002 - 0.007) 0.027 (0.000 - 0.067) 0.298 0.198 0.337 
Pig 0.001 (0.000 - 0.002) 0.002 (0.000 - 0.004) 
Isoleucine# Human 0.004 (0.004 - 0.005) 0.008 (0.006 - 0.010) 0.001* <0.001* 0.074 
Pig 0.014 (0.010 - 0.017) 0.024 (0.016 - 0.032) 
Fumarate# Human 0.003 (0.002 - 0.004) 0.004 (0.002 - 0.006) 0.012* 0.002* 0.295 
Pig 0.007 (0.004 - 0.009) 0.010 (0.007 - 0.013) 
Data reported as “Arithmetic Mean (95% Confidence Interval), unless stated otherwise 
#Analyses were log-transformed in the analysis, hence are reported as “Geometric mean (95% CI) 
*Significant at p<0.05 
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Figure 4.14: A Comparison Between Concentrations of Selected Metabolites in Pig 
& Human Kidney Perfusate at 45 Minutes and 4 Hours of HMP 
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4.5 DISCUSSION 
 
4.5.1 THE PORCINE MODEL 
 
Development of a porcine model was the first requirement for this part of the study. In 
designing the model, consideration had to be given to the facilities available.  
 
Ideally, a porcine auto-transplant model would have been developed. This would 
have allowed a kidney to be removed from a pig, stored as required, and then 
transplanted back into the same pig with simultaneous nephrectomy of the other 
kidney. The major advantage with such a model is the ability to measure graft 
function after storage through biochemistry, urine measurements and/or histology. 
Reproducible models of this type have been reported (Jochmans et al., 2009). 
Unfortunately, this type of facility is not available locally and, even if it were, it would 
most likely have been prohibitively expensive. This was a reasonable first step and 
corresponds to the clinical situation. 
 
An alternative option was to source pig kidneys from a local abattoir. Although an 
element of warm ischaemic time is unavoidable in this situation, pairs of pig kidneys 
could be retrieved and flushed in a relatively short time frame and with little expense. 
There were some initial issues with trial retrievals where damage to kidneys or 
vessels occurred. This meant that some kidneys had to be rejected at source but the 
procedure was improved and refined as more experiments were performed. As there 
was no option to transplant stored kidneys back into pigs, for the purposes of this 
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study it was assumed that all kidneys would be of similar quality and likely to display 
immediate graft function. 
 
A number of modifications were made to the model as the experiment progressed. 
The level of sterility was improved after concerns were raised regarding possible 
bacterial contamination of the porcine samples. Amino acids detected by NMR 
analysis could have been produced by breakdown of bacteria. Efforts were made to 
improve the retrieval and transport process. However, these amino acids were also 
detected in the human samples were levels of sterility are very high so these were 
unlikely to be contaminants.  
 
Use of the preservation fluid for the first five kidney pairs was not ideal. Initially, a 1-
litre bag of KPS® was split between the pair of kidneys at retrieval. Then, the HMP 
kidney was transferred to the machine with a fresh 1-litre bag of fluid. This could 
have diluted true concentrations and also meant that calculations were more 
complicated than necessary. This was adjusted for further experiments. 
 
Porcine HMP kidneys were stored on the laboratory research machine by the same 
method as used for the human kidneys. As the porcine kidneys were stored for 
longer, there was some difficulty keeping the kidney cool for the extended length of 
storage time in a warm laboratory. The machine stops if the temperature rises above 
7°C. This problem was solved by moving the machine to a cold room. The machine 
also only records HMP parameters for 48 hours, a problem not arising with human 
kidneys. 
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4.5.2 PORCINE ISCHAEMIC TIMES 
 
Warm ischaemic time in the porcine model was a median of 18 minutes followed by a 
period of SCS or HMP, mostly 48 hours but occasionally up to 120 hours. Using a 
porcine model allowed storage to be extended beyond what would be appropriate for 
human kidneys used for transplantation. 
 
This type of model is a reasonable representation of the DCD kidney retrieval & 
storage process in the UK, albeit with extended storage times for the porcine 
kidneys. It may not be as applicable to the DBD donation and storage process. 
 
 
4.5.3 PORCINE HMP PARAMETERS 
 
Flow increased and resistance decreased during porcine kidney HMP time. As 
previously experienced with the human kidneys, these changes occurred mostly 
within the first hour.  
 
Machine perfusion pressure was set at 30mmHg. This was selected as it is the 
recommended perfusion pressure for human kidneys. This is supported by additional 
work on a porcine auto-transplant model which showed that perfusion at 30mmHg 
improved kidney viability whereas perfusion at a higher pressure of 60mmHg was 
detrimental to the kidney (Maathuis et al., 2007). 
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4.5.4 PORCINE NMR ANALYSIS 
 
A total of 30 metabolites were identified in the perfusate of porcine kidneys. 
Concentrations were measured at three standard timepoints – 45 minutes, 4 hours 
and 28 hours during SCS or HMP. Some samples were examined at extended 
timepoints but the numbers analysed were insufficient for statistical analysis 
 
Glutathione was the only metabolite with statistically significant differences for all the 
measured parameters – change in overall concentration over time, concentration 
between storage groups and rate of change between storage groups. Overall, 
Glutathione levels decreased over experimental time. Concentrations were lower in 
HMP porcine kidneys compared to SCS porcine kidneys and concentrations 
decreased over time during HMP but remained fairly constant during SCS.  
 
Glutathione, in its reduced form, is present in the perfusion fluid (3mM) as a free 
radical scavenger. When exposed to oxygen or light, glutathione is altered to its 
oxidised form. Levels detected by NMR in this experiment represent reduced 
glutathione only. Improved oxygenation and increased likelihood of exposure to light 
in the HMP group, could have resulted in increased oxidisation of reduced 
glutathione and hence the lower levels detected. It should also be noted that when 
oxidised glutathione loses its scavenging abilities. It has been suggested that 
oxidisation can affect glutathione levels in perfusate prior to use and that 
supplemental glutathione may be necessary (van Breussegem et al., 2011). This 
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may be of particular importance during HMP given the changes shown in the porcine 
model.  
 
Several metabolites changed significantly over time and were significantly different 
between storage groups. These included amino acids (alanine, glutamate, leucine, 
valine, glycine, isoleucine and tyrosine), hypoxanthine and fumarate. 
 
Concentrations of all of these amino acids increased over experimental time but 
more so in the HMP group. It is known that larger proteins are released into the 
perfusate during HMP as a sign of cellular damage (Hoogland et al., 2013) and the 
release of amino acids could be due to the same process. However, the results from 
the clinical part of this study (and other published material) suggest that HMP kidneys 
show improved function post-transplantation compared to SCS kidneys and might 
therefore have been exposed to less tissue damage. Concentrations of cellular 
damage markers in the perfusate might therefore be expected to be less in the HMP 
group. These results could be a true reflection of cellular injury or it could be that the 
pulsatile flushing of the kidney during HMP leads to a more efficient washout than the 
‘one off’ flush prior to sampling in the SCS kidneys.  
 
Hypoxanthine, and inosine, are end-products of ischaemic adenine nucleotide 
catabolism in isolated renal tissue (Buhl & Buhl, 1979). Hypoxanthine levels 
increased over experimental time, more so in the HMP group. Again, the increased 
levels detected in the HMP perfusate could be a true reflection of increased cellular 
damage or, more likely, could reflect improved washout of breakdown products. 
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Inosine concentrations, however, were no different between porcine SCS and HMP 
perfusate.  
 
Fumarate is a metabolite of the citric acid cycle. Exogenous fumurate has been 
shown to have a role in preserving cell integrity in studies of cardiac IR injury 
(Laplante et al., 1997). Its role in this case is unclear, but levels in HMP perfusate 
were higher than in SCS perfusate. 
 
Concentrations of lactate, citrate, pyruvate and hippurate all increased over time in 
both storage groups at similar rates. Lactate and pyruvate are involved in glycolysis 
and their accumulation in ischaemic tissue is expected. Citrate is an intermediate of 
the citric acid cycle and its excretion into the urine in a porcine model has been 
shown to correlate with favourable graft outcomes post transplant (Hauet et al., 
2000b). Levels in the perfusate were similar for both storage methods in this porcine 
experiment but transplantation was not performed. In the human kidneys, pre-
transplant perfusate levels of citrate did not differ between IGF and DGF kidneys. It 
might be that citrate has a role in reperfusion injury rather than ischaemic injury 
alone. Hippurate is an acyl glycine and a normal constituent of urine. 
 
Levels of ribose and 3-methylxanthine were different between the storage groups 
although the rate of change was similar. Ribose levels were lower in the HMP 
perfusate. If ribose is being used as an energy source then this could reflect 
increased metabolic activity in the HMP stored kidneys but, as with the human HMP 
kidneys, adenine levels did not decrease to correspond with this mechanism. 3-
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Methylxanthine levels were higher in the perfusate of HMP porcine kidneys – this 
again probably represents improved wash out of waste products. 
 
Overall concentrations, rate of change and difference between storage groups was 
not found to be significant for the other measured metabolites.  
 
 
4.5.5 PORCINE HISTOLOGY 
 
Use of the porcine model allowed multiple biopsies to be performed. It became clear 
following examination of the first few samples that light microscopy lacked the power 
to define any differences between the SCS and HMP kidneys. Similar limitations of 
LM have been reported in other studies examining porcine kidney histology (Gallinat 
et al., 2012). Electron Microscopy, however, did suggest some interesting differences 
between kidneys stored by the different storage methods. 
 
There were no differences found between SCS and HMP kidneys when endothelial 
cells and peri-tubular capillaries were examined. There was evidence of increased 
histological injury in the SCS kidneys when epithelial cells, GBM and tubules were 
examined. 
 
The epithelial cells in the 28 hour samples, showed increased cytoplasmic swelling 
and paler nuclei in the SCS group compared to the HMP group. Cellular swelling is 
one of the consequences of depletion of energy sources in anaerobic conditions 
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(Hosgood et al., 2010). HMP may act to better preserve energy levels by improved 
delivery of nutrients to the tissue and therefore reduce cellular swelling compared to 
SCS.  
 
There appeared to be some damage to the GBM of the SCS kidneys but not the 
HMP kidneys. This was only present in one of the pig pairs but similar changes have 
been shown in other studies (Hosgood et al., 2010). 
 
Changes to the tubules were variable but there was some brush border loss in one of 
the SCS kidneys by 28 hours that was not evident in the HMP paired kidney. This 
has been demonstrated in other models of porcine preservation (Hosgood et al., 
2010). 
 
In terms of injury related to HMP, there was evidence of damage to the arteriolar 
smooth muscle layer with associated vacuolation in the HMP kidneys. This change 
was distinctive in both kidneys pairs. It is possible that this is related to the perfusion 
pressure during HMP. This has not previously been reported. 
 
 
4.5.6 COMPARISON OF PORCINE & HUMAN HMP KIDNEYS 
 
In an attempt to make a valid comparison, porcine kidneys were compared with SCD 
human kidneys that displayed IGF. Two assumptions were made in comparing these 
groups. Firstly, that porcine kidneys were equivalent to SCD human kidneys. This 
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seems reasonable as all kidneys were from young pigs and were disease free. 
Secondly, that the porcine kidneys would have had IGF. Unfortunately, the model 
cannot verify this as there is no method to measure graft outcome post-storage. 
 
The porcine model described in this thesis, more accurately represents DCD retrieval 
in humans. The numbers of DCD human kidneys in this study were too small to use 
as a comparator group, so DBD human kidneys were used in the analysis. The main 
difference between the HMP human and porcine kidneys, in terms of pre-
preservation factors, was therefore the WIT. 
 
The median WIT for porcine kidneys during recovery was 18 minutes whereas none 
of the comparator human group experienced a warm ischaemic insult. Average CIT 
during transport and prior to storage was also much shorter for the porcine group 
(152.5 minutes) compared to the human group (465 minutes).  
 
The pattern of flow and resistance change whilst on HMP was the same for human 
and porcine kidneys – it was only the absolute measurements that were different at 
each timepoint. Human kidneys displayed higher flow and lower resistance readings 
at all timepoints compared to the porcine group. It is unknown whether this would 
have been reflected in outcome. It may simply be a product of the size of the vessels 
in the different species. Increasing perfusion pressure may have resulted in 
increased flow and lower resistance within the porcine kidneys. However, evidence 
suggests that this may be detrimental to the kidney (Maathuis et al., 2007). 
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Although there were some differences between the species, the metabolomic profile 
of human and porcine kidney perfusate was comparable. The majority of metabolites 
were present in similar concentrations in both species (53.3%).  
 
For the metabolites present in different concentrations for the two species, all 
metabolites other than 3-hydroxybutryate had comparable rates of change in 
concentration for pig and human samples. This would imply that the active metabolic 
pathways or processes of cellular damage during HMP in both human and porcine 
kidneys are broadly similar. The kidney cannot synthesise the ketone body 3-
hydroxybutyrate to any significant extent but can consume it as an energy source 
and this process is likely to be more pronounced in hypothermic conditions. 
Interspecies differences of levels of the degradatory enzyme 3-hydroxybutyrate 
dehydrogenase with in the renal cortex and plasma levels of 3-hydroxybutyrate have 
been reported and may account for this finding (Koundakjian & Snoswell, 1970). 
 
Differences in metabolite concentrations between the two species could well be due 
to the variation in retrieval conditions mentioned previously. Porcine kidneys were 
subjected to WIT during retrieval whereas human kidneys were not in this 
experiment. In the clinical situation, WIT would occur at the time of transplantation.  
The CIT during transport for the pig kidneys was shorter than the human group. In 
addition, human kidneys were subjected to the global metabolic changes associated 
with brain death prior to retrieval including thyroid, catecholamine and glycaemic 
effects (Gramm et al., 1992; Powner et al., 1990; Smith, 2004; Wood et al., 2004). 
Such difference in retrieval conditions is likely to account for many of the interspecies 
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differences found such as the trend towards higher levels of lactate in the human 
kidneys. 
 
 
4.5.7 LIMITATIONS 
 
There are several limitations to this part of the study, some of which have already 
been alluded to.  
 
The main issue is the lack of kidney outcome for the porcine model i.e. no auto-
transplant model. The assumption is therefore made that the porcine kidneys would 
all display IGF so be comparable to the human IGF kidneys. This is likely to be true 
but there is no proof of this. 
 
Histology findings are interesting and potentially represent some insight into the 
mechanism of action of HMP. Again, sample numbers were small due to limited 
resources and logistical issues but further study of these findings might be very 
useful. 
 
A short WIT was unavoidable for the porcine kidneys. A better human comparator 
might therefore have been human DCD kidneys but numbers of these were too small 
to be statistically useful.  
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Perfusate analysis determines the concentration of metabolites in the extracellular 
environment of the kidney. Whilst the intracellular activity of many metabolites can be 
inferred from this, metabolomic analysis of kidney tissue would provide a more 
detailed account of the intracellular activity. It would also address the issue of 
whether increased levels of metabolites in HMP compared to SCS kidneys are ‘true’ 
or result from the improved flushing mechanism. 
 
In terms of the statistical analysis of the porcine metabolites, there is a high likelihood 
of both false positive and false negative errors due to the number of comparisons 
and small sample size. Also, where human and porcine metabolites are compared, 
small numbers may mean that it lacks the power to detect small interspecies 
differences. There are likely to be several false positive results at the p=0.05 
significance level.  
 
 
4.5.8 CONCLUSIONS 
 
This study demonstrates that the behaviour of human and porcine kidneys during 
HMP is similar. Machine parameters show comparable trends and NMR based 
metabolomics profiles are also similar. This implies that the same underlying 
metabolic pathways and cellular processes are occurring during preservation in the 
two species. This appears to validate the porcine HMP model as a valid comparator 
for human studies and would suggest that a defined optimal metabolic support 
protocol for HMP in a pig model would be translatable into clinical practice 
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CHAPTER 5: CONCLUDING REMARKS 
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Improving transplant opportunities for kidney failure patients and optimising care for 
renal transplant recipients has the potential to have a huge impact on a significant 
proportion of the population. This is demonstrated in a better survival and quality of 
life for patients receiving a functioning kidney transplant. Improvements in all aspects 
of transplantation can also have a major impact on healthcare budgets. 
 
Organ storage is only one of many steps in the complex process of clinical 
transplantation. Donor and recipient demographics, organ viability, procurement 
methods and warm/cold ischaemic times are only a few of the other factors that 
impact on transplant outcomes. However, the method of storage used during CIT and 
its application can have a significant effect on outcome. Hypothermic Machine 
Perfusion is an alternative form of organ storage with many potential benefits. This 
thesis aimed to investigate its role and underlying mechanism. 
 
The introduction of HMP into clinical practice was examined in the first part of this 
study. This was initiated by developing and instigating an organ storage protocol 
based on donor-recipient readiness and theatre availability. The aim of this was to 
use HMP as a tool to extend CIT and allow surgery to take place under optimum 
conditions without detriment to graft function. As already discussed, a number of 
preceding trials had demonstrated improved graft function with HMP. Others had 
suggested that HMP might allow longer, safe storage times. Our department 
recognised the potential benefits of this time extension for improving service 
provision and patient safety. 
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Managing the process of kidney transplantation from the acceptance of a deceased 
donor organ through to operation and discharge from hospital is a detailed process. 
Many difficulties recognised at UHB will be relevant to other transplant units. Renal 
failure patients are a high risk group with significant co-morbidity which increases 
their peri-operative risk compared to that of the general population. In addition UHB, 
as with other regional transplant units, has a large catchment area with patients 
being managed by different healthcare providers. Often patients require dialysis or 
further optimization which will delay surgery. Many reports, such as the CEPOD 
documents, outline the risks of operating out-of-hours. Attempting to perform as 
many transplants as possible during normal working hours when maximal expertise 
is available, therefore, seems logical. 
 
The introduction of HMP at UHB proved to have several benefits. These resulted 
from the principal finding that HMP allowed extended periods of CIT whilst 
maintaining post transplant graft function. This provided more time to optimise peri-
operative conditions and operate during normal working hours with a specialist team.  
 
Despite the protocol, a number of transplants were still performed out of hours. This 
highlighted the difficulty in predicting time to theatre when so many factors have to be 
addressed and ‘emergency’ theatre time is shared between multiple specialties. As 
an observation, there also appeared to be some concern in extending CIT for the 
small number of DCD kidneys examined. Traditionally, much importance had been 
placed on minimising CIT for these organ types. However, marginal organs, such as 
DCD kidneys, might be the type to benefit the most from the use of HMP. Further 
  224 
dissemination of the evidence might be useful to reassure medical staff that HMP is a 
safe option for DCD kidneys.  
 
Along with further investigation of kidney subgroups, long-term outcomes will be 
essential to prove the benefits of HMP. These were not available in the required 
timeframe but would be a useful addition to the data. 
 
Consistent HMP outcomes might be achieved, both locally and UK-wide, by adopting 
HMP at recovery. It is not currently used routinely and it’s introduction would require 
re-organisation at a national level and evidence of financial benefit. 
 
Cost-effectiveness was discussed but not investigated as part of this thesis. This is 
key to introducing any new technology, especially on a national scale. Previous 
health economic reviews have suggested that there is an overall cost benefit to HMP. 
Despite the initial cost outlay, return is gained by lower rates of DGF and reduced 
hospital stays.  
 
There has also been increasing interest in normothermic perfusion which has gained 
favour in some specialists units. Currently, the required techniques  are much more 
complex and labour intensive and would be difficult to institute on a wider scale. This 
may change in the future as technology improves. 
 
The second part of the study involved analysing the perfusate of HMP kidneys using 
NMR. The aim of this was to identify differences between IGF and DGF kidney 
  225 
perfusate and find potential biomarkers relating to kidney injury. Accurate 
assessment of graft quality is essential to achieve good outcomes and maximise the 
use of valuable donor organs. Current methods have limited capacity to predict graft 
function  and no single biomarkers has proven to be reliable.  
 
The metabolomic profile of HMP perfusate from human cadaveric kidneys has not 
previously been examined. In this study, the metabolomic profile of the perfusate 
changed markedly within only 45 minutes with significant differences identified 
between IGF and DGF kidneys.  
 
Several metabolites showed promise as predictors of DGF – glucose, inosine, 
leucine and gluconate – with good values on ROC curves.  This was a small unique 
study and these require further examination and validation.  
 
NMR appears to be a useful tool to identify potential markers or biological pathways 
of interest. From my experience, time required for processing and analysis prevents 
NMR from being clinically useful at present. Other groups have suggested that it is 
possible to utilise it in a viable timeframe for transplantation. It might be that NMR 
can identify markers that can then be measured with more simple bedside tests. It 
may also be possible to combine these markers with machine parameters to create a 
prediction index. Similar prediction methods do already exist and some are in clinical 
use but a single simple marker would be an improvement. 
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If further metabolomics examination can identify harmful pathways within stored 
kidneys it might then be possible to modify these processes. This may allow salvage 
of damaged kidneys which might otherwise have suffered from dysfunction or been 
discarded. Further information might be gained by examining kidney tissue using 
NMR. This may help to determine which processes are actively occurring within the 
kidneys and which substances are being excreted only. It is also possible to ‘tag’ 
substances, such as carbon, which are involved in several potential pathways which 
could also help to elucidate metabolic activity in the stored kidney. 
 
The final part of the study aimed to establish a porcine model to test future 
hypothesis and allow modifications to stored kidneys. A porcine model of HMP was 
established which proved to be an acceptable comparator for human studies. This 
will allow further investigation to continue.  
 
Different perfusion patterns and pressures could be tested along with varying 
perfusates at different temperatures. Initial examination of histological samples also 
produced some interesting findings which could be further examined. The ability to 
transplant the stored organ back into a pig to test for graft outcomes would be most 
useful. 
 
Organ perfusion is still in its infancy. It seems likely that with further refinement of the 
methodology longer CIT can be achieved. This might allow for manipulation of 
immunogenicity and modulation of repair and regeneration within the stored kidney. 
Organ discard would be reduced allowing more life-changing transplants to take 
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place. In the future, safe extended storage times might allow for further reaching, 
even worldwide, patterns of organ exchange. 
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Appendix 1 
Algorithm for Machine Perfusion of Kidneys at QEH 
Kidney'Accepted
No'concerns
No'delays'
(<12'hours'
CIT)'
expected
Transplant
Transplant
>12'hours'CIT'
expected/Delays
Machine'perfuse
Concerns'–
?Acute'kidney'injury
Diagnostics'
Resistance'
<0.4'after'3'hours
Resistance'
•>0.4'after'3'hours
•(>0.7'?discard)
Question'with'clinical/Biopsy'data
Discard
Concerns'–
?'Chronic'kidney'
damage
Biopsy
Pathway'for'Kidneys'for'machine'perfusion
Recipient'and'or'logistical'factors'may'also'influence'the'time'of'implantation
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Appendix 2 Recipient Consent Form 
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Appendix 3 
 
Recipient Information Sheet  
!
!
Machine!Perfusion!in!Kidney!Transplantation!
!
!
Thank!you!for!reading!this!leaflet!which!explains!the!study!we!are!running!and!that!hopefully!
you!will!take!a!part!in.!
!
What%is%the%study?%
!
This! study! is! looking! at! how!well! kidneys! function! following! transplantation!depending!on!
how!they!are!stored!and!transported!prior!to!the!operation.!
!
There!are!two!methods!of!storing!and!transporting!kidneys!prior!to!transplantation.!One!is!in!
an!ice!box!(static!cold!storage)!and!the!alternative!is!in!a!perfusion!machine.!In!addition!to!
providing!a! cold!environment,! the!perfusion!machine!continuously! circulates! fluid! through!
the!kidney.!Both!methods!are!acceptable!and!safe.!
!
Several! large! international!studies!have!suggested!that!machine!perfusion! is!beneficial!and!
improves! outcomes! for! patients! receiving! these! kidneys.! The! machine! may! also! improve!
kidneys!which!might!otherwise!have!been!rejected!for!transplantation!allowing!more!kidney!
transplants!to!take!place.!Kidneys!can!also!be!stored!for!longer!on!the!machine!which!gives!
us!more!time!to!prepare!recipients!for!their!surgery.!Because!of!these!results,!we!are!trying!
to!machine!perfuse!most!kidneys!that!are!transplanted!at!the!Queen!Elizabeth!Hospital.!We!
are!hoping!to!better!understand!how!the!perfusion!machine!works!and!improve!outcomes!
for!our!kidney!transplant!patients.!
!
The!results!of!the!study!will!also!be!used!towards!an!educational!qualification.!!
!
Why%are%you%doing%it?%
!
You! will! be! receiving! a! kidney! which! has! been! stored! and! transported! by! the! perfusion!
machine.! In! order! for! us! to! ensure! we! are! achieving! the! best! outcomes! possible! for! our!
patients,! we! would! like! to! collect! some! data! to! record! how! well! your! transplant! kidney!
works.!This!will!include!results!of!your!blood!tests!for!kidney!function!and!any!problems!you!
may!encounter!following!your!transplant.!We!hope!this!will!help!us!to!improve!outcomes!for!
kidney!transplant!patients!and!increase!the!number!of!kidney!transplants!that!we!can!do.!
!
!
!
!
%
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%
What%would%I%have%to%do?!
!
We!need!your!permission!to!record!the!results!of!your!blood!tests!after!your!operation!and!
record!information!on!how!well!your!kidney!is!working!and!any!problems!you!might!have.!
!
There!are!no!extra! tests,! needles!or! extra!appointments.! The! results!we!normally!use! to!
take!care!of!you! following!your! transplant!will!be!recorded!separately!and!securely.!These!
will!be!used!to!help!us!determine!how!we!get!the!best!results!for!our!patients.!
!!
Will%being%in%the%study%change%my%treatment%at%all?%
!
Whether!you!take!part!in!the!study!or!not!will!not!influence!the!treatment!you!receive!in!any!
way.! You! are! also! free! to! stop! being! in! the! study! at! any! point.! If! you! choose! to! stop!
participating!in!the!study!your!treatment!will!remain!exactly!the!same.!!
!
Can%I%get%the%results%of%the%study?%
!
If!you!are!interested!in!the!results!of!the!study,!a!summary!can!be!sent!to!you!once!all!the!
analysis!is!completed.!
!
What%do%I%need%to%do%if%I%do%want%to%be%in%the%study?%
!
All!you!need!to!do!to!take!part!is!to!agree!and!sign!the!consent!form.!It!is!important!to!take!
the!time!to!read!this!information!and!ask!any!questions!you!have.!Once!you!have!agreed!to!
be!in!the!study!the!information!will!be!collected.!Once!the!study!is!finished!all!data!will!be!
destroyed.!
!
Thank!you!very!much!for!reading!this!information!and!we!hope!you!will!be!part!of!the!study.!
Feel!free!to!ask!any!questions.!!
!
If! you! would! like! general,! impartial! advice! on! taking! part! in! research! studies! we! would!
suggest!contacting!the!PALS!office!on !!
!
!
!
!
!
!
!
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Ethics Advice 
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7.2 ETHICS FAVOURABLE OPINION LETTER 
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7.3 CUT-OFF VALUES FOR ROC CURVES 
 !
Predictor) Cutoff) Sensitivity) Specificity) Youden’s)J)Glucose!(45!Mins)! 9.0! 100%! 74%! 0.737!Glucose!(4!Hours)! 9.7! 100%! 68%! 0.684!Inosine!(45!Mins)! 0.0056! 100%! 68%! 0.684!Leucine!(45!Mins)! 0.0087! 67%! 84%! 0.509!Gluconate!(4!Hours)! 52.0! 83%! 84%! 0.675!
!Based!on!Youden’s!J!statistic!
Due to small sample size, cutoffs are likely to have a wide degree of error 
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7.4 METABOLITE CONCENTRATIONS (MM) MEASURED IN KIDNEY 
 PERFUSATE OF SCS & HMP PORCINE KIDNEYS (ALL METABOLITES) 
 
 
Timepoint p-Values 
 Storage 45 Minutes 4 Hours 28 Hours Time Storage Int. 
Gluconate# HMP 59.7 (52.3 - 67.0) 58.8 (50.9 - 66.8) 61.1 (55.3 - 66.8) 0.954 0.143 0.659 
SCS 64.3 (57.7 - 70.8) 65.8 (61.3 - 70.3) 64.7 (60.9 - 68.5) 
Mannitol# HMP 35.7 (30.7 - 40.7) 35.9 (30.0 - 41.7) 38.7 (34.3 - 43.0) 0.106 0.628 0.481 
SCS 31.5 (27.9 - 35.0) 35.0 (30.0 - 40.1) 40.5 (34.1 - 46.8) 
Glucose# HMP 7.6 (6.2 - 9.0) 8.6 (6.4 - 10.7) 9.8 (7.9 - 11.6) 0.084 0.947 0.432 
SCS 8.2 (7.1 - 9.3) 8.8 (7.8 - 9.9) 9.1 (8.5 - 9.7) 
Adenine# HMP 4.5 (3.8 - 5.2) 4.5 (3.6 - 5.3) 4.7 (4.3 - 5.1) 0.955 0.407 0.500 
SCS 4.8 (4.3 - 5.4) 4.9 (4.6 - 5.2) 4.9 (4.3 - 5.5) 
Ribose# HMP 2.5 (1.9 - 3.0) 2.3 (1.7 - 2.9) 2.4 (2.0 - 2.7) 0.846 0.004* 0.696 
SCS 3.3 (2.8 - 3.8) 3.4 (3.0 - 3.9) 3.4 (3.1 - 3.8) 
Glutathione# HMP 0.96 (0.80 - 1.11) 0.39 (0.24 - 0.54) 0.00 (0.00 - 0.00) <0.001* <0.001* <0.001* 
SCS 1.59 (1.33 - 1.86) 1.64 (1.38 - 1.91) 1.55 (1.31 - 1.79) 
Lactate# HMP 0.58 (0.16 - 0.99) 0.65 (0.47 - 0.83) 1.23 (0.92 - 1.55) <0.001* 0.126 0.755 
SCS 0.43 (0.18 - 1.04) 0.19 (0.12 - 0.27) 0.83 (0.44 - 1.22) 
Citrate HMP 2.3 (1.4 - 3.9) 2.6 (1.7 - 4.1) 3.1 (2.2 - 4.4) <0.001* 0.737 0.236 
SCS 1.6 (0.8 - 3.4) 2.3 (1.1 - 4.7) 3.4 (1.7 - 6.8) 
Alanine HMP 0.065 (0.049 - 
0.085) 
0.107 (0.075 - 
0.152) 
0.201 (0.152 - 
0.266) 
<0.001* <0.001* 0.056 
SCS 0.025 (0.015 - 
0.041) 
0.031 (0.019 - 
0.051) 
0.103 (0.069 - 
0.152) 
Glutamate HMP 0.38 (0.24 - 0.61) 0.98 (0.74 - 1.30) 2.15 (1.89 - 2.45) 0.001* <0.001* 0.733 
SCS 0.06 (0.03 - 0.15) 0.11 (0.05 - 0.23) 0.25 (0.11 - 0.58) 
Acetate HMP 0.21 (0.15 - 0.28) 0.23 (0.17 - 0.30) 0.25 (0.21 - 0.29) 0.141 0.437 0.266 
SCS 0.17 (0.07 - 0.43) 0.12 (0.07 - 0.21) 0.24 (0.11 - 0.51) 
Hypoxanthine HMP 0.12 (0.07 - 0.18) 0.18 (0.12 - 0.28) 0.26 (0.22 - 0.32) 0.015* 0.003* 0.704 
SCS 0.04 (0.02 - 0.07) 0.04 (0.02 - 0.09) 0.08 (0.03 - 0.20) 
Formate HMP 0.09 (0.07 - 0.13) 0.09 (0.06 - 0.13) 0.10 (0.08 - 0.13) 0.124 0.798 0.428 
SCS 0.09 (0.03 - 0.27) 0.06 (0.03 - 0.12) 0.11 (0.04 - 0.29) 
Fumarate HMP 0.0033 (0.0016 - 
0.0068) 
0.0053 (0.0030 - 
0.0094) 
0.0161 (0.0124 - 
0.0209) 
<0.001* 0.022* 0.362 
SCS 0.0014 (0.0006 - 
0.0036) 
0.0011 (0.0004 - 
0.0031) 
0.0064 (0.0039 - 
0.0106) 
Leucine HMP 0.017 (0.012 - 
0.023) 
0.023 (0.016 - 
0.034) 
0.035 (0.027 - 
0.044) 
<0.001* 0.013* 0.247 
SCS 0.004 (0.002 - 
0.008) 
0.008 (0.004 - 
0.017) 
0.017 (0.008 - 
0.035) 
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Valine HMP 0.016 (0.012 - 
0.020) 
0.024 (0.016 - 
0.036) 
0.035 (0.027 - 
0.046) 
<0.001* 0.008* 0.256 
SCS 0.005 (0.002 - 
0.009) 
0.008 (0.004 - 
0.013) 
0.017 (0.008 - 
0.037) 
Glycine HMP 0.58 (0.45 - 0.75) 1.47 (1.12 - 1.93) 2.63 (2.32 - 2.98) <0.001* <0.001* 0.504 
SCS 0.10 (0.04 - 0.23) 0.18 (0.13 - 0.24) 0.52 (0.37 - 0.74) 
Pyruvate 
 
HMP 0.006 (0.003 - 
0.012) 
0.009 (0.005 - 
0.019) 
0.017 (0.007 - 
0.043) 
0.022* 0.169 0.414 
SCS 0.005 (0.002 - 
0.013) 
0.003 (0.001 - 
0.006) 
0.009 (0.004 - 
0.021) 
3- 
Hydroxybutyrate 
HMP 0.02 (0.01 - 0.02) 0.02 (0.01 - 0.02) 0.02 (0.01 - 0.02) 0.390 0.515 0.397 
SCS 0.04 (0.00 - 0.33) 0.01 (0.01 - 0.01) 0.03 (0.01 - 0.05) 
Ethanol HMP 0.04 (0.02 - 0.07) 0.04 (0.02 - 0.07) 0.03 (0.01 - 0.07) 0.178 0.984 0.163 
SCS 0.02 (0.01 - 0.06) 0.03 (0.01 - 0.08) 0.06 (0.02 - 0.19) 
Hippurate HMP 0.0002 (0.0001 - 
0.0007) 
0.0007 (0.0001 - 
0.0038) 
0.0015 (0.0003 - 
0.0067) 
0.025* 0.532 0.620 
SCS 0.0002 (0.0001 - 
0.0005) 
0.0005 (0.0002 - 
0.0018) 
0.0005 (0.0001 - 
0.0021) 
Inosine HMP 0.0003 (0.0001 - 
0.0014) 
0.0008 (0.0001 - 
0.0041) 
0.0016 (0.0004 - 
0.0069) 
0.181 0.693 0.588 
SCS 0.0003 (0.0001 - 
0.0008) 
0.0013 (0.0010 - 
0.0018) 
0.0006 (0.0001 - 
0.0040) 
Isoleucine HMP 0.009 (0.007 - 
0.011) 
0.014 (0.010 - 
0.020) 
0.021 (0.016 - 
0.027) 
0.004* 0.024* 0.348 
SCS 0.005 (0.002 - 
0.011) 
0.005 (0.003 - 
0.009) 
0.015 (0.009 - 
0.023) 
Isopropranolol HMP 0.014 (0.013 - 
0.015) 
0.013 (0.012 - 
0.014) 
0.013 (0.012 - 
0.015) 
0.274 0.087 0.314 
SCS 0.021 (0.002 - 
0.189) 
0.007 (0.006 - 
0.007) 
0.004 (0.002 - 
0.008) 
N- 
Phenylacetylglyci
ne 
HMP 0.0002 (0.0000 - 
0.0014) 
0.0010 (0.0001 - 
0.0067) 
0.0007 (0.0001 - 
0.0031) 
0.648 0.287 0.651 
SCS 0.0003 (0.0001 - 
0.0011) 
0.0003 (0.0001 - 
0.0010) 
0.0003 (0.0001 - 
0.0013) 
Malonate HMP 1.4 (0.6 - 3.3) 1.3 (0.6 - 2.8) 1.7 (0.9 - 3.2) 0.885 0.188 0.231 
SCS 0.7 (0.3 - 1.8) 1.3 (0.7 - 2.5) 1.0 (0.5 - 2.4) 
Tyrosine HMP 0.009 (0.007 - 
0.012) 
0.013 (0.009 - 
0.020) 
0.020 (0.016 - 
0.024) 
<0.001* 0.012* 0.211 
SCS 0.004 (0.002 - 
0.006) 
0.005 (0.003 - 
0.008) 
0.013 (0.007 - 
0.024) 
Uracil HMP 0.002 (0.000 - 
0.010) 
0.003 (0.000 - 
0.019) 
0.002 (0.000 - 
0.009) 
0.845 0.450 0.743 
SCS 0.003 (0.002 - 
0.006) 
0.004 (0.002 - 
0.007) 
0.005 (0.002 - 
0.009) 
3-Methylxanthine HMP 0.009 (0.003 - 
0.028) 
0.008 (0.002 - 
0.028) 
0.017 (0.016 - 
0.018) 
0.190 0.007* 0.579 
SCS 0.002 (0.001 - 
0.003) 
0.002 (0.001 - 
0.004) 
0.002 (0.001 - 
0.005) 
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7.5 BOX AND WHISKER PLOT TO REPRESENT CONCENTRATIONS OF 
METABOLITES IN HMP AND SCS PORCINE KIDNEY PERFUSATE (NON-
SIGNIFICANT METABOLITES) 
 
Metabolites with no significant change in concentration over time and no significant 
difference in concentrations between concentration or rate of change in concentration 
between storage groups 
 
Gluconate 
 
Mannitol 
Time (Hours)
28.004.00.75
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Glucose 
 
 
Adenine 
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Acetate Formate 
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3-Hydroxybutyrate 
 
Ethanol 
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Inosine 
 
Isopropranolol 
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N-Phenylacetylglycine Malonate 
Time (Hours)
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Uracil 
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Metabolomic Analysis of Perfusate During
Hypothermic Machine Perfusion of
Human Cadaveric Kidneys
Alison J. Guy,1,5 Jay Nath,1 Mark Cobbold,2 Christian Ludwig,3 Daniel A. Tennant,4
Nicholas G. Inston,1 and Andrew R. Ready1
Background. Themetabolic processes occurringwithin the preserved kidney during hypothermicmachine perfusion (HMP)
are not well characterized. The aim of this study was to use nuclear magnetic resonance (NMR) spectroscopy to examine the
metabolomic profile of HMP perfusate from human cadaveric kidneys awaiting transplantation and to identify possible
discriminators between the profiles of kidneys with delayed graft function (DGF) and immediate graft function (IGF).
Methods. Perfusates from HMP kidneys were sampled at 45 min and 4 hr of preservation with the LifePort Kidney
Transporter 1.0 (Organ Recovery Systems, Chicago, IL) using KPS-1. Prepared samples underwent 1-D Proton-NMR
spectroscopy, and resultant spectra were analyzed. Clinical parameters were collected prospectively.
Results. Perfusate of 26 transplanted cadaveric kidneys was analyzed; 19(73%) with IGF and 7(27%) with DGF. Glucose
concentrations were significantly lower in DGF kidneys compared to those with IGF at both 45min (7.772 vs. 9.459 mM,
P = 0.006) and 4 hr (8.202 vs. 10.235 mM, P = 0.003). Concentrations of inosine and leucine were significantly different
between DGF and IGF kidneys at 45 min (0.002 vs. 0.013 mM, P = 0.009 and 0.011 vs. 0.006 mM, P = 0.036), and
gluconate levels were also significantly different between DGF and IGF kidneys at 4 hr (49.099 vs. 59.513 mM, P = 0.009).
Conclusion. Significant metabolic activity may be occurring in kidneys during HMP. The NMR spectroscopy of the
perfusate can identify differences in the metabolomic profiles of DGF and IGF kidneys that might have a predictive
role in viability assessment. Modification of harmful metabolic processes may improve outcomes for HMP kidneys.
Keywords: Cadaveric kidney, Hypothermic machine perfusion, Metabolomics, NMR, Transplantation.
(Transplantation 2014;00: 00Y00)
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